

L16 ANSWER 1 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1989:601626 CAPLUS
 DOCUMENT NUMBER: 111:201626
 ORIGINAL REFERENCE NO.: 111:33389a,33392a
 TITLE: Manufacture of slow-release pharmaceuticals
 containing nicotinic acid
 derivatives
 INVENTOR(S): Kurono, Masatsune; Kojima, Akio; Inoe, Tsuneaki;
 Inoue, Tsuneaki; Watanabe, Koji; Sugimoto, Manabu;
 Kondo, Yoshiya; Sawai, Kiichi
 PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63310827	A	19881219	JP 1987-146954	19870615 <--
PRIORITY APPLN. INFO.:			JP 1987-146954	19870615
AB A slow-release pharmaceutical contains a nicotinic acid deriv. as the major component and a water-soluble polymer as the carrier. Niceritol 250, HPMC 100, and Mg stearate 2.5 g were mixed and made into capsules (niceritol 125 mg/ capsule).				

L16 ANSWER 2 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2000:535063 CAPLUS
 DOCUMENT NUMBER: 133:155518
 TITLE: Polymer material for packaging a
 nicotine-containing product
 INVENTOR(S): Levander, Gustav; Karlsson, Anders H. F.; Hildingsson,
 Ingemar
 PATENT ASSIGNEE(S): Pharmacia and Upjohn AB, Swed.
 SOURCE: PCT Int. Appl., 16 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044559	A1	20000803	WO 2000-SE17	20000112 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2359246	A1	20000803	CA 2000-2359246	20000112 <--
EP 1154902	A1	20011121	EP 2000-902222	20000112 <--
EP 1154902	B1	20060329		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
AU 745647	B2	20020328	AU 2000-23352	20000112 <--

JP 2002535454	T	20021022	JP 2000-595838	20000112 <--
CN 1113747	C	20030709	CN 2000-803156	20000112 <--
NZ 512522	A	20030725	NZ 2000-512522	20000112 <--
NZ 522608	A	20030829	NZ 2000-522608	20000112 <--
RU 2215656	C2	20031110	RU 2001-123218	20000112 <--
AT 321657	T	20060415	AT 2000-902222	20000112
PT 1154902	T	20060630	PT 2000-902222	20000112
ES 2259601	T3	20061016	ES 2000-902222	20000112
TW 266692	B	20061121	TW 2000-89101576	20000129
US 6790496	B1	20040914	US 2001-889772	20011017
HK 1043341	A1	20031031	HK 2002-104924	20020702 <--

PRIORITY APPLN. INFO.:

	SE 1999-215	A	19990126
	NZ 2000-512522	A1	20000112
	WO 2000-SE17	W	20000112

AB A title material comprises a polymer based on dimethyl-2,6-naphthalene dicarboxylate and/or 2,6-naphthalene dicarboxylic acid, such as poly(ethylene naphthalate) or poly(trimethylene naphthalate); or a liquid crystal polymer from hydroxybenzoic acid and hydroxynaphthenic acid. The material can be laminated with one or more metal such as aluminum and/or polymer foil(s). A laminate can also contain a barrier layer of one or more of polyacrylonitrile, polyamide, poly(vinylidene chloride), fluoropolymers, ethylene-vinyl alc. copolymer, poly(vinyl alc.), ionomers, polyethylene, polypropylene and poly(ethylene terephthalate). The material can be used for packaging transdermal nicotine patches, nicotine-containing chewing gum or tablets, and nasal sprays, and can be formed into packages having indentations into which tablets or lozenges can be cast.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:42092 CAPLUS
 DOCUMENT NUMBER: 138:112443
 TITLE: Tablet compositions for poorly-compressible pharmaceuticals
 INVENTOR(S): Matharu, Amol Singh; Patel, Mahendra R.
 PATENT ASSIGNEE(S): Geneva Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 20 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003004009	A1	20030116	WO 2002-US20323	20020627 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002316418	A1	20030121	AU 2002-316418	20020627 <--
US 20030021841	A1	20030130	US 2002-183881	20020627 <--
PRIORITY APPLN. INFO.:			US 2001-302613P	P 20010702
			WO 2002-US20323	W 20020627

AB The present invention relates to a process for preparing tablet dosage forms of poorly-compressible pharmaceuticals and to tablet dosage forms. The process is especially useful for preparing tablets of the poorly-compressible drug metformin-HCl. Thus, tablets contained metformin-HCl 500, HPMC 320, stearyl alc. 200, and Mg stearate mg/unit.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:295803 CAPLUS
 DOCUMENT NUMBER: 142:379358
 TITLE: Medical composition for treating hyperlipidemia
 INVENTOR(S): Zhao, Zhiqian
 PATENT ASSIGNEE(S): Lunan Pharmaceutical Co., Ltd., Peop. Rep. China
 SOURCE: Faming Zhuanli Shengqing Gongkai Shuomingshu, 11 pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
CN 1457786	A	20031126	CN 2003-122340	20030430 <--
CN 1194691	C	20050330		
PRIORITY APPLN. INFO.:			CN 2003-122340	20030430

AB The medical compn. is composed of nicotinic acid or its deriv. and rosuvastatin (at a ratio of 20-50:1). The nicotinic acid deriv. is inositol nicotinate, vitamin E nicotinate, or acipimox.

L16 ANSWER 5 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2002:213707 CAPLUS
 DOCUMENT NUMBER: 136:252489
 TITLE: Sustained-release polymer blend for pharmaceutical applications
 INVENTOR(S): Guo, Jian Hwa; Skinner, George William
 PATENT ASSIGNEE(S): Hercules Incorporated, USA
 SOURCE: U.S., 9 pp., Cont.-in-part of U.S. 6,210,710.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 6358525	B1	20020319	US 1999-343425	19990630 <--
US 6210710	B1	20010403	US 1997-847842	19970428 <--
NO 9801893	A	19981029	NO 1998-1893	19980427 <--
HU 9800985	A2	19990201	HU 1998-985	19980428 <--
HU 9800985	A3	20000628		
PRIORITY APPLN. INFO.:			US 1997-847842	A2 19970428

AB A pharmaceutical compn. has a blend of at least first and second components and a medicament in a sufficient amount to be therapeutic where the first component is hydroxypropylcellulose and the second component is at least one other polymer selected from the group consisting of methylcellulose, ethylhydroxyethylcellulose, hydroxyethylmethylcellulose, hydrophobically modified

hydroxyethylcellulose, hydrophobically modified ethylhydroxyethylcellulose, carboxymethylhydroxyethylcellulose, carboxymethyl hydrophobically modified hydroxyethylcellulose, guar, pectin, carrageenan, agar, algin, gellan gum, acacia, starch and modified starches, co-polymers of carboxyvinyl monomers, co-polymers of acrylate or methacrylate monomers, mono- and co-polymers of oxyethylene and oxypropylene and mixts. thereof and a medicament in a sufficient amount to be therapeutic, with the proviso that low-substituted hydroxypropylcellulose is excluded from said first and second components. The medicament can be a variety of drugs or nutritional supplements. The pharmaceutical compn. releases the medicament for a prolonged or sustained period of time and can be formulated into many dosage forms. A tablet contained Klucel HXF 37.5, Aqualon CMC 7L2P 112.5, phenylpropanolamine hydrochloride 75, avicel PH-101 162, povidone 12, reduced granulation 299, Avicel PH-102 96, magnesium stearate 5%.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs 6-136

L16 ANSWER 6 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:512584 CAPLUS
 DOCUMENT NUMBER: 146:468650
 TITLE: Ophthalmic and contact lens solutions containing forms of vitamin B
 INVENTOR(S): Smith, Francis X.
 PATENT ASSIGNEE(S): FXS Ventures, LLC, USA
 SOURCE: U.S. Pat. Appl. Publ., 5 pp., Cont.-in-part of U.S. Ser. No. 544,150.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070104744	A1	20070510	US 2007-620318	20070105
CA 2428994	A1	20020815	CA 2001-2428994	20011108 <--
WO 2002062260	A2	20020815	WO 2001-US46841	20011108 <--
WO 2002062260	A3	20021017		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1331902	A2	20030806	EP 2001-999161	20011108 <--
EP 1331902	B1	20080820		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004526186	T	20040826	JP 2002-562269	20011108
EP 1992340	A1	20081119	EP 2008-14693	20011108
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, AL, LT, LV, MK, RO, SI				

US 20060148665 A1 20060706 US 2005-544150 20050801
 WO 2008086270 A2 20080717 WO 2008-US50375 20080107

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
 CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
 FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
 KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
 PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2000-246689P P 20001108
 US 2000-246707P P 20001108
 US 2000-246708P P 20001108
 US 2000-246709P P 20001108
 WO 2001-US46841 W 20011108
 US 2005-544150 A2 20050801
 EP 2001-999161 A3 20011108
 US 2007-620318 A 20070105

AB The present invention relates to improved ophthalmic solns. that
 employ select B vitamins; pyridoxine and its salts; and thiamine and its
 salts in order to more effectively preserve solns. and to reduce
 the degree to which cationic preservatives will deposit on contact lenses.
 Ophthalmic solns. include contact lens treatment solns
 ., such as cleaners, soaking solns., conditioning solns
 . and lens storage solns., as well as wetting solns.
 and in-eye solns. for treatment of eye conditions. Formulations
 containing pyridoxine-HCl, and thiamine-HCl were prepared in a 0.2% phosphate
 buffer. The soln. containing pyridoxine-HCl and thiamine-HCl showed
 an improvement in the activity against C. albicans as compared to the
 buffer control.

L16 ANSWER 7 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:90531 CAPLUS

DOCUMENT NUMBER: 130:158409

TITLE: Tannic acid-polymer compositions
 for controlled release of pharmaceutical
 agents, particularly in the oral cavity

INVENTOR(S): Lerner, E. Itzhak; Rosenberger, Vered; Flashner, Moshe

PATENT ASSIGNEE(S): Perio Products Ltd., Israel

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9904764	A1	19990204	WO 1998-US15096	19980722 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NA, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

CA 2296654	A1	19990204	CA 1998-2296654	19980722 <--
AU 9885784	A	19990216	AU 1998-85784	19980722 <--
EP 1003483	A1	20000531	EP 1998-936955	19980722 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9811478	A	20000815	BR 1998-11478	19980722 <--
HU 2000002490	A2	20001228	HU 2000-2490	19980722 <--
JP 2001510788	T	20010807	JP 2000-503824	19980722 <--
NO 2000000284	A	20000322	NO 2000-284	20000120 <--
PRIORITY APPLN. INFO.:			US 1997-899121	A2 19970723
			WO 1998-US15096	W 19980722

AB The invention is directed to controlled- or sustained-release compns. for the release of pharmaceuticals or other agents. Essential components in the compns. of the present invention include one or more polymers and tannic acid or tannin. Release of the pharmaceutical or other agent is for a predetd. period of time and at a predetd. concentration. The site of action of the agent is topical, local or systemic. Polymers are cellulosic or proteinaceous. A soln. containing tannic acid 1.7 and water 1.7 g was added dropwise into a soln. containing Byco E 3.1 and water 3.1 g, and 0.45 g of the tannic acid-Byco preparation was mixed with 0.63 g of nicotine-encapsulated MLV liposomes consisting of egg phosphatidylcholine 60.9, phosphatidylethanolamine 6.6, and cholesterol 32.5 %. The mixture was applied in polypropylene molds (280 mg/well) and dried at 35° in the oven to form oral patches containing nicotine ≤ 2 mg. Release of nicotine from the oral patches was monitored through in vitro and in vivo assays using saliva samples.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 8 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1998:723752 CAPLUS
 DOCUMENT NUMBER: 129:347319
 ORIGINAL REFERENCE NO.: 129:70617a,70620a
 TITLE: Sustained release polymer blend matrix for pharmaceutical application
 INVENTOR(S): Skinner, George William
 PATENT ASSIGNEE(S): Hercules Incorporated, USA
 SOURCE: Eur. Pat. Appl., 15 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 875245	A2	19981104	EP 1998-107427	19980423 <--
EP 875245	A3	19990908		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6210710	B1	20010403	US 1997-847842	19970428 <--
NO 9801893	A	19981029	NO 1998-1893	19980427 <--
HU 9800985	A2	19990201	HU 1998-985	19980428 <--
HU 9800985	A3	20000628		

PRIORITY APPLN. INFO.: US 1997-847842 A 19970428

AB A pharmaceutical compn. has a blend of at least first and second components and a medicament in a sufficient amount to be therapeutic where the first component is selected from hydroxypropyl cellulose (HPC), Et cellulose (EC), or derivs. of HPC, EC and

hydroxyethyl cellulose (HEC) and the second component is at least one polymer. When HPC is the first component, hydroxypropyl Me cellulose (HPMC), HEC or CM-cellulose will not be the second component and when EC is the first component, HPMC will not be the second component. The medicament can be a variety of drugs or nutritional supplements. The pharmaceutical compn. releases the medicament for a prolonged or sustained period of time and can be formulated into many dosage forms. Formulations of solid oral dosage forms contain phenylpropanolamine and a variety of HPC and CMC or guar.

L16 ANSWER 9 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:483202 CAPLUS
 DOCUMENT NUMBER: 143:13388
 TITLE: Medical composition for treating hyperlipidemia
 INVENTOR(S): Sun, Yong
 PATENT ASSIGNEE(S): Lunan Pharmaceutical Co., Ltd., Peop. Rep. China
 SOURCE: Faming Zhuanli Shengqing Gongkai Shuomingshu, 18 pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1425374	A	20030625	CN 2003-100575	20030120 <--
CN 1205934	C	20050615		
WO 2004064840	A1	20040805	WO 2003-CN855	20031013
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003272864	A1	20040813	AU 2003-272864	20031013
PRIORITY APPLN. INFO.:			CN 2003-100575	A 20030120
			WO 2003-CN855	W 20031013

AB The medical compn. is composed of 25-50 part nicotinic acid and/or its deriv., 1 part 3-hydroxy-3-methylglutaryl- CoA (HMG-CoA) reductase inhibitor, and adjuvant. The nicotinic acid deriv. is inositol nicotinate, vitamin E nicotinate, or acipimox. The HMG-CoA reductase inhibitor is lovastatin, simvastatin, pravastatin, fluvastatin, cerivastatin, or atorvastatin.

L16 ANSWER 10 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1986:224818 CAPLUS
 DOCUMENT NUMBER: 104:224818
 ORIGINAL REFERENCE NO.: 104:35659a, 35662a
 TITLE: Synthesis and partition profiles of nicotinic acid derivatives with oligomeric carriers
 AUTHOR(S): Ghedini, Nadia; Zecchi, Vittorio; Tartarini, Annarosa; Scapini, Giancarlo; Andrisano, Vincenza; Ferruti, Paolo
 CORPORATE SOURCE: Ist. Chim. Farm. Tossicol., Bologna, 40126, Italy

SOURCE: Journal of Controlled Release (1986),
3(2-3), 185-91
CODEN: JCREEC; ISSN: 0168-3659
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Nicotinic acid esters with polyoxyalkylenes were prepared and their partition in a iso-Pr myristate-H₂O system studied to simulate skin absorption for possible application to pharmaceutical transdermal systems. Polyethylene glycol (PEG), polypropylene glycol (PPG), tetraethylene glycol monoesters and diester of the 1st 2 compds. were prepared by esterification of the glycols with nicotinodylimidazole or nicotinoyl chloride. A linear relation was observed between partition rate consts. and partition coeffs., indicating that penetration rates are increased by enhancement of their hydrophobic properties. PPG were more efficient vehicles than the PEG's. Monosubstituted derivs. of PPG are likely to be absorbed less efficiently than disubstituted derivs. The substitution of an ether group for an OH group has the same effect as disubstitution.

L16 ANSWER 11 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:5757 CAPLUS

DOCUMENT NUMBER: 138:78449

TITLE: Pharmaceutical compositions of
dispersions of drugs and neutral polymers
INVENTOR(S): Friesen, Dwayne Thomas; Gunkowski, Michael Jon;
Ketner, Rodney James; Lorenz, Douglas Alan;
Nightingale, James Alan Schriver; Shanker, Ravi
Mysore; West, James Blair

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 210 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000235	A1	20030103	WO 2002-IB1783	20020510 <--
WO 2003000235	A9	20031224		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2450957	A1	20030103	CA 2002-2450957	20020510 <--
AU 2002258090	A1	20030108	AU 2002-258090	20020510 <--
EP 1404300	A1	20040407	EP 2002-727944	20020510
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002010518	A	20040622	BR 2002-10518	20020510
JP 2004534812	T	20041118	JP 2003-506882	20020510
US 20030091643	A1	20030515	US 2002-175132	20020618 <--
MX 2003PA11784	A	20040402	MX 2003-PA11784	20031217
US 20060216351	A1	20060928	US 2006-383520	20060516
PRIORITY APPLN. INFO.:			US 2001-300255P	A1 20010622

WO 2002-IB1783 W 20020510
US 2002-175132 A1 20020618

AB Pharmaceutical compns. comprising dispersions of an acid-sensitive drug and a neutral dispersion polymer are disclosed. The acid-sensitive drug has improved chemical stability relative to dispersions of the drug and acidic polymers. In another aspect, pharmaceutical compns. of poorly-soluble drugs and amphiphilic, hydroxy-functional vinyl copolymers are disclosed. A dispersion of quinoxaline-2-carboxylic acid [(4(R)-carbamoyl-1(S)-3-fluorobenzyl)-2(S),7-dihydroxy-7-methyloctyl]amide and the neutral polymer hydroxypropyl Me cellulose (HPMC) was made by preparing a soln. containing 0.125% drug and 0.375% HPMC in methanol, and spraying the soln. into a drying chamber by using an atomizing spray nozzle.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 12 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:226981 CAPLUS

DOCUMENT NUMBER: 120:226981

ORIGINAL REFERENCE NO.: 120:40120h,40121a

TITLE: Compositions of oral dissolvable medicaments

INVENTOR(S): Stanley, Theodore H.; Hague, Brian

PATENT ASSIGNEE(S): University of Utah, USA

SOURCE: U.S., 22 pp. Cont.-in-part of U.S. 4,863,737.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5288497	A	19940222	US 1989-403751	19890905 <--
US 4671953	A	19870609	US 1985-729301	19850501 <--
EP 487520	A1	19920603	EP 1989-909497	19890816 <--
EP 487520	B1	19950412		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 05501539	T	19930325	JP 1989-504878	19890816 <--
JP 2801050	B2	19980921		
AU 641127	B2	19930916	AU 1989-40704	19890816 <--
AT 120953	T	19950415	AT 1989-909497	19890816 <--
CA 1338978	C	19970311	CA 1989-609378	19890824 <--
AU 9050352	A	19910408	AU 1990-50352	19890905 <--
AU 645966	B2	19940203		
EP 493380	A1	19920708	EP 1990-902584	19890905 <--
EP 493380	B1	19971029		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 5132114	A	19920721	US 1989-402881	19890905 <--
JP 05501854	T	19930408	JP 1990-502779	19890905 <--
CA 1339075	C	19970729	CA 1989-610329	19890905 <--
AT 159658	T	19971115	AT 1990-902584	19890905 <--
CA 2066423	A1	19910306	CA 1990-2066423	19900803 <--
CA 2066423	C	19980414		
WO 9103237	A1	19910321	WO 1990-US4384	19900803 <--
W: AU, CA, JP, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
AU 9062877	A	19910408	AU 1990-62877	19900803 <--
AU 645265	B2	19940113		
EP 490916	A1	19920624	EP 1990-912733	19900803 <--

EP 490916	B1	19951018		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 05503917	T	19930624	JP 1990-512229	19900803 <--
EP 630647	A1	19941228	EP 1994-111352	19900803 <--
EP 630647	B1	19990303		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
AT 129148	T	19951115	AT 1990-912733	19900803 <--
ES 2077686	T3	19951201	ES 1990-912733	19900803 <--
AT 177007	T	19990315	AT 1994-111352	19900803 <--
ES 2133448	T3	19990916	ES 1994-111352	19900803 <--
NO 9200565	A	19920213	NO 1992-565	19920213 <--
NO 304056	B1	19981019		
DK 9200193	A	19920214	DK 1992-193	19920214 <--
DK 175779	B1	20050214		
NO 9200857	A	19920406	NO 1992-857	19920304 <--
NO 304348	B1	19981207		
NO 9200855	A	19920410	NO 1992-855	19920304 <--
NO 9200854	A	19920427	NO 1992-854	19920304 <--
DK 9200300	A	19920505	DK 1992-300	19920305 <--
DK 175773	B1	20050214		
AU 9455218	A	19940428	AU 1994-55218	19940218 <--
AU 668004	B2	19960418		
AU 9460697	A	19940623	AU 1994-60697	19940427 <--
US 5824334	A	19981020	US 1996-636828	19960419 <--
US 5783207	A	19980721	US 1997-795359	19970204 <--
US 5785989	A	19980728	US 1997-822560	19970319 <--
PRIORITY APPLN. INFO.:			US 1985-729301	A2 19850501
			US 1987-60045	A2 19870608
			EP 1989-909497	A 19890816
			WO 1989-US3518	W 19890816
			US 1989-403751	A 19890905
			WO 1989-US3801	A 19890905
			EP 1990-912733	A3 19900803
			WO 1990-US4384	A 19900803
			US 1993-152396	B1 19931112
			US 1994-333233	B2 19941102
			US 1995-439127	B1 19950511

AB Compns. and methods of manufacture for producing a medicament compn. capable of absorption through the mucosal tissues of the mouth, pharynx, and esophagus are disclosed. The present invention relates to such compns. and methods which are useful in administering lipophilic and nonlipophilic drugs in a dose-to-effect manner that sufficient drug is administered to produce precisely a desired effect. The invention also relates to a manufacturing technique that enables a therapeutic agent or drug to be incorporated into a flavored dissolvable matrix. An appliance or holder is preferably attached to the dissolvable matrix. Employing the present invention the drug may be introduced into the patient's bloodstream almost as fast as through injection, and much faster than using the oral administration route, while avoiding the neg. aspects of both of these methods. The present invention achieves these advantages by incorporating the drug into a carbohydrate, fat, protein, wax, or other dissolvable matrix compn. The dissolvable matrix may include permeation enhancers to increase the drug absorption by the mucosal tissues of the mouth. The matrix compn. may also include pH buffering agents to modify the salivary pH thereby increasing the absorption of the drug through the mucosal tissue. Methohexital sodium was incorporated into a dissolvable matrix including citric acid; ribotide; Comptitol 888; aspartame; vanilla, wild cherry, and peppermint microcapsules; compressible sugar; and maltodextrin.

ACCESSION NUMBER: 2001:279528 CAPLUS
 DOCUMENT NUMBER: 134:300794
 TITLE: Sustained release polymer blend for pharmaceutical applications
 INVENTOR(S): Skinner, George William
 PATENT ASSIGNEE(S): Hercules Inc., USA
 SOURCE: U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 847,842.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6217903	B1	20010417	US 1999-343860	19990630 <--
US 6210710	B1	20010403	US 1997-847842	19970428 <--
NO 9801893	A	19981029	NO 1998-1893	19980427 <--
HU 9800985	A2	19990201	HU 1998-985	19980428 <--
HU 9800985	A3	20000628		

PRIORITY APPLN. INFO.: US 1997-847842 A2 19970428

AB A pharmaceutical compn. has a blend of at least first and second components and a medicament in a sufficient amount to be therapeutic where the first component is Et cellulose (EC) and the second component is at least one other polymer selected from the group consisting of Me cellulose (MC), Et hydroxyethyl cellulose (EHEC), hydroxyethyl Me cellulose (HEMC), hydrophobically modified hydroxyethyl cellulose (HMEHC), hydrophobically modified Et hydroxyethyl cellulose (HMEHEC), carboxymethyl hydroxyethyl cellulose (CMHEC), carboxymethyl hydrophobically modified hydroxyethyl cellulose (CMHMEHC), guar, pectin, carrageenan, agar, algin, gellan gum, acacia, starch and modified starches, mono- and co-polymers of carboxyvinyl monomers, mono- and co-polymers of acrylate or methacrylate monomers, mono- and co-polymers of oxyethylene and oxypropylene and mixts. thereof. The medicament can be a variety of drugs or nutritional supplements. The pharmaceutical compn. releases the medicament for a prolonged or sustained period of time. For example, tablets of a model drug phenylpropanolamine monohydrochloride (PPA) were prepared by blending (a) a wet granulation containing Klucel HXF 37.57 mg, Aqualon CMC 7L2P 112.5 mg, PPA 75 mg, Avicel PH-101 162 mg, and Povidone 12 mg, and (b) a dried/reduced granulation 399 mg, Avicel PH-102 96 mg, and Mg stearate 5 mg.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 14 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2001:850916 CAPLUS
 DOCUMENT NUMBER: 135:376770
 TITLE: Hydrogel composition for transdermal drug delivery
 INVENTOR(S): Kim, Ho Chin; Yoon, Hye Jeong
 PATENT ASSIGNEE(S): Samyang Corporation, S. Korea
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2001087276 A1 20011122 WO 2001-KR783 20010515 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
KR 2002002199 A 20020109 KR 2001-26202 20010514 <--
CA 2409069 A1 20011122 CA 2001-2409069 20010515 <--
CA 2409069 C 20080909
EP 1282408 A1 20030212 EP 2001-977953 20010515 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2003533471 T 20031111 JP 2001-583744 20010515 <--
JP 4091768 B2 20080528
BR 2001010843 A 20031230 BR 2001-10843 20010515 <--
AU 2001295211 B2 20041028 AU 2001-295211 20010515
NZ 522532 A 20050429 NZ 2001-522532 20010515
CN 1239203 C 20060201 CN 2001-809586 20010515
MX 2002PA11174 A 20040819 MX 2002-PA11174 20021113
US 20030170295 A1 20030911 US 2002-276498 20021115 <--
PRIORITY APPLN. INFO.: KR 2000-26091 A 20000516
WO 2001-KR783 W 20010515

AB The present invention relates to a hydrogel compn. for
transdermal drug delivery, more specifically to a hydrogel compn
. for transdermal drug delivery containing acrylate polymers such as
acrylic acid polymer, methacrylic acid polymer, alkyl
acrylate polymer, alkyl methacrylate polymer or
copolymers which enable both hydrophilic and lipophilic permeation
enhancers to be applicable in the hydrogel compn. in order to
effectively control skin penetration of drugs. Thus, a formulation
contained buprenorphine-HCl 2.0, propylene glycol 19.0, triacetin 8.5,
EtOH 14.0, lauryl alc. 0.5, glycerol 4.0, Kollicoat MAE 30D 8.3, water
5.7, hydroxyethyl cellulose 4.0, Kollidon-90 10.0, and PVA 24.0%.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 15 OF 136 CAPLUS COPYRIGHT 2009 ACS on SIN
ACCESSION NUMBER: 2002:971056 CAPLUS
DOCUMENT NUMBER: 138:44441
TITLE: Hair growth stimulant compositions
containing polyethylenimine derivatives and
method for promoting hair growth
INVENTOR(S): Miura, Hiromitsu; Ono, Toshihiko
PATENT ASSIGNEE(S): Kureha Chemical Industry Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002370987	A	20021224	JP 2001-183539	20010618 <--
PRIORITY APPLN. INFO.:			JP 2001-183539	20010618

AB The invention relates to a hair growth stimulant compn. containing
water-soluble polymers and solvent dispersible or dissolvable the

water-soluble polymer, wherein the water-soluble polymer contains polyethylenimine and/or polyethylene imine deriv. A hair growth stimulant compn. containing carrot extract 0.5, dipotassium glycyrrhizinate 0.1, nicotinic acid amide 0.1, pantothenyl Et ether 0.1, l-menthol 0.05, polyethylene imine soln (Epomin P-1000) 6.7, hydroxypropyl Me cellulose 0.5, trehalose 0.5, preservative q.s., ethanol 10, pH adjuster q.s., and water balance to 100 % was prepared

L16 ANSWER 16 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:226984 CAPLUS

DOCUMENT NUMBER: 120:226984

ORIGINAL REFERENCE NO.: 120:40121a,40124a

TITLE: Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments

INVENTOR(S): Stanley, Theodore H.; Hague, Brian

PATENT ASSIGNEE(S): University of Utah Research Foundation, USA

SOURCE: U.S., 20 pp. Cont.-in-part of U.S. 4,863,737.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5288498	A	19940222	US 1989-403752	19890905 <--
US 4671953	A	19870609	US 1985-729301	19850501 <--
EP 487520	A1	19920603	EP 1989-909497	19890816 <--
EP 487520	B1	19950412		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 05501539	T	19930325	JP 1989-504878	19890816 <--
JP 2801050	B2	19980921		
AU 641127	B2	19930916	AU 1989-40704	19890816 <--
AT 120953	T	19950415	AT 1989-909497	19890816 <--
CA 1338978	C	19970311	CA 1989-609378	19890824 <--
AU 9050352	A	19910408	AU 1990-50352	19890905 <--
AU 645966	B2	19940203		
EP 493380	A1	19920708	EP 1990-902584	19890905 <--
EP 493380	B1	19971029		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 5132114	A	19920721	US 1989-402881	19890905 <--
JP 05501854	T	19930408	JP 1990-502779	19890905 <--
CA 1339075	C	19970729	CA 1989-610329	19890905 <--
AT 159658	T	19971115	AT 1990-902584	19890905 <--
CA 2066403	A1	19910306	CA 1990-2066403	19900803 <--
CA 2066403	C	19980414		
WO 9103236	A1	19910321	WO 1990-US4369	19900803 <--
W: AU, CA, JP, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
AU 9063371	A	19910408	AU 1990-63371	19900803 <--
AU 642664	B2	19931028		
EP 490944	A1	19920624	EP 1990-913359	19900803 <--
EP 490944	B1	19960529		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 05500058	T	19930114	JP 1990-512483	19900803 <--
JP 2749198	B2	19980513		
AT 138562	T	19960615	AT 1990-913359	19900803 <--
ES 2089027	T3	19961001	ES 1990-913359	19900803 <--
NO 9200565	A	19920213	NO 1992-565	19920213 <--
NO 304056	B1	19981019		

DK 9200193	A	19920214	DK 1992-193	19920214 <--
DK 175779	B1	20050214		
NO 9200858	A	19920304	NO 1992-858	19920304 <--
NO 9200855	A	19920410	NO 1992-855	19920304 <--
NO 9200854	A	19920427	NO 1992-854	19920304 <--
DK 9200300	A	19920505	DK 1992-300	19920305 <--
DK 175773	B1	20050214		
AU 9460697	A	19940623	AU 1994-60697	19940427 <--
US 5855908	A	19990105	US 1994-339655	19941115 <--

PRIORITY APPLN. INFO.:

			A2	19850501
			A2	19870608
			A	19890816
			W	19890816
			A	19890905
			A	19890905
			A	19900803
			B1	19931112

AB Compns. and methods of manufacture for producing a medicament compn. capable of absorption through the mucosal tissues of the mouth, pharynx, and esophagus are disclosed. The present invention relates to such compns. and methods which are useful in administering lipophilic and nonlipophilic drugs in a dose-to-effect manner such that sufficient drug is administered to produce precisely a desired effect. The invention also relates to manufacturing techniques that enable therapeutic agents to be incorporated into nondissolvable drug containment matrixes which are capable of releasing the drug within a patient's mouth. An appliance or holder is preferably attached to the drug containment matrix. Employing the present invention the drug may be introduced into the patient's bloodstream almost as fast as through injection, and much faster than using the oral administration route, while avoiding the neg. aspects of both of these methods. The nondissolvable drug containment matrix may include permeation enhancers to increase the drug adsorption by the mucosal tissues of the mouth. The matrix compn. may also include pH buffering agents to modify the saliva pH thereby increasing the absorption of the drug through the mucosal tissues. Figures show views of some dosage forms.

L16 ANSWER 17 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:791376 CAPLUS
 DOCUMENT NUMBER: 139:296981
 TITLE: Pharmaceutical formulations containing combinations of epinastine, Belladonna, and pseudoephedrine
 INVENTOR(S): Seko, Noritaka
 PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany
 SOURCE: Eur. Pat. Appl., 22 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1350512	A1	20031008	EP 2002-7568	20020403 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20030228359	A1	20031211	US 2003-396234	20030325 <--
CA 2477751	A1	20031009	CA 2003-2477751	20030328 <--
WO 2003082285	A1	20031009	WO 2003-EP3263	20030328 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003221532 A1 20031013 AU 2003-221532 20030328 <--
 BR 2003008982 A 20050104 BR 2003-8982 20030328
 EP 1492532 A1 20050105 EP 2003-717248 20030328
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2005522467 T 20050728 JP 2003-579822 20030328
 MX 2004PA09582 A 20050111 MX 2004-PA9582 20041001
 PRIORITY APPLN. INFO.: EP 2002-7568 A 20020403
 WO 2003-EP3263 W 20030328

AB Oral pharmaceutical compns. comprise a combination of an antihistaminic-effective amount of epinastine or a salt, an anticholinergic amount of Belladonna alkaloids (Belladonna) or a salt and of a decongestant-effective amount of pseudoephedrine or its salt. Optionally, the formulation may comprise methylephedrine (methylephrine). The formulation further comprises suitable or excipients. Another aspect of the present invention relates to methods for the preparation of these compns. and methods of using them in the treatment of allergic diseases and/or disorders. In particular the inventive compn. is useful in the treatment of seasonal allergic rhinitis and seasonal allergic conjunctivitis. Sustained-release granules contained pseudoephedrine-HCl 42.00, methylephedrine-HCl 42.00, Belladonna 0.21, HPC 4.00, sucrose 66.79, methacrylic acid copolymer 40.60, glycerides 3.10, and talc 1.30 mg.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 18 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:394194 CAPLUS

DOCUMENT NUMBER: 129:58805

ORIGINAL REFERENCE NO.: 129:12121a,12124a

TITLE: Pharmaceutical aerosol compositions and devices comprising fluorocarbon propellants and polyol carriers

INVENTOR(S): McCarthy, Paul; Goodman, Michael; Lindahl, Ake

PATENT ASSIGNEE(S): Bioglan Ireland (R & D) Limited, Ire.; McCarthy, Paul; Goodman, Michael; Lindahl, Ake

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9824420	A1	19980611	WO 1997-GB3360	19971204 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,				

GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
 GN, ML, MR, NE, SN, TD, TG

CA 2273835	A1	19980611	CA 1997-2273835	19971204 <--
AU 9854028	A	19980629	AU 1998-54028	19971204 <--
AU 726510	B2	20001109		
ZA 9710923	A	19980902	ZA 1997-10923	19971204 <--
EP 1011646	A1	20000628	EP 1997-947786	19971204 <--
EP 1011646	B1	20050817		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO

NZ 336049	A	20000929	NZ 1997-336049	19971204 <--
JP 2001505171	T	20010417	JP 1998-525362	19971204 <--
AT 301991	T	20050915	AT 1997-947786	19971204
ES 2244008	T3	20051201	ES 1997-947786	19971204
NO 9902677	A	19990715	NO 1999-2677	19990602 <--
US 6413496	B1	20020702	US 1999-325927	19990604 <--

PRIORITY APPLN. INFO.:

	GB 1996-25171	A	19961204
	GB 1996-26449	A	19961220
	US 1997-913226	B2	19970909
	WO 1997-GB3360	W	19971204

AB A device for providing pharmaceutical doses comprising a container, filled with a pharmaceutical compn. including a pharmaceutically active agent in a soln. of liquefied 1,1,1,2-tetrafluoroethane (HFC-134a), or 1,1,1,2,3,3,3-heptafluoropropane (HFC-227) and a carrier. The carrier can be a pharmaceutically acceptable alc., polyol, (poly)alkoxy deriv., fatty acid alkyl ester, polyalkylene glycol, or DMSO. The device includes valve means arranged for delivering aerosol doses of said pharmaceutical compn. to the exterior of the container, and at least a portion of the device is formed from a polyester. An aerosol device contained beclomethasone dipropionate (I) 0.164, 96% ethanol 4.992, and HFC-134a 94.844%. It expelled dose of the above formulation was .apprx. 25µL and provided 50µg of I. A schematic drawing of the aerosol is depicted.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 19 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2000:456854 CAPLUS
 DOCUMENT NUMBER: 133:79354
 TITLE: Pharmaceutical composition for oral administration designed to prevent misuse at the expense of a third party
 INVENTOR(S): Dufour, Alain; Ahond, Christian
 PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.
 SOURCE: PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038649	A1	20000706	WO 1999-FR3120	19991214 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

FR 2787715 A1 20000630 FR 1998-16309 19981223 <--
FR 2787715 A1 20020510
EP 1140011 A1 20011010 EP 1999-959478 19991214 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: FR 1998-16309 A 19981223
WO 1999-FR3120 W 19991214

AB The invention concerns a pharmaceutical compn. for
oral administration to prevent misuse at the expense of a third party. A
three-layer 260 mg oral tablet containing 15 mg zolpidem
hemitartrate (I) in the active layer was prepared The dissoln. of I was
≥80% after 15 min.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 20 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:151477 CAPLUS

DOCUMENT NUMBER: 136:205406

TITLE: Tablet comprising a delayed release
polymer coating
Seth, Pawan

INVENTOR(S): Pharma Pass L.L.C., USA

PATENT ASSIGNEE(S): U.S., 6 pp.

SOURCE: CODEN: USXXAM
Patent
English

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6350471	B1	20020226	US 2000-584386	20000531 <--

PRIORITY APPLN. INFO.: US 2000-584386 20000531

AB The invention provides a delayed release tablet, comprising: (i)
a core comprising an active ingredient selected from the group consisting
of oxybutynin hydrochloride, propranolol hydrochloride, buspirone
hydrochloride, niacin, cetirizine hydrochloride, cerivastatin sodium,
metoprolol fumarate, and alendronate sodium, and conventional excipients;
and (ii) a coating consisting essentially of a water-insol.,
water-permeable film-forming polymer, e.g., Et cellulose, a
plasticizer, e.g., stearic acid, and a water-soluble polymer, e.g.,
polyvinylpyrrolidone. For example, a metoprolol fumarate delayed-release
tablet was prepared from a core containing metoprolol fumarate 200.00
mg, polyvinylpyrrolidone 10.00 mg, glyceryl behenate 2.00 mg, and water
100.00 mg, and a coating compn. containing Et cellulose 10.00 mg,
hydroxypropyl cellulose 5.00 mg, stearic acid 1.50 mg, and alc. 160.00 mg.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 21 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:740260 CAPLUS

DOCUMENT NUMBER: 126:9479

ORIGINAL REFERENCE NO.: 126:2063a,2066a

TITLE: Environmentally friendly nontoxic water-soluble
cleaning compositions for release of
polymers from surfaces
Sakata, Shigenobu

INVENTOR(S): Japan

PATENT ASSIGNEE(S): Jpn. Kokai Tokkyo Koho, 3 pp.

SOURCE:

DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08239693	A	19960917	JP 1995-81645	19950302 <--
			JP 1995-81645	19950302

PRIORITY APPLN. INFO.:

AB The comps. comprise Na chondroitinsulfate (I), cyclodextrin (II), xanthan gum (III), xylan, xylose, Na pantothenate (IV), Na pyruvate (V), Na erythorbate (VI), 4-isopropyltropone (VII), H₂O, benzyl alc. (VIII), and iso-PrOH and optionally contain monosaccharides, polysaccharides, antioxidants, lactic acids, preservatives, bactericides, secondary alcs., higher alcs., amino alcs., and/or microorganisms. An aqueous soln. containing 70% mixture of I ≤25, xylan 0.1-0.5, xylose 0.1-0.5, glucose 0.1-0.5, III 0.1-0.5, II 1-3, VII 0.01-0.05, IV 1-5, V 1-5, VI 1-5, 10% VIII, and 20% iso-PrOH exhibited good polymer release properties on contacting a polymer coating on a metal surface with the soln. for 5-10 min at room temperature

L16 ANSWER 22 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1990:618234 CAPLUS
 DOCUMENT NUMBER: 113:218234
 ORIGINAL REFERENCE NO.: 113:36753a,36756a
 TITLE: Manufacture of pharmaceutical compositions by continuous dosing of components

INVENTOR(S): Klimesch, Roger; Bleckmann, Gerhard; Schlemmer, Lothar
 PATENT ASSIGNEE(S): BASF A.-G., Fed. Rep. Ger.
 SOURCE: Eur. Pat. Appl., 13 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 337256	A2	19891018	EP 1989-105917	19890405 <--
EP 337256	A3	19910206		
EP 337256	B1	19921119		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
DE 3812567	A1	19891026	DE 1988-3812567	19880415 <--
CA 1338929	C	19970225	CA 1989-595661	19890404 <--
AT 82495	T	19921215	AT 1989-105917	19890405 <--
ES 2036737	T3	19930601	ES 1989-105917	19890405 <--
PRIORITY APPLN. INFO.:			DE 1988-3812567	A 19880415
			EP 1989-105917	A 19890405

AB A method for the manufacture of pharmaceutical comps. by continuous dosing of components is described. N-Vinylpyrrolidone-vinyl acetate (45 parts), stearyl alc. 5, and theophylline 50 parts were mixed and extruded through the funnel of an extruder. The temperature of the extruder mantle was 30-60°. The extruded mass was compressed into tablets.

L16 ANSWER 23 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2000:865097 CAPLUS
 DOCUMENT NUMBER: 134:32988

TITLE: Nasal pharmaceutical composition
for water-soluble drugs
INVENTOR(S): Kloecker, Norbert
PATENT ASSIGNEE(S): Hexal A.-G., Germany
SOURCE: Ger. Offen., 6 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19925289	A1	20001207	DE 1999-19925289	19990602 <--
WO 2000074652	A1	20001214	WO 2000-EP4800	20000526 <--
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1189596	A1	20020327	EP 2000-935121	20000526 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2005505491	T	20050224	JP 2001-501189	20000526
PRIORITY APPLN. INFO.:			DE 1999-19925289	A 19990602
			DE 1999-19936545	A 19990803
			WO 2000-EP4800	W 20000526

AB A pharmaceutical compn. for nasal administration consists of at least a water-soluble drug, neutral oil, and a soln. mediator, in which no preservatives and propellants are present and the compn. is essentially water-free. Thus, polyhexanide was dissolved in Miglyol-840 and the compn. was sterilized and filled into a pump spray.

L16 ANSWER 24 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:374907 CAPLUS
DOCUMENT NUMBER: 122:142588
ORIGINAL REFERENCE NO.: 122:26323a,26326a
TITLE: Controlled-release pharmaceutical compositions based on pharmaceutically acceptable salts of γ -hydroxybutyric acid
INVENTOR(S): Conte, Ubaldo; La Manna, Aldo; Tessitore, Giuseppe
PATENT ASSIGNEE(S): Laboratorio Farmaceutico C.T. S.r.l., Italy
SOURCE: Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 635265	A1	19950125	EP 1994-111279	19940720 <--
EP 635265	B1	20000202		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			
HU 75150	A2	19970428	HU 1994-2077	19940712 <--
AT 189384	T	20000215	AT 1994-111279	19940720 <--
US 5594030	A	19970114	US 1994-278517	19940721 <--

PL 176211	B1	19990531	PL 1994-304389	19940721 <--
RU 2140266	C1	19991027	RU 1994-26104	19940721 <--
JP 07053365	A	19950228	JP 1994-191998	19940722 <--
JP 2930875	B2	19990809		

PRIORITY APPLN. INFO.: IT 1993-MI1631 A 19930722

AB Controlled-release oral pharmaceutical compns. contain as the active principle ≥ 1 GABA salt with a pharmaceutically acceptable cation for treatment of alcoholism, addiction to opiumlike substances, heroin addiction, food and nicotine addiction, depression, and anxiety. The compns. comprise (a) a nucleus in the form of granules or tablets containing an active principle dispersed in a cellulosic matrix, and optionally (b) a protective film coating. Thus, granules were prepared from GABA Na salt 1000, ethylcellulose 50, Methocel K100M 150, talc 60, and Mg stearate 18 mg, pressed into tablets, and coated with a soln. of Eudragit RS100 1.20, Eudragit RL100 4.80, and di-Et phthalate 0.30 g in 100 mL acetone/iso-PROH (50:50).

L16 ANSWER 25 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003/9/1890 CAPLUS
DOCUMENT NUMBER: 140:19874
TITLE: Pulmonary compositions containing buffered liquid nicotine
INVENTOR(S): Warchol, Mark P.; Moren, Folke; Thyresson, Kristina; Sthengel, Elisabeth; Andersson, Sven-boerje
PATENT ASSIGNEE(S): Pharmacia Ab, Swed.
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101454	A1	20031211	WO 2003-SE890	20030530 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2487699	A1	20031211	CA 2003-2487699	20030530 <--
AU 2003243074	A1	20031219	AU 2003-243074	20030530 <--
AU 2003243074	B2	20081120		
EP 1509227	A1	20050302	EP 2003-756140	20030530
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011451	A	20050315	BR 2003-11451	20030530
CN 1658876	A	20050824	CN 2003-812809	20030530
JP 2005533770	T	20051110	JP 2004-508811	20030530
RU 2283111	C2	20060910	RU 2004-139067	20030530
NZ 536863	A	20070531	NZ 2003-536863	20030530
US 20040034068	A1	20040219	US 2003-453808	20030602
MX 2004PA12041	A	20050816	MX 2004-PA12041	20041202
ZA 2004009793	A	20060830	ZA 2004-9793	20041202
PRIORITY APPLN. INFO.:			SE 2002-1669	A 20020603

US 2002-391886P P 20020625
WO 2003-SE890 W 20030530

AB The compn. consists of liquid pharmaceutical formulation comprising nicotine in any form for administration essentially to the lungs. The formulation is acidified and/or alkalinized by buffering and/or pH regulation, which provides a tmax of nicotine in arterial blood of a subject within a short period of time after administration. The administration preferably implies spraying an aerosol into the oral cavity for further distribution, essentially to the lungs. A method for manufacturing the formulation is also included, as well as use of the formulation in therapy, e.g. for treating addiction to tobacco. For example, an acidic oral spray was prepared by mixing 60g 90% ethanol and 9.9g polyethylene propylene glycol with 1g nicotine, then adjusting pH to 3.0 by sulfuric acid.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 26 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1991:566625 CAPLUS

DOCUMENT NUMBER: 115:166625

ORIGINAL REFERENCE NO.: 115:28359a,28362a

TITLE: Sustained-release pharmaceutical tablets

INVENTOR(S): Agrawala, Prafulla; Palepu, Nageswara R.; Boyd, Brian K.

PATENT ASSIGNEE(S): Erbamont, Inc., USA

SOURCE: Can. Pat. Appl., 22 pp.

CODEN: CPXXEB

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2018167	A1	19901208	CA 1990-2018167	19900604 <--
CA 2018167	C	19990323		
US 5002774	A	19910326	US 1989-363038	19890608 <--
PRIORITY APPLN. INFO.:			US 1989-363038	A 19890608

AB A sustained-release tablet for delivering a drug to the gastrointestinal tract comprises, (1) an active pharmaceutical powder, (2) a compression aid agent, (3) water-soluble or water-swellaable hydrophilic polymer, and (4) microcryst. cellulose to enable the active agent to be gradually released in the gastrointestinal tract over a period of time. The compression aid agent can be a mixture of a water-insol. wax material and water-soluble hydrophilic polymer, such as polyethylene glycol. Thus, Mg lactate powder (active agent, 76 parts) was added to a mixture of stearic acid, carnauba wax, and polyethylene glycol (3.2, 3.6, and 2.3 parts, resp.); the whole was again mixed with microcryst. cellulose 7.2, polyethylene glycol 7.2, and Ca stearate 0.5 parts. Tablets produced contained 834.6 mg Mg lactate/each. The tablets had low friability and showed no capping.

L16 ANSWER 27 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:511859 CAPLUS

DOCUMENT NUMBER: 139:90459

TITLE: Use of an immediate-release powder in pharmaceutical and nutraceutical compositions

INVENTOR(S): Besse, Jerome; Besse, Laurence

PATENT ASSIGNEE(S): Fr.
 SOURCE: U.S. Pat. Appl. Publ., 5 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030124191	A1	20030703	US 2002-106923	20020325 <--
FR 2834212	A1	20030704	FR 2001-16934	20011227 <--
FR 2834212	B1	20040709		
CA 2471903	A1	20030710	CA 2002-2471903	20021227 <--
WO 2003055464	A1	20030710	WO 2002-FR4575	20021227 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002364489	A1	20030715	AU 2002-364489	20021227 <--
EP 1458356	A1	20040922	EP 2002-799854	20021227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015380	A	20041207	BR 2002-15380	20021227
JP 2005520799	T	20050714	JP 2003-556042	20021227
HU 2005000509	A2	20050928	HU 2005-509	20021227
RU 2302232	C2	20070710	RU 2004-122919	20021227
MX 2004PA06181	A	20050419	MX 2004-PA6181	20040622
NO 2004003172	A	20040914	NO 2004-3172	20040726
US 20050118272	A1	20050602	US 2005-500213	20050204
PRIORITY APPLN. INFO.:			FR 2001-16934	A 20011227
			WO 2002-FR4575	W 20021227

AB The present invention relates to the use of a powder comprising at least one active substance, at least one surfactant, at least one wetting agent and at least one diluent, for preparing a pharmaceutical or nutraceutical compn., this compn. allowing rapid and immediate release of the active substance. Granules containing phloroglucinol 10, sorbitol 89, and propylene glycol 1% were prepared

L16 ANSWER 28 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:678498 CAPLUS
 DOCUMENT NUMBER: 139:202506
 TITLE: Pharmaceutical composition
 comprising riboflavin 5'-monophosphate and solubilized
 riboflavin
 INVENTOR(S): Grobin, Adam; Hird, Geoffrey; Lambert, Bill; Onai,
 Katsumi; Pullen, Stuart
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 14 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030162751	A1	20030828	US 2001-24877	20011219 <--
PRIORITY APPLN. INFO.:			US 2001-24877	20011219

AB In recognition of the need to facilitate the use of riboflavin as a pharmaceutical and addnl. to increase the efficacy and stability of water soluble forms of riboflavin (that may contain precipitated riboflavin or that are subject to photodegrdn.), the present invention provides solubilized riboflavin, methods for solubilizing riboflavin, kits comprising solubilized riboflavin and provides photostable compns . comprising riboflavin and derivs. A compn. containing riboflavin 5'-phosphate sodium and sucrose was prepared

L16 ANSWER 29 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:730530 CAPLUS

DOCUMENT NUMBER: 135:293950

TITLE: A self-emulsifying system combined with a polymer matrix for transmucosal and transdermal delivery

INVENTOR(S): Hong, Chung Il; Shin, Hee Jong; Ki, Min Hyo; Lee, Seok Kyu; Kweon, Don Sun

PATENT ASSIGNEE(S): Chong Kun Dang Pharmaceutical Corp., S. Korea

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072282	A1	20011004	WO 2001-KR509	20010329 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG KR 2001093728 A 20011029 KR 2001-16140 20010328 <-- US 20030129219 A1 20030710 US 2002-239529 20020923 <-- PRIORITY APPLN. INFO.:				
			KR 2000-16257	A 20000329
			WO 2001-KR509	W 20010329

AB A novel pharmaceutical compn. of a self-emulsifying matrix preparation, which is a preparation for transmucosal or transdermal absorption in which a self-emulsifying drug delivery system is grafted to a polymeric matrix preparation is described. For this, fatty alc., fatty acid or their derivs. of 6 to 20 carbon atoms having a drug absorption-accelerating action through the skin or mucous membrane is used as an oil phase. Also, to increase the drug content in the matrix, a liquid phase material having a b.p. of 100°C or more is used as a soln. adjuvant. Using such materials, the self-emulsifying system with a surfactant is prepared A hydrophilic or hydrophobic polymer is added and dissolved in the self-emulsifying system, and the resulting mixture is dried to prepare the matrix preparation containing the self-emulsifying system. The self-emulsifying matrix preparation thus prepared maintains a constant

drug-releasing rate during its application period by virtue of its excellent stability and exhibits an extraordinarily high skin-absorption rate. For example, a self-emulsifying system was prepared using oleyl alc. 10, glycerin (1) oleic acid ester 10, diethylene glycol monoethyl ether 40, and Cremophor RH40 40 parts, resp., as an oily phase. Upon the addition of water, a self-emulsification was obtained. To 10 g of the self-emulsifying matrix prepared was added 5 g of arecoline monohydrobromide as a drug. Sixty grams of poly(ethylene oxide) was dissolved into 30 g of water and 30 g of ethanol to form a polymer soln. This prepolymer soln. was added to the self-emulsifying system containing the drug to give a transparent viscous soln., which was then dried at 80° for 10 min to form a self-emulsifying matrix with a thickness of 505 µm. During the process of drying, UV ray may be irradiated for 5 min, if necessary.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 30 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1969:78737 CAPLUS

DOCUMENT NUMBER: 70:78737

ORIGINAL REFERENCE NO.: 70:14721a,14724a

TITLE: High-molecular-weight polymeric inhibitors for serum complement fixation

INVENTOR(S): Lauenstein, Karl; Pieper, Gustav; Resz, Raoul; Bayer, Otto

PATENT ASSIGNEE(S): Farbenfabriken Bayer A.-G.

SOURCE: S. African, 14 pp.

CODEN: SFXAB

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ZA 6802514		19680918	ZA	19680419 <--

AB Polymeric esters from poly(vinyl alc.) and nicotinic acid or isonicotinic acid are oxidized with hydrogen superoxide (I) yielding compns. useful as inhibitors for serum complement fixation. Thus, 170 g. of a poly(vinyl nicotinate) prepared from poly(vinyl alc.) by esterification with nicotinoyl chloride in pyridine was dissolved in 1 l. HOAc and oxidized at 60° for 20 hrs. with 250 cc. 30% I. The soln. was subsequently dialyzed 72 hrs. under running tap water to remove HOAc and I, and the poly-N-oxide precipitated with acetone after the addition of 20 cc. concentrated HCl. The initially tacky precipitate was comminuted with fresh acetone and, after drying, was a colorless powder which was readily soluble in water (172 g. yield). By adding to the powder the amount of NaHCO3 required for neutralizing the HCl, the pH value in the aqueous soln. was adjusted to 7. Since the preparation as a whole was not satisfactory in the immune-biol. test, the aqueous soln. acidified with HCl was precipitated by the portion-wise addition of acetone. The values of the fractions indicated that the effect was rapidly reduced below a mol. weight of .apprx.30,000. The fractionation was simplified by adding the total amount of acetone required for the precipitation of the 90,000 to 74,000 mol. weight fractions in 1 portion and isolating the materials thus precipitated

L16 ANSWER 31 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:988109 CAPLUS
 DOCUMENT NUMBER: 124:37704
 ORIGINAL REFERENCE NO.: 124:7009a,7012a
 TITLE: Use of fatty acid esters as bioadhesive substances
 INVENTOR(S): Hansen, Jens; Sylvest Nielsen, Lise; Norling, Tomas
 PATENT ASSIGNEE(S): A/S Dumex, Den.
 SOURCE: PCT Int. Appl., 117 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9526715	A2	19951012	WO 1995-DK143	19950329 <--
WO 9526715	A3	19951116		
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2186750	A1	19951012	CA 1995-2186750	19950329 <--
CA 2186750	C	20080805		
AU 9522550	A	19951023	AU 1995-22550	19950329 <--
AU 685262	B2	19980115		
EP 752855	A1	19970115	EP 1995-915817	19950329 <--
EP 752855	B1	19990609		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09510980	T	19971104	JP 1995-525360	19950329 <--
JP 4137179	B2	20080820		
AT 180971	T	19990615	AT 1995-915817	19950329 <--
ES 2135723	T3	19991101	ES 1995-915817	19950329 <--
FI 9603867	A	19961127	FI 1996-3867	19960927 <--
NO 9604113	A	19961127	NO 1996-4113	19960927 <--
PRIORITY APPLN. INFO.:				
			DK 1994-370	A 19940330
			WO 1995-DK143	W 19950329
AB The fatty acid esters as bioadhesive substances have mol. wts. < 1000 dalton and the fatty acid component of the fatty acid ester is a saturated or unsatd. fatty acid having a total number of carbon atoms of C8-22. Particularly suitable fatty acid esters for use according to the invention are esters of polyhydric alcs., hydroxycarboxylic acids, monosaccharides, glycerylphosphate derivs., glycerylsulfate deriv., and mixts. thereof. Excellent bioadhesive properties have been observed for fatty acid esters of glyceryl monooleate, glyceryl monolinoleate or glyceryl monolinolenate. Methods are described for administering an active or protective substance to undamaged or damaged skin or mucosa of an animal such as a human by combining the active or protective substance with a bioadhesive fatty acid ester. The mucosa may be the oral, aural, nasal, lung, gastrointestinal, vaginal, or rectal mucosa. The administration may also be to body cavities such as the oral cavity, e.g. via buccal administration. Glyceryl monooleate (GMO) 48 was mixed with ethanol 32 and lidocaine-HCl 20 g, resp., and tested for bioadhesiveness. A residual amount of .apprx.71% weight/weight GMO was found after testing.				

L16 ANSWER 32 OF 136 CAPLUS COPYRIGHT 2009 ACS on STM
 ACCESSION NUMBER: 2008:253585 CAPLUS
 DOCUMENT NUMBER: 148:269477
 TITLE: Film product containing a drug and saccharide- and nonsaccharide-based polymer

INVENTOR(S): Myers, Garry L.; Fuisz, Richard C.
PATENT ASSIGNEE(S): Monosolrx, Lic., USA
SOURCE: U.S. Pat. Appl. Publ., 30pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 17

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080050422	A1	20080228	US 2006-526996	20060926
US 7425292	B2	20080916	US 2002-74272	20020214 <--
US 20030107149	A1	20030612		
WO 2008039737	A2	20080403	WO 2007-US79357	20070925
WO 2008039737	A3	20080522		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.:
US 2001-328868P P 20011012
US 2002-74272 A2 20020214
US 2006-526996 A 20060926

AB The invention relates to a fast-dissolving film product containing at least one drug; and a water soluble polymer compn. comprising a saccharide- and nonsaccharide-based polymer and sugar alc. The invention further relates to methods of administering the film product. The method includes administering the film to the oral cavity of a subject in need of the drug; and administering a fluid in the oral cavity while the film is present therein to substantially dissolve the film and form a soln. or dispersion thereof to be ingested by the subject. Desirably, ingestion of the thus-formed soln. or dispersion provides increased blood levels of the drug as compared to the film taken without the fluid. E.g., films were prepared containing PEG in combination with PVP, CM cellulose, HPMC, or hydroxypropyl cellulose.

L16 ANSWER 33 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:462814 CAPLUS

DOCUMENT NUMBER: 141:17635

TITLE: Method of treating neurological diseases and etiologically related symptomatology using carbonyl trapping agents in combination with medicaments

INVENTOR(S): Shapiro, Howard K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S., 33 pp., Cont.-in-part of U.S. Ser. No. 883,290, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6746678	B1	20040608	US 2000-545870	20000406
US 5668117	A	19970916	US 1993-62201	19930629 <--
PRIORITY APPLN. INFO.:			US 1991-660561	B1 19910222
			US 1993-26617	B2 19930223
			US 1993-62201	A2 19930629
			US 1997-883290	B2 19970626

OTHER SOURCE(S): MARPAT 141:17635

AB The invention discloses a method for treatment of several neurol. diseases and pathophysiol. related symptomol., the diseases including peripheral neuropathies, secondary symptomol. of diabetes, Alzheimer's disease, Parkinson's disease, alc. polyneuropathy and age-onset symptomol., as well as analogous veterinary disease states. An opportunity exists for pharmacol. intervention in some neurol. diseases by use of water-soluble, small-mol.-weight primary amine agents and chemical derivs. thereof. Examples of such primary pharmacol. agents include 4-aminobenzoic acid and derivs. thereof. The invention also includes: (1) oral use of optional nonabsorbable polyamine polymeric co-agents, e.g. chitosan, (2) oral use of optional known antioxidant co-agents and related nutritional factors, and (3) use of the primary agents and above co-agents in optional combination with medicaments recognized as effective for treatment of the diseases addressed herein or symptoms thereof.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 34 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1987:125907 CAPLUS

DOCUMENT NUMBER: 106:125907

ORIGINAL REFERENCE NO.: 106:20465a,20468a

TITLE: Pharmaceutical transdermal gels containing poly(vinyl alcohol) and an absorption accelerator
 INVENTOR(S): Sato, Susumu; Matsumoto, Kenji; Sakai, Isoji; So, Isao
 PATENT ASSIGNEE(S): Nitto Electric Industrial Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61277613	A	19861208	JP 1985-119254	19850531 <--
PRIORITY APPLN. INFO.:			JP 1985-119254	19850531

AB Pharmaceutical transdermal gels contain a sulfoxide as absorption accelerator, poly(vinyl alc.) as the base, a drug, and at least one organic liquid additive selected from the group consisting of C8-22 alcs., C5-30 hydrocarbons, C11-26 alc. aliphatic carboxylates, C10-24 mono- or di-ethers, C11-15 ketones, C5-20 alc. 2-pyrrolidone carboxylates, and C4-20 alc. nicotinates. Pharmaceuticals are rapidly absorbed by the skin from the gels. Thus, 31.6 g poly(vinyl alc.) powder was dissolved in 90 g dimethylsulfoxide at 80°, and 9 g lauryl alc. and 1.3 g hydrocortisone acetate were added. The mixture was made into a 2 mm-thick tape.

L16 ANSWER 35 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:553395 CAPLUS

DOCUMENT NUMBER: 133:155456

TITLE: Topical sprays containing film-forming polymers
 INVENTOR(S): Lulla, Amar; Malhotra, Geena; Raut, Preeti
 PATENT ASSIGNEE(S): Cipla Limited, India
 SOURCE: PCT Int. Appl., 25 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000045795	A2	20000810	WO 2000-GB366	20000207 <--
WO 2000045795	A3	20010809		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
IN 186668	A1	20011020	IN 1999-BO93	19990205 <--
IN 1999BO00092	A	20050318	IN 1999-BO92	19990205
IN 1999BO00382	A	20050318	IN 1999-BO382	19990520
IN 1999BO00582	A	20051230	IN 1999-BO582	19990817
CA 2359640	A1	20000810	CA 2000-2359640	20000207 <--
CA 2359640	C	20081118		
AU 2000024472	A	20000825	AU 2000-24472	20000207 <--
AU 759515	B2	20030417		
BR 2000007997	A	20011030	BR 2000-7997	20000207 <--
EP 1150661	A2	20011107	EP 2000-902727	20000207 <--
EP 1150661	B1	20031022		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
HU 2001005336	A2	20020629	HU 2001-5336	20000207 <--
HU 2001005336	A3	20040628		
JP 2002536319	T	20021029	JP 2000-596915	20000207 <--
NZ 513208	A	20030530	NZ 2000-513208	20000207 <--
AT 252380	T	20031115	AT 2000-902727	20000207 <--
PT 1150661	T	20040227	PT 2000-902727	20000207
ES 2209812	T3	20040701	ES 2000-902727	20000207
PL 196413	B1	20071231	PL 2000-350186	20000207
RO 121628	B1	20080130	RO 2001-893	20000207
US 6962691	B1	20051108	US 2000-503843	20000215
ZA 2000005727	A	20001221	ZA 2000-5727	20001017 <--
NO 2001003815	A	20011002	NO 2001-3815	20010803 <--
HK 1042043	A1	20040408	HK 2002-103295	20020502
US 20040213744	A1	20041028	US 2003-686517	20031016
PRIORITY APPLN. INFO.:			IN 1999-BO92	A 19990205
			IN 1999-BO93	A 19990205
			IN 1999-BO382	A 19990520
			IN 1999-BO582	A 19990817
			WO 1999-GB2998	A 19990909
			IN 2000-MU43	A 20000113
			IN 2000-MU44	A 20000113
			WO 2000-GB366	W 20000207
			US 2000-503843	A1 20000215

AB A topical, medicinal spray compn. comprises one or more medicaments in a volatile vehicle, and one or more film-forming

polymers. When sprayed on a topical site, the compn. forms a stable, breathable film from which the medicaments are transdermally available. Preferably, the compn. comprises 0.1-30 % of one or more medicaments, 0.1-15 % film-forming polymers, 0.1-10 % solubilizers, 0.1-8 % permeation enhancers, 1.0-10 % plasticizers, and a vehicle q.s. 100 %. The invention includes a spray dispenser containing the topical compn. An aerosol contained estradiol 2, PVP K-30 6, vinylacetate-vinylpyrrolidone copolymer 4, vitamin E 1, polyethylene glycol-6000 2, polyethylene glycol 3, dichlorodifluoromethane 24.9, and trichloromonofluoromethane 57.1 %.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 36 OF 136 CAPLUS COPYRIGHT 2009 ACS on SIN

ACCESSION NUMBER: 2002:185616 CAPLUS

DOCUMENT NUMBER: 136:252482

TITLE: Preparation of aqueous clear solution dosage forms with bile acids

INVENTOR(S): Yoo, Seo Hong

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 35 pp., Cont.--in-part of U. S. 6,251,428.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020031558	A1	20020314	US 2001-778154	20010205 <--
US 7303768	B2	20071204		
US 6251428	B1	20010626	US 1999-357549	19990720 <--
US 20030186933	A1	20031002	US 2002-309603	20021204 <--
US 7166299	B2	20070123		
US 20050158408	A1	20050721	US 2004-996945	20041124
AU 2004325203	A1	20060601	AU 2004-325203	20041124
CA 2588168	A1	20060601	CA 2004-2588168	20041124
EP 1819318	A1	20070822	EP 2004-812094	20041124
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 10065110	A	20071031	CN 2004-80044467	20041124
BR 2004019213	A	20071218	BR 2004-19213	20041124
JP 2008521800	T	20080626	JP 2007-543006	20041124
AU 2006203315	A1	20060824	AU 2006-203315	20060803
AU 2006203315	B2	20080828		
US 20070072828	A1	20070329	US 2006-522162	20060915
IN 2007CN02532	A	20070907	IN 2007-CN2532	20070612
KR 2007098821	A	20071005	KR 2007-714361	20070622
US 20080057133	A1	20080306	US 2007-934505	20071102
PRIORITY APPLN. INFO.:				
			US 1998-94069P	P 19980724
			US 1999-357549	A2 19990720
			US 2000-180268P	P 20000204
			AU 2001-236685	A3 20010205
			US 2001-778154	A3 20010205
			US 2004-996945	A2 20041124
			WO 2004-US39507	A 20041124

AB Compns. for pharmaceutical and other uses comprise clear aqueous solns. of bile acids which do not form any detectable ppts. over selected ranges of pH values of the aqueous soln. The compns. comprise (i) water, (ii) a bile acid component in the form

of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and (iii) either or both an aqueous soluble starch conversion product and an aqueous soluble non-starch polysaccharide. The compn. remains in soln. without forming a precipitate over a range of pH values and, according to one embodiment, remains in soln. for all pH values obtainable in an aqueous system. The compn. may further contain a pharmaceutical compound, such as insulin, heparin, bismuth compds., amantadine and rimantadine. For example, soln. dosage forms that did not show any precipitation at any pH were prepared containing ursodeoxycholic acid (UDCA) 22 g, 1N NaOH 75 mL, chenodeoxycholic acid (CDCA) 3 g, maltodextrin 875 g, bismuth citrate 4 g, citric acid or lactic acid as needed, and purified water to make 1 L.

REFERENCE COUNT: 211 THERE ARE 211 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 37 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1992:181165 CAPLUS
DOCUMENT NUMBER: 116:181165
ORIGINAL REFERENCE NO.: 116:30529a, 30532a
TITLE: Oral osmotic device for delivering nicotine
INVENTOR(S): Place, Virgil A.; Wong, Patric S. L.; Barclay, Brian L.; Childers, Jerry D.
PATENT ASSIGNEE(S): Alza Corp., USA
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9201445	A1	19920206	WO 1991-US5089	19910718 <--
W: AU, FI, JP, KR, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 9182924	A	19920218	AU 1991-82924	19910718 <--
AU 652952	B2	19940915		
ZA 9105648	A	19920527	ZA 1991-5648	19910718 <--
EP 540623	A1	19930512	EP 1991-913859	19910718 <--
EP 540623	B1	19940914		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 06502622	T	19940324	JP 1991-512955	19910718 <--
ES 2064117	T3	19950116	ES 1991-913859	19910718 <--
CA 2047418	A1	19920124	CA 1991-2047418	19910719 <--
US 5147654	A	19920915	US 1991-793058	19911115 <--
NO 9300134	A	19930121	NO 1993-134	19930115 <--
PRIORITY APPLN. INFO.:			US 1990-557434	A 19900723
			WO 1991-US5089	A 19910718

AB An osmotic device for controlled systemic delivery of nicotine (I) through oral mucosal membrane is disclosed. The device is easily retained in the mouth for extended periods of time. The device comprises a semipermeable wall surrounding a compartment containing a I salt and an alkali metal salt which is capable of reacting with the nicotine salt in the presence of water to form I base. I base is delivered from the compartment through a passageway in the wall. The I salt exhibits good stability and shelf life, while the I base exhibits excellent absorption through oral mucosal membranes. I bitartrate 0.73, Na2CO3 1.50, poly(ethylene oxide) (II) 83.27, HPMC 5.00, Na saccharin 3.00 g and flavors q.s. were mixed and pressed to form a I layer. II 64.5, NaCl 29.0, HPMC 5.0, Mg stearate 0.5 g, and colors q.s. wa pressed to form a

layer in contact with the I layer. The semipermeable walls for bilayer 250 mg tablets was made by blending a soln. containing 78.0 g cellulose acetate in 3550 mL acetone with 320 mL water and 31.2 g PEG, 13.0 g sorbitol, 2.6 g Na saccharin, and flavors q.s. The tablets were coated with the above soln., dried, and two passageways were drilled through the semipermeable wall on the side of the coated tablet adjacent the I layer.

L16 ANSWER 38 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1985:459328 CAPLUS
DOCUMENT NUMBER: 103:59328
ORIGINAL REFERENCE NO.: 103:9493a,9496a
TITLE: Pharmaceutical composition with delayed action for topical use
INVENTOR(S): Carrasco Yufera, Emilio
PATENT ASSIGNEE(S): Industrial Farmaceutica de Levante S. A., Spain
SOURCE: Span., 19 pp.
CODEN: SPXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ES 518878	A1	19840301	ES 1983-518878	19830110 <--
PRIORITY APPLN. INFO.:			ES 1983-518878	19830110

AB Several examples are given for preparing delayed-release topical formulations which can be applied to the skin in the form of laminates retained by an adhesive, elastic band, etc. The manufacturing procedure involves free radical polymn. of monomers such as tetrafluoroethylene, vinylidene chloride, acrylonitrile, etc.; with incorporation of a plasticizer such as poly(vinyl alc.) [9002-89-5], and polymn. initiators. The mixture is heated in an atmospheric of N, the catalyst removed, and a polyhydroxylated agent (cellulose [9004-34-6], glucose [50-99-7], etc.) containing the drug (dexamethasone [50-02-2], benzoic acid [65-85-0], nitroglycerin [55-63-0], methyl salicylate [119-36-8]). Bioavailability studies in patients with the nitroglycerin formulation are described.

L16 ANSWER 39 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:150458 CAPLUS
DOCUMENT NUMBER: 146:212873
TITLE: Bioadhesive progressive hydration tablets
INVENTOR(S): Levine, Howard L.; Bologna, William J.; De Ziegler, Dominique
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 41pp., Cont.-in-part of U.S. Ser. No. 778,151.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070031491	A1	20070208	US 2006-431611	20060511
US 6126959	A	20001003	US 1998-145172	19980901 <--
CN 1246369	A	20000308	CN 1998-117463	19980902 <--
EP 1356806	A1	20031029	EP 2003-11701	19980908 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, LT, LV, FI, RO, CY

ZA 9808328	A	19990223	ZA 1998-8328	19980911 <--
US 6248358	B1	20010619	US 1999-379310	19990823 <--
CN 1879608	A	20061220	CN 2005-10137594	19990824
ZA 9905445	A	20001127	ZA 1999-5445	19990825 <--
US 20020012677	A1	20020131	US 2000-510527	20000222 <--
US 6699494	B2	20040302		
US 20020044964	A1	20020418	US 2001-877218	20010611 <--
US 6624200	B2	20030923		
AU 2003200753	A1	20030501	AU 2003-200753	20030228 <--
US 20040001887	A1	20040101	US 2003-421840	20030424
US 7153845	B2	20061226		
US 20040234606	A1	20041125	US 2004-778151	20040217

PRIORITY APPLN. INFO.:

US 1997-58789P	P	19970912
US 1998-97843P	P	19980825
US 1998-145172	A3	19980901
US 1999-379310	A2	19990823
US 2000-510527	A2	20000222
US 2000-596073	B2	20000616
US 2001-877218	A2	20010611
US 2002-376545P	P	20020501
US 2003-421840	A2	20030424
US 2004-778151	A2	20040217
EP 1998-943548	A3	19980908
AU 1999-55826	A3	19990824
CN 1999-812200	A3	19990824

AB A bioadhesive controlled, extended release progressive hydration compn. wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process, as necessary or desired, and more importantly may be protected from moisture and the immediate septic environment until well after the patient has applied the compn., and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the compn. is available for absorption (bioavailable).

L16 ANSWER 40 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1992:46338 CAPLUS

DOCUMENT NUMBER: 116:46338

ORIGINAL REFERENCE NO.: 116:7893a,7896a

TITLE: Flexible and durable pharmaceutical transdermal tapes

INVENTOR(S): Hidaka, Osafumi; Murakami, Satoshi

PATENT ASSIGNEE(S): Teyson Pharmaceuticals Co., Ltd., Japan; Teijin Ltd.

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9116044	A1	19911031	WO 1991-JP541	19910423 <--
W: AU, CA, JP, KR, US				

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, NL, SE
 AU 9176582 A 19911111 AU 1991-76582 19910423 <--
 AU 637496 B2 19930527
 EP 484543 A1 19920513 EP 1991-908477 19910423 <--
 EP 484543 B1 19951213
 R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE
 AT 131384 T 19951215 AT 1991-908477 19910423 <--
 JP 2505674 B2 19960612 JP 1991-507553 19910423 <--
 PRIORITY APPLN. INFO.: JP 1990-106442 A 19900424
 JP 1990-187094 A 19900717
 JP 1990-202408 A 19900801
 JP 1990-202409 A 19900801
 WO 1991-JP541 A 19910423

AB A pharmaceutical transdermal tape is prepared which is durable and flexible, releasing the drug readily into the skin without causing skin irritation. It consists of a polyester film, an acrylic polymer as adhesive, and a drug such as isosorbide nitrate, nitroglycerin, buprenorphine, estradiol, progesterone, ketotifen, vinpocetin, and nicotine. For example, 8.8 parts progesterone was mixed with an adhesive soln. (500 parts) containing 2-ethylhexyl acrylate-methacrylic acid-polyethylene glycol dimethacrylate copolymer, and the mixture was spread over a silicone-coated removable film. The side of the adhesive layer was laminated with a woven fabric prepared with synthetic fibers of di-Me terephthalate-ethylene glycol-Na 3,5-bis(carbomethoxy)benzenesulfonate copolymer to give a transdermal tape.

L16 ANSWER 41 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1981:109080 CAPLUS
 DOCUMENT NUMBER: 94:109080
 ORIGINAL REFERENCE NO.: 94:17735a,17738a
 TITLE: Cosmetic products containing nicotines
 INVENTOR(S): Szego, Ferenc; Makk, Antal
 PATENT ASSIGNEE(S): Ferrokemia Ipari Szovetkezet, Hung.
 SOURCE: Belg., 16 pp.
 CODEN: BEXXAL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 881494	A1	19800801	BE 1980-9707	19800201 <--
HU 28961	A2	19840130	HU 1979-FE1046	19790601 <--
HU 184626	B	19840928		
NO 8000039	A	19801202	NO 1980-39	19800108 <--
NO 152773	B	19850812		
NO 152773	C	19851120		
SE 8000131	A	19801202	SE 1980-131	19800108 <--
IL 59100	A	19840229	IL 1980-59100	19800109 <--
CA 1150152	A1	19830719	CA 1980-343518	19800111 <--
AU 545868	A	19801204	AU 1980-54586	19800114 <--
AU 531858	B2	19830908		
DK 8000205	A	19801202	DK 1980-205	19800117 <--
FI 8000155	A	19801202	FI 1980-155	19800118 <--
GB 2049419	A	19801231	GB 1980-1794	19800118 <--
GB 2049419	B	19840307		
US 4329338	A	19820511	US 1980-114425	19800122 <--
NL 8000446	A	19801203	NL 1980-446	19800124 <--
FR 2457684	A1	19801226	FR 1980-2070	19800131 <--

CH 644263 A5 19840731 CH 1980-1389 19800221 <--
 DE 3014045 A1 19801211 DE 1980-3014045 19800411 <--
 JP 56018909 A 19810223 JP 1980-60815 19800509 <--
 PRIORITY APPLN. INFO.: HU 1979-FE1046 A 19790601

OTHER SOURCE(S): MARPAT 94:109080

AB Shampoos, liniments for stimulating hair, rheumatic ointments, and dentifrices with improved storage stability were prepared containing derivs. of nicotinic acid (I) with polyhydroxy compds. These derivs. were prepared by treating I or its salts with a polyhydroxy compound, e.g. glucose [50-99-7], mannitol [69-65-8], glycol, etc. Thus, 0.1 mol glucose was treated with 0.05 mol nicotinoyl chloride [10400-19-8] in presence of Na2CO3 to give glucose mononicotinate (II) [53831-21-3]. A hair stimulating liniment was prepared containing II 1, propylene glycol mononicotinate [76601-43-9] 1, iso-PROH 50, perfume, sorbitol 0.5, and chamomile to 100 parts.

L16 ANSWER 42 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:643945 CAPLUS

DOCUMENT NUMBER: 125:284927

ORIGINAL REFERENCE NO.: 125:53121a, 53124a

TITLE: A process for the preparation of an emulsion network for a transdermal drug delivery system

INVENTOR(S): Yuk, Soonhong; Cho, Sunhang; Lee, Haibang

PATENT ASSIGNEE(S): Korea Research Institute of Chemical Technology, S. Korea

SOURCE: PCT Int. Appl., 17 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9625923	A1	19960829	WO 1996-KR26	19960222 <--
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
KR 159145	B1	19981201	KR 1995-3712	19950224 <--
PRIORITY APPLN. INFO.:			KR 1995-3712	A 19950224

AB A process for the preparation of an emulsion network for a transdermal drug delivery system comprises the steps of mixing a polymer (or monomer) aqueous soln. with oil using a homogenizer to produce an emulsion soln., adding drugs and additives to the emulsion soln., solidifying the emulsion soln. by the process of adding metal ions, cooling, irradiating ultra violet rays based on the polymer used and shaping the solidified emulsion soln. applicable to the use thereof. A soln. of 4% sodium alginate 30, coconut oil 20, and nicotine (I) 10 parts were mixed and homogenized, then the soln. was cast on a glass panel, dried and treated with calcium chloride and solidified. The emulsion network was shaped to a disk-like form by a punch having 1 cm of radius. The transdermal system showed a constant I release pattern over 12 h.

L16 ANSWER 43 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1976:499130 CAPLUS

DOCUMENT NUMBER: 85:99130

ORIGINAL REFERENCE NO.: 85:15827a, 15830a

TITLE: Vinyl acetate/crotonic acid copolymer as a dry binder for tablet manufacture by direct compression

AUTHOR(S): El-Khawas, F. M.; Abd el-Khalek, M. M.; El-Rashedy, R. M.

CORPORATE SOURCE: Fac. Pharm., Univ. Alexandria, Alexandria, Egypt
SOURCE: Pharmazeutische Industrie (1976), 38(7),
648-52
CODEN: PHINAN; ISSN: 0031-711X

DOCUMENT TYPE: Journal
LANGUAGE: English

AB A comparison of vinyl acetate-crotonic acid copolymer (C.A. 14)(I) [25609-89-6] and polyethylene glycol (PEG 6000) [25322-68-3] as binders for direct compression of tablets of 19 model drugs showed that I has little influence whereas PEG 6000 significantly improves powder flowability. PEG 6000 gave tablets with less hardness than I in 5% concentration and PEG 6000 tablets friability were not of reasonable stds. whereas I tablets gave much better results. Tablets prepared with PEG 6000 disintegrate in a much shorter time than those containing I. The presence of I leads to a slight dissoln. retardation as compared to PEG, the effect depending on the active ingredient. Thus, I could be considered a good tablet binder.

L16 ANSWER 44 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1988:534913 CAPLUS
DOCUMENT NUMBER: 109:134913

ORIGINAL REFERENCE NO.: 109:22385a,22388a

TITLE: Nicotine skin penetration characteristics
using aqueous and nonaqueous vehicles, anionic
polymers, and silicone matrixes

AUTHOR(S): Aungst, Bruce J.

CORPORATE SOURCE: Med. Prod. Dep., DuPont Co., Wilmington, DE, 19898,
USA

SOURCE: Drug Development and Industrial Pharmacy (1988
, 14(11), 1481-94

CODEN: DDIPD8; ISSN: 0363-9045

DOCUMENT TYPE: Journal
LANGUAGE: English

AB Nicotine is a rational candidate for transdermal delivery for smoking withdrawal. In vitro expts. were performed to characterize nicotine skin penetration and some factors affecting skin penetration. These included pH, nonaq. solvents, and anionic polymers. Nicotine penetrated skin rapidly, and fairly high doses can be delivered transdermally. A 30% aqueous soln. vehicle, as administered transdermally in clin. trials, produced very rapid initial absorption but the absorption rate decreased with time. Because nicotine has such high skin permeability, one objective in developing a delivery system would be to control the delivery rate, rather than allowing skin permeability to be rate-limiting. A feasible approach to a rate-controlled delivery system was to use vulcanized poly(dimethyl siloxane) as a monolithic matrix.

L16 ANSWER 45 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1991:566614 CAPLUS
DOCUMENT NUMBER: 115:166614

ORIGINAL REFERENCE NO.: 115:28359a,28362a

TITLE: Oral osmotic device with hydrogel driving member

INVENTOR(S): Barclay, Brian L.; Childers, Jerry D.; Wright, Jeri;
Place, Virgil A.; Wong, Patrick S. L.

PATENT ASSIGNEE(S): Alza Corp., USA

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9101130	A1	19910207	WO 1990-US3882	19900711 <--
W: AU, FI, JP, KR, NO, US				
RU: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
AU 9060476	A	19910222	AU 1990-60476	19900711 <--
AU 633340	B2	19930128		
EP 482075	A1	19920429	EP 1990-911340	19900711 <--
EP 482075	B1	19940504		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 05502215	T	19930422	JP 1990-510587	19900711 <--
AT 105182	T	19940515	AT 1990-911340	19900711 <--
ES 2052263	T3	19940701	ES 1990-911340	19900711 <--
CA 2020955	C	20001031	CA 1990-2020955	19900711 <--
US 5053032	A	19911001	US 1990-633590	19901221 <--
NO 9105043	A	19920113	NO 1991-5043	19911220 <--
US 5776493	A	19980707	US 1993-171875	19931222 <--
US 5869096	A	19990209	US 1994-353568	19941209 <--

PRIORITY APPLN. INFO.:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 1989-380229	A2	19890714		
EP 1990-911340	A	19900711		
WO 1990-US3882	A	19900711		
US 1992-781234	B1	19920107		
US 1993-171875	A1	19931222		

AB An osmotic device (tablet) for delivering a drug into the oral cavity of a patient for an extended period is disclosed. The device comprises (1) a semipermeable wall surrounding a compartment containing a drug, and (2) a layer of a water-swellaable hydrophilic polymer. Passageways in the wall connect the drug compartment with the exterior of the tablet. The wall is permeable to aqueous fluid (saliva) but impermeable to the polymer. Means are provided for displaying the amount of drug remaining to be delivered.

L16 ANSWER 46 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:708579 CAPLUS

DOCUMENT NUMBER: 131:327309

TITLE: Lathering surfactants in cleansing compositions for skin and/or hair which also deposits skin care actives

INVENTOR(S): Albacarys, Lourdes Dessus; McAtee, David Michael; Deckner, George Endel

PATENT ASSIGNEE(S): Procter + Gamble Co., USA

SOURCE: PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9955303	A1	19991104	WO 1999-IB635	19990412 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2332948	A1	19991104	CA 1999-2332948	19990412 <--

AU 9929524	A	19991116	AU 1999-29524	19990412 <--
AU 756691	B2	20030123		
BR 9909629	A	20001219	BR 1999-9629	19990412 <--
EP 1071396	A1	20010131	EP 1999-910615	19990412 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002512944	T	20020508	JP 2000-545503	19990412 <--
CN 1198581	C	20050427	CN 1999-805418	19990412
MX 2000PA10386	A	20010731	MX 2000-PA10386	20001023 <--
PRIORITY APPLN. INFO.:			US 1998-83015P	P 19980424
			WO 1999-IB635	W 19990412

AB The present invention relates to a substantially dry, disposable, personal cleansing article useful for both cleansing the skin or hair and delivering skin care actives onto the skin or hair. These articles are used by the consumer by (i) wetting the dry article with water and (ii) generating lather by subjecting the wetted article to mech. forces, e.g., rubbing. The article comprises a water insol. substrate, a lathering surfactant, and a skin care active component. Preferably, the articles of the present invention further comprise a deposition aid and/or a conditioning component. E.g., a surfactant phase was prepared by dissolving hydroxyethyl cellulose 0.25% and guar gum 0.25% in water (to 100% by weight) and then adding the following ingredients: Na lauroyl sarcosinate 3.33, cocamidopropyl betaine 3.33, decyl polyglucoside 3.33, Me paraben 0.25, phenoxyethanol 0.3, and benzyl alc. 0.3%, resp.. At the end, a 1.5-2.5 g of the mixture containing water 2.0 g, butylene glycol 2.0 g, and Pr paraben 0.15 g was added to the first mixture and dried. A skin care active phase was prepared containing SEFA cottonate 43.0, petrolatum 10.00, tribehenin 5.0, polyethylene wax 9.0, synthetic beeswax 3.0, C10-30 cholesterol/lanosterol esters 23.0, vitamin A acetate 2.0, and TiO2 5.0 parts. A 0.05-0.75 g of this phase was mixed with the surfactant phase to obtain a skin or hair cleansing compn.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 47 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2001:319681 CAPLUS
 DOCUMENT NUMBER: 134:331629
 TITLE: Oral transmucosal drug dosage using solid solution
 INVENTOR(S): Zhang, Hao; Croft, Jed
 PATENT ASSIGNEE(S): Anesta Corp., USA
 SOURCE: PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2001030288	A1	20010503	WO 2000-US28113	20001012 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6264981	B1	20010724	US 1999-428071	19991027 <--
CA 2388610	A1	20010503	CA 2000-2388610	20001012 <--

CA 2388610 C 20070821
 EP 1242013 A1 20020925 EP 2000-972083 20001012 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL
 JP 2003512402 T 20030402 JP 2001-532709 20001012 <--
 MX 2002PA04235 A 20040421 MX 2002-PA4235 20020426
 JP 2008201805 A 20080904 JP 2008-121345 20080507

PRIORITY APPLN. INFO.: US 1999-428071 A 19991027
 JP 2001-532709 A3 20001012
 WO 2000-US28113 W 20001012

AB The present invention is directed toward formulation and method for oral transmucosal delivery of a pharmaceutical. The invention provides a drug formulation comprising a solid pharmaceutical agent in solid soln. with a dissoln. agent. The formulation is administered into a patient's oral cavity, delivering the pharmaceutical agent by absorption through a patient's oral mucosal tissue. The formulation and method provide for improved oral mucosal delivery of the pharmaceutical agent. Oral transmucosal formulation containing piroxicam 2, mannitol 10, Emdex 86.7, sodium hydroxide 0.24, and magnesium stearate 1% was prepared. The Cmax and AUC of the drug was two fold of the wet granulation formulation and it was absorbed into the blood stream faster.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 48 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:116847 CAPLUS
 DOCUMENT NUMBER: 120:116847
 ORIGINAL REFERENCE NO.: 120:20447a,20450a
 TITLE: Biodegradable controlled release melt-spun delivery system
 INVENTOR(S): Fuisz, Richard C.
 PATENT ASSIGNEE(S): Fuisz Technologies, Ltd., USA
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9324154	A1	19931209	WO 1993-US5307	19930602 <--
W: AU, CA, HU, JP, KR, PL, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5518730	A	19960521	US 1992-893238	19920603 <--
AU 9344058	A	19931230	AU 1993-44058	19930602 <--
AU 665844	B2	19960118		
JP 07507548	T	19950824	JP 1994-500877	19930602 <--
JP 3941878	B2	20070704		
EP 746342	A1	19961211	EP 1993-914373	19930602 <--
EP 746342	B1	20020814		

R: BE, CH, DE, DK, FR, GB, IE, IT, LI, LU, NL, SE
 PRIORITY APPLN. INFO.: US 1992-893238 A2 19920603
 WO 1993-US5307 A 19930602

AB Biodegradable controlled-release delivery systems using melt-spun biodegradable polymers as carriers for bio-effecting agents such as pharmaceutical actives are disclosed. Oral dose forms as well as implants are described. For example, polyglycolide was melt-spun in combination with various drugs such as vancomycin, gentamicin, tolmetin, diphenhydramine, ibuprofen, and insulin and

controlled drug release was demonstrated.

L16 ANSWER 49 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1989:428547 CAPLUS

DOCUMENT NUMBER: 111:28547

ORIGINAL REFERENCE NO.: 111:4833a,4836a

TITLE: Pharmaceutical patches containing polyvinyl alcohol and unsaturated carboxylic acid polymers and nonionic tensides

INVENTOR(S): Fankhauser, Peter; Sinnreich, Joel; Dobmeier, Rolf

PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.

SOURCE: Eur. Pat. Appl., 9 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 283434	A2	19880921	EP 1988-810107	19880222 <--
EP 283434	A3	19910102		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4855142	A	19890808	US 1988-156639	19880217 <--
JP 63227522	A	19880921	JP 1988-40896	19880225 <--
DK 8801004	A	19880828	DK 1988-1004	19880226 <--
AU 8812350	A	19880901	AU 1988-12350	19880226 <--
PRIORITY APPLN. INFO.:			CH 1987-755	A 19870227

AB Pharmaceutical patches for application to the mucosa consist of 2 layers. They contain a cover layer comprising polyvinyl alc. (<10% acetylated, insol. in cold H₂O), optionally ≥ 1 plasticizer, and a water-insol. composite adhesive layer comprising a carboxylic acid polymer and an ethoxylated nonionic tenside, optionally ≥ 1 pharmacol. active agent, and optionally ≥ 1 absorption enhancer. The carboxylic acid polymer contains >10% carboxyl groups; the ethoxylated tenside contains ≥ 2 ethoxy units and has a mol. weight of <4000; and the composite contains polycarboxylic acid and tenside in a 50:1-1:20 ratio. A mixture containing Mowiol 28-99 9.83, H₂O 88.5, glycerol 1.1, and Fe2O₃ 0.56 g was spread onto a glass sheet and H₂O was evaporated to give a smooth cover layer. An adhesive gel was prepared by combining a mixture containing TiO₂ 0.94, Methocel MC 0.33, EtOH 853.42, and Carbopol 934P 37.72 g with a mixture containing Brij-78 3.77, EtOH 99.68, glycerol 4.14, ZnSO₄·H₂O 3.12, and Na heparin 0.95 g. The gel was spread onto the cover foil and dried; the patch contained 0.15 mg heparin/cm² and 0.5 mg ZnSO₄·H₂O/cm².

L16 ANSWER 50 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:456886 CAPLUS

DOCUMENT NUMBER: 133:94514

TITLE: Controlled release galantamine compositions for treating Alzheimer's dementia

INVENTOR(S): McGee, John Paul; Gilis, Paul Marie Victor; De Weer, Marc Maurice Germain; De Conde, Valentin Florent Victor; De Bruijn, Herman Johannes Catherina; Van Dycke, Frederic Anne Rodolf

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE			
WO 2000038686	A1	20000706	WO 1999-EP10257	19991220 <--			
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW							
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG							
CA 2358062	A1	20000706	CA 1999-2358062	19991220 <--			
CA 2358062	C	20061219					
BR 9916835	A	20010925	BR 1999-16835	19991220 <--			
EP 1140105	A1	20011010	EP 1999-965527	19991220 <--			
EP 1140105	B1	20031022					
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO							
HU 2001004778	A2	20020429	HU 2001-4778	19991220 <--			
HU 2001004778	A3	20040528					
JP 2002533396	T	20021008	JP 2000-590639	19991220 <--			
EE 200100319	A	20021015	EE 2001-319	19991220 <--			
NZ 511643	A	20030725	NZ 1999-511643	19991220 <--			
AT 252386	T	20031115	AT 1999-965527	19991220 <--			
AU 775914	B2	20040819	AU 2000-21006	19991220			
AP 1414	A	20050613	AP 2001-2219	19991220			
CN 100370990	C	20080227	CN 1999-814988	19991220			
TW 262079	B	20060921	TW 1999-88122698	19991223			
IN 2001MN00558	A	20050304	IN 2001-MN558	20010515			
BG 105564	A	20020131	BG 2001-105564	20010605 <--			
HR 2001000463	A1	20020831	HR 2001-463	20010619 <--			
ZA 2001005132	A	20020621	ZA 2001-5132	20010621 <--			
MX 2001PA06529	A	20010910	MX 2001-PA6529	20010622 <--			
US 7160559	B1	20070109	US 2001-868991	20010726			
US 20060062856	A1	20060323	US 2005-262668	20051031			
US 20060093671	A1	20060504	US 2005-304128	20051215			
PRIORITY APPLN. INFO.:			EP 1998-204447	A 19981224			
			WO 1999-EP10257	W 19991220			
			US 2001-868991	A1 20010726			
AB	The present invention is concerned with controlled release comps for oral administration comprising galantamine; and with processes of preparing such controlled release comps. A method of treating Alzheimer's dementia and related dementias comprises administering the controlled release galantamine formulation.						
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT					
L16 ANSWER 51 OF 136	CAPLUS	COPYRIGHT 2009 ACS on SIN					
ACCESSION NUMBER:	1992:433734	CAPLUS					
DOCUMENT NUMBER:	117:33734						
ORIGINAL REFERENCE NO.:	117:5907a,5910a						
TITLE:	Nicotine-containing patches for applying oral mucous membrane						
INVENTOR(S):	Yamada, Akiya; Wato, Takahiko; Konishi, Tatsuya; Mizobuchi, Tadafumi						
PATENT ASSIGNEE(S):	Teikoku Seiyaku Co., Ltd., Japan						
SOURCE:	Jpn. Kokai Tokkyo Koho, 4 pp.						
	CODEN: JKXXAF						
DOCUMENT TYPE:	Patent						

LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03209326	A	19910912	JP 1990-4037	19900111 <--
PRIORITY APPLN. INFO.:			JP 1990-4037	19900111
AB Patches for applying oral mucous membrane are composed of (i) adhesive film and (ii) pharmaceutical reservoir film containing nicotine on the adhesive film. Jurymer EN 05 (water-insol. polymer) 10.0, hydroxypropyl Me cellulose acetate succinate 10.0, nicotine 6.0, lactic acid 6.0, tri-Et citrate 2.0, H2O 20.0, and EtOH 45.0 g were mixed and spread on a release paper to give a pharmaceutical transdermal film (100 µm thickness). Jurymer EN-05 10.0, poly(vinyl alc.) 20.0, Jurymer SH-8 (water-insol. polymer) 5.0, butanediol 10.0, TiO2 1.0, H2O 80.0, and EtOH 74.0 g were mixed and spread on a removal paper to give an adhesive film (100 µm thickness). The pharmaceutical film and the adhesive film were laminated and cut to give oval-shaped patches (size 1.9 cm2), which showed nicotine elution rate of 80.4, 92.4, and 98.6% after 30, 60, and 120 min, resp., and good storage stability.				

L16 ANSWER 52 OF 136 CAPLUS COPYRIGHT 2009 ACS on SIN

ACCESSION NUMBER: 2006:469240 CAPLUS
 DOCUMENT NUMBER: 144:474944
 TITLE: Transdermal therapeutic system comprising ergoline derivatives
 INVENTOR(S): Windt-Hanke, Fred; Gunther, Clemens; Horowski, Reinhard; Tack, Johannes; Engfer, Adalbert; Bostedt, Katalin Tisa; Schenk, Dirk
 PATENT ASSIGNEE(S): Germany
 SOURCE: U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of Appl. No. PCT/DE04/001133.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060105030	A1	20060518	US 2005-87754	20050324
US 20070243240	A9	20071018		
DE 10043321	A1	20020328	DE 2000-10043321	20000824 <--
DE 10043321	B4	20050728		
DE 10053397	A1	20020502	DE 2000-10053397	20001020 <--
WO 2002015889	A1	20020228	WO 2001-EP9823	20010824 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
WO 2002015890	A1	20020228	WO 2001-EP9824	20010824 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,				

	LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
WO 2002034267	A1	20020502	WO 2001-EP9826 20010824 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
US 20040092544	A1	20040513	US 2003-362182 20030703
US 7258871	B2	20070821	
US 20040101550	A1	20040527	US 2003-362248 20030707
US 20040028723	A1	20040212	US 2003-362183 20030721
DE 10341317	B4	20081023	DE 2003-10341317 20030903
DE 10341317	A1	20050331	
WO 2005025546	A1	20050324	WO 2004-DE1133 20040530
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
WO 2006099946	A1	20060928	WO 2006-EP2093 20060302
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		

PRIORITY APPLN. INFO.:

DE 2000-10043321	A	20000824
DE 2000-10053397	A	20001020
WO 2001-EP9823	W	20010824
WO 2001-EP9824	W	20010824
WO 2001-EP9826	W	20010824
US 2003-362182	A2	20030703
US 2003-362248	A2	20030707
US 2003-362183	A2	20030721
DE 2003-10341317	A	20030903
WO 2004-DE1133	A2	20040530
US 2005-87754	A	20050324

OTHER SOURCE(S): MARPAT 144:474944

AB The invention concerns a transdermal therapeutic system containing ergoline derivs., preferably lisuride, with a stabilized ergoline compound

Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat-soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.-butylmethoxyphenols, tocopherols or ubiquinones and a basic polymer. Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline deriv. or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy. Thus, a transdermal therapeutic system was prepared by dissolving Kollidon VA 64 15 mg in isopropanol 15 mg. To this suspension lisuride 5 mg and polyacrylate adhesive (Gelva 7881) 80 mg was added and rinsed with isopropanol 30 mg. After mixing, the crystal-free mixture was spread onto a siliconized liner. Permeation flux measurements resulted daily values of ($\mu\text{g}/\text{cm}^2/\text{h}$) 0.43 and 0.44, maximal value 0.85.

L16 ANSWER 53 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:798235 CAPLUS

DOCUMENT NUMBER: 135:339212

TITLE: The use of azalide antibiotic compositions for treating or preventing a bacterial or protozoal infection in mammals

INVENTOR(S): Boettner, Wayne Alan; Canning, Peter Connor

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081358	A1	20011101	WO 2001-IB519	20010326 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2407448	A1	20011101	CA 2001-2407448	20010326 <--
EP 1276747	A1	20030122	EP 2001-915612	20010326 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001010382	A	20030624	BR 2001-10382	20010326 <--
HU 2003000585	A2	20030628	HU 2003-585	20010326 <--
HU 2003000585	A3	20030929		
JP 2004516233	T	20040603	JP 2001-578446	20010326
CN 1227258	C	20051116	CN 2001-808630	20010326
US 20020019353	A1	20020214	US 2001-829672	20010410 <--
IN 2002DN00925	A	20050121	IN 2002-DN925	20020920
BG 107168	A	20030731	BG 2002-107168	20021003 <--
ZA 2002008603	A	20031024	ZA 2002-8603	20021024 <--
NO 2002005134	A	20021219	NO 2002-5134	20021025 <--
MX 2002PA10586	A	20030310	MX 2002-PA10586	20021025 <--
US 20040235759	A1	20041125	US 2003-745748	20031223

PRIORITY APPLN. INFO.: US 2000-199961P P 20000427
 WO 2001-IB519 W 20010326
 US 2001-829672 B1 20010410

OTHER SOURCE(S): MARPAT 135:339212

AB Methods for treating or preventing bacterial or protozoal infections in mammals by administering a single dose of an antibiotic compn. comprising a mixture of azalide isomers and a pharmaceutically acceptable vehicle are disclosed. Methods for increasing acute or chronic injection-site toleration in mammals by administering a single dose of antibiotic compns. comprising a mixture of azalide isomers and a pharmaceutically acceptable vehicle are also disclosed. A combination comprising an antibiotic compn. comprising a mixture of azalide isomers, a pharmaceutically acceptable carrier, and instructions for use in a single-dose administration is also disclosed.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 54 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:808496 CAPLUS

DOCUMENT NUMBER: 133:366191

TITLE: Skin care compositions containing ceramide production-accelerating agents and film-forming polymers

INVENTOR(S): Yamaki, Kazuhiro; Sano, Tomohiko; Ohashi, Yukihiro; Hori, Kimihiko; Takagi, Yutaka

PATENT ASSIGNEE(S): Kao Corporation, Japan

SOURCE: Eur. Pat. Appl., 1/ pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1051965	A2	20001115	EP 2000-109171	20000508 <--
EP 1051965	A3	20010530		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2000319157	A	20001121	JP 1999-128255	19990510 <--
JP 4035258	B2	20080116		
US 6878378	B1	20050412	US 2000-564549	20000504
US 20050013790	A1	20050120	US 2004-915332	20040811
PRIORITY APPLN. INFO.:			JP 1999-128255	A 19990510
			US 2000-564549	A1 20000504

AB The invention relates to an external skin care compn. comprising a ceramide production-accelerating agent and a film-forming polymer. The external skin care compn. can enhance the barrier function of the skin and has an excellent skin roughness-improving effect. A lotion containing Eucalyptus extract 0.01, polyethylene glycol 1, polyoxyethylene

(29) sorbitan monolaurate 1.5, glycerol 2, parabens 0.1, and water q.s. to 100% was prepared

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 55 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:89809 CAPLUS

DOCUMENT NUMBER: 136:139844

TITLE: Compositions useful for regulating hair growth containing metal complexes of oxidized

INVENTOR(S): carbohydrates
Gardlik, John Michael; Severynse-Stevens, Diana;
Comstock, Bryan Gabriel
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002007700	A2	20020131	WO 2001-US23425	20010725 <--
WO 2002007700	A8	20031030		
WO 2002007700	A3	20020829		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 20020119174 A1 20020829 US 2001-909440 20010719 <--
PRIORITY APPLN. INFO.: US 2000-220756P P 20000726

AB A stable cosmetic, dermatol., or pharmaceutical compn. comprising: (a) about 0.001-99.9%, by weight, of at least one metal complex of an oxidized carbohydrate, wherein the metal complex of an oxidized carbohydrate is neither zinc gluconate, manganese gluconate, nor lithium gluconate; and (b) about 0.1-99.999%, by weight, of a vehicle, wherein the vehicle comprises at least about 5%, by weight of the compn., of propylene glycol. The compn. is administered orally, parenterally or topically. For example, a topical compn. was prepared containing zinc lactobionate 5.0%, zinc gluconate 3.0%, minoxidil 2.5%, propylene glycol 8.0%, dimethylisobutylidene 19.0%, and ethanol and minors up to 100%.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 56 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:725436 CAPLUS
DOCUMENT NUMBER: 133:301171
TITLE: Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
Chen, Feng-jing; Patel, Manesh V.
INVENTOR(S): Lipocine, Inc., USA
PATENT ASSIGNEE(S): PCT Int. Appl., 99 pp.
SOURCE: CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059475	A1	20000102	WO 2000-US7342	20000316 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,				

CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6383471 B1 20020507 US 1999-287043 19990406 <--
CA 2366702 A1 20001012 CA 2000-2366702 20000316 <--
EP 1165048 A1 20020102 EP 2000-916547 20000316 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: US 1999-287043 A 19990406
WO 2000-US7342 W 20000316

AB The present invention is directed to a pharmaceutical compn. including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of preparing such compns. by providing a compn. of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compns. of the invention are particularly suitable for use in oral dosage forms. A carrier containing concentrated phosphoric acid 0.025, Tween-20 0.3, Arlacel 186 0.2, sodium taurocholate 0.15, propylene glycol 0.3 g was formulated. Itraconazole was included in the carrier at 30 mg/mL for testing the stability of the itraconazole soln. upon dilution in simulated gastric fluid.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 57 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:502726 CAPLUS

DOCUMENT NUMBER: 137:68164

TITLE: Pharmaceutical aerosols containing hydrofluorocarbon propellants and devices for their administration

INVENTOR(S): Goodman, Michael; Lindahl, Ake

PATENT ASSIGNEE(S): Biogland Ireland (R&D) Limited, Ire.

SOURCE: U.S., 8 pp., Cont.-in-part of U.S. Ser. No. 913,226, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6413496	B1	20020702	US 1999-325927	19990604 <--
WO 9824420	A1	19980611	WO 1997-GB3360	19971204 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				

ZA 9710923	A	19980902	ZA 1997-10923	19971204	--
PRIORITY APPLN. INFO.:			GB 1996-25171	A	19961204
			GB 1996-26449	A	19961220
			US 1997-913226	B2	19970909
			WO 1997-GB3360	A2	19971204

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002085	A2	20020110	WO 2001-EP7051	20010622 <---
WO 2002002085	A3	20020620		
W: AU, BR, CA, CN, CZ, HU, IL, IN, JP, KR, MX, NZ, PL, RU, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
DE 10032456	A1	20020131	DE 2000-10032456	20000704 <---
CA 2414665	A1	20030106	CA 2001-1414665	20010622 <---
CA 2506712	A1	20030106	CA 2001-2506712	20010622 <---
EP 1296661	A2	20030402	EP 2001-945296	20010622 <---
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
HU 2003001410	A2	20030929	HU 2003-1410	20010622 <---
HU 2003001410	A3	20050228		
BR 2001012495	A	20031202	BR 2001-12495	20010622 <---
JP 2004501958	T	20040122	JP 2002-506707	20010622 <---
EP 1588701	A2	20051026	EP 2005-10436	20010622 <---
EP 1588701	A3	20080723		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
AU 2001267552	B2	20051117	AU 2001-267552	20010622 <---
NZ 523426	A	20051223	NZ 2001-523426	20010622 <---

CN 1720916	A	20060118	CN 2005-10089198	20010622
RU 2297213	C2	20070420	RU 2003-100500	20010622
NZ 540435	A	20080731	NZ 2001-540435	20010622
ZA 2003000316	A	20030522	ZA 2003-316	20030113 <--
MX 2003PA00476	A	20030514	MX 2003-PA476	20030117 <--
US 20040028732	A1	20040212	US 2003-332064	20030227
AU 2005202270	A1	20050616	AU 2005-202270	20050525
AU 2005202270	B2	20061026		
JP 2005255694	A	20050922	JP 2005-168248	20050608
IN 2005DN04151	A	20070831	IN 2005-DN4151	20050914
IN 2007DN06612	A	20070921	IN 2007-DN6612	20070827

PRIORITY APPLN. INFO.:

		DE 2000-10032456	A	20000704
		AU 2001-267552	A3	20010622
		CA 2001-2414665	A3	20010622
		CN 2001-812333	A3	20010622
		EP 2001-945296	A3	20010622
		JP 2002-506707	A3	20010622
		NZ 2001-523426	A3	20010622
		WO 2001-EP/051	W	20010622
		IN 2003-DN12	A3	20030101

AB The invention relates to flat administrable drug delivery forms (wafers) which decompose or dissolve rapidly in an aqueous medium, and rapidly release active ingredients in the oral cavity, in body openings and body cavities. The drug delivery systems comprise a matrix which contains at least one water-soluble polymer; in addition to at least one active ingredient; and is characterized in that the polymer matrix incorporates cavities or bubbles. The oral formulations exhibit improved mouth feel. Thus 111.43 g distilled water was mixed with 22.38 g Mowiol 8-88 at 80°C for 30 min; after cooling to 40°C 1.8 g PEG 400 and 1.8 g PEG 4000 were added, and the mixture was homogenized. Further components were added (g): aspartame 0.18; aroma 5.58; nicotine hydrogentartrate 26.46; silica 1.8. Mixing was continued below 50°C for 2 h and foam was beaten; the foam was spread and dried.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 59 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:319266 CAPLUS

DOCUMENT NUMBER: 138:343857

TITLE: Pharmaceutical formulations and systems for improved absorption and multistage release of active agents

INVENTOR(S): Chen, Feng-Jing; Venkateshwaran, Srinivasan; Krill, Steven L.; Patel, Mahesh V.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 55 pp., Cont.-in-part of U.S. Ser. No. 898,553.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 13

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030077297	A1	20030424	US 2002-74687	20020211 <--
US 7374779	B2	20080520		
US 6294192	B1	20010925	US 1999-258654	19990226 <--
US 6267985	B1	20010731	US 1999-345615	19990630 <--
US 6248363	B1	20010619	US 1999-447690	19991123 <--
EP 2000130	A1	20081210	EP 2008-16180	20000602

R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,
 NL, PT, SE

US 20030064097 A1 20030403 US 2001-800593 20010306 <--
 US 6569463 B2 20030527
 US 20020032171 A1 20020314 US 2001-877541 20010608 <--
 US 6761903 B2 20040713
 US 20020012680 A1 20020131 US 2001-898553 20010702 <--
 US 6451339 B2 20020917
 WO 2003068186 A1 20030821 WO 2003-US4195 20030211 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003213020 A1 20030904 AU 2003-213020 20030211 <--
 PRIORITY APPLN. INFO.:
 US 1999-258654 A1 19990226
 US 1999-345615 A2 19990630
 US 1999-447690 A3 19991123
 US 2001-800593 A2 20010306
 US 2001-877541 A2 20010608
 US 2001-898553 A2 20010702
 US 1999-375636 A2 19990817
 EP 2000-938039 A3 20000602
 US 2000-751968 A2 20001229
 US 2002-74687 A 20020211
 WO 2003-US4195 W 20030211

AB The present invention pertains to pharmaceutical formulations and systems for delivery of active agents, wherein a first fraction of an active agent is suspended in a vehicle and a second fraction of active agent is solubilized in the vehicle, with the suspended fraction representing about 5 weight % to about 80 weight % of the active agent and the second fraction representing about 20 weight % to about 95 weight % of the active agent. One or more addnl. active agents, which may be fully solubilized, partially solubilized, or suspended, may also be present. The first and second fractions of the active agent may or may not have different release profiles. Generally, a significant fraction of the solubilized drug will release rapidly, providing for rapid onset, while the suspended drug may be formulated for delayed and/or sustained release. A pharmaceutical suspension contained isotretinoin 40, soybean oil 200, Maisine 35-1 100, and Lutrol F68 100 mg.

L16 ANSWER 60 OF 136 CAPLUS COPYRIGHT 2009 ACS ON STN
 ACCESSION NUMBER: 2004:589392 CAPLUS
 DOCUMENT NUMBER: 141:145399
 TITLE: Oral care compositions based on a film
 INVENTOR(S): Boyd, Thomas J.; Xu, Guofeng; Carale, M. Teresa R.;
 Boff, Beth Ann
 PATENT ASSIGNEE(S): Colgate-Palmolive Company, USA
 SOURCE: PCT Int. Appl., 79 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2004060335	A1	20040722	WO 2003-US40562	20031219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6669929	B1	20031230	US 2002-331312	20021230 <--
US 20040136924	A1	20040715	US 2003-739803	20031218
CA 2512159	A1	20040722	CA 2003-2512159	20031219
AU 2003301110	A1	20040729	AU 2003-301110	20031219
AU 2003301110	B2	20081023		
EP 1589938	A1	20051102	EP 2003-814876	20031219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017805	A	20051129	BR 2003-17805	20031219
RU 2307644	C2	20071010	RU 2005-124283	20031219
MX 2005PA07221	A	20050912	MX 2005-PA7221	20050630
IN 2007DN07189	A	20071005	IN 2007-DN7189	20070918
PRIORITY APPLN. INFO.:			US 2002-331312	A 20021230
			US 2003-530077P	P 20031216
			US 2003-739803	A 20031218
			WO 2003-US40562	W 20031219
			IN 2005-DN3137	A3 20050714

AB An oral or personal care compn. comprising a film made of a functional materials or a plurality of film fragments entrained in a carrier is described. The film or plurality of film fragments can comprise repeated shapes. Also disclosed is a compn. comprising a plurality of discernable lamellar fragments entrained in a carrier. A method for administering a functional material to a human or animal subject in need thereof, comprising applying to the subject a compn. comprising a film or a plurality of film fragments entrained in a carrier, wherein the film comprises the functional material is also described. The compn. is preferably a dentifrice, containing shaped and/or colored film fragments. For example, a silver colored, star shaped film matrix contained starch 21.0%, HPMC 40.0%, glycerin 5.0%, vegetable oil 3.0%, Tween 80 1.0%, SLS 1.0%, sodium saccharin 0.3%, titanium-coated mica 3.8%, flavor 24.6%, and zinc gluconate 0.3%. A transparent green base dentifrice carrier material contained PEG 600 3.0%, sodium CM-cellulose 0.55%, sorbitol 74.0%, water 6.357%, sodium fluoride 0.243%, tetrasodium pyrophosphate 0.50%, sodium saccharin 0.30%, Zeodent 115 4.0%, Zeodent 165 8.8%, sodium lauryl sulfate 1.2%, flavor 1.0%, and FD&C Green (2% soln.) 0.05%. A dentifrice compn. was produced by combining a star shaped film fragments with transparent green dentifrice carrier material in a 0.3% weight/weight film/carrier ratio and packaged in a standard toothpaste tube.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 61 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1994:612973 CAPLUS
 DOCUMENT NUMBER: 121:212973
 ORIGINAL REFERENCE NO.: 121:38643a
 TITLE: Transdermal pharmaceutical films containing ethylene-vinyl acetate graft copolymers
 INVENTOR(S): Istin, Michel; Grognet, Jean-Marc; Darnez, Charles

PATENT ASSIGNEE(S): Commissariat a l'Energie Atomique, Fr.
 SOURCE: Fr. Demande, 48 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2699406	A1	19940624	FR 1992-15377	19921221 <--
FR 2699406	B1	19950310		
CA 2130332	A1	19940707	CA 1993-2130332	19931220 <--
WO 9414425	A1	19940707	WO 1993-FR1272	19931220 <--
W: CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 625901	A1	19941130	EP 1994-902838	19931220 <--
EP 625901	B1	19981104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07508291	T	19950914	JP 1993-514869	19931220 <--
AT 172877	T	19981115	AT 1994-902838	19931220 <--
ES 2126739	T3	19990401	ES 1994-902838	19931220 <--
PRIORITY APPLN. INFO.:				
			FR 1992-15377	A 19921221
			WO 1993-FR1272	W 19931220

AB Transdermal pharmaceutical films containing ethylene-vinyl acetate graft copolymers are disclosed. An aqueous soln. containing 18.56 kg acrylic acid was stirred with 60 kg of ethylene-vinyl acetate copolymer in presence of Mohr salt followed by irradiation under N to obtain a film. A transdermal pharmaceutical film containing 10% ketoprofen was prepared having average release rate of 2.61 mg/24/cm2.

L16 ANSWER 62 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:279399 CAPLUS
 DOCUMENT NUMBER: 134:300613
 TITLE: A washing composition for keratinous materials based on a surfactant, a cationic vinyl lactam polymer and an acrylic terpolymer
 INVENTOR(S): Maurin, Veronique; Beauquey, Bernard
 PATENT ASSIGNEE(S): L'oreal, Fr.
 SOURCE: Eur. Pat. Appl., 12 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1092420	A1	20010418	EP 2000-402664	20000926 <--
EP 1092420	B1	20040519		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2798853	A1	20010330	FR 1999-12171	19990929 <--
FR 2798853	B1	20011123		
AT 267001	T	20040615	AT 2000-402664	20000926
ES 2216838	T3	20041101	ES 2000-402664	20000926
US 6403542	B1	20020611	US 2000-671194	20000928 <--
JP 2001233745	A	20010828	JP 2000-336706	20000929 <--
PRIORITY APPLN. INFO.:				
			FR 1999-12171	A 19990929

AB A hair wash comprising a surfactant, a cationic vinyl lactam

polymer and an acrylic terpolymer is disclosed (Markush structures given). A shampoo contained 30% cocoyl betaine 6, 70% sodium lauryl ether sulfate 16, Luviquat FC905 (vinylpyrrolidone-methylvinylimidazolium chloride copolymer) 0.75, Structure Plus (an acrylic terpolymer) 1, glycol distearate 2, preservatives q.s., and water q.s. 100 g.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 63 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:185870 CAPLUS

DOCUMENT NUMBER: 134:224336

TITLE: Electrostatic aerosol compositions containing nonionic surfactant

INVENTOR(S): Harper, Duncan Roger; Harrison, Neale; Morgan, John Douglas; Clint, John Howard; Abela, Mario

PATENT ASSIGNEE(S): Reckitt Benckiser (UK) Limited, UK; Reckitt Benckiser (Australia) Pty. Limited

SOURCE: PCI Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001018145	A2	20010315	WO 2000-GB3426	20000905 <--
WO 2001018145	A3	20011115		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
GB 2354006	A	20010314	GB 2000-21829	20000905 <--
GB 2354006	B	20011031		
CA 2382524	A1	20010315	CA 2000-2382524	20000905 <--
BR 2000013860	A	20020514	BR 2000-13860	20000905 <--
EP 1409605	A2	20040421	EP 2000-958811	20000905
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY			
CN 1161441	C	20040811	CN 2000-812561	20000905
AU 776621	B2	20040916	AU 2000-70229	20000905
CN 1554488	A	20041215	CN 2004-10048312	20000905
US 20030096878	A1	20030522	US 2002-91284	20020305 <--
MX 2002PA02426	A	20020930	MX 2002-PA2426	20020306 <--
ZA 2002001862	A	20030306	ZA 2002-1862	20020306 <--
IN 2002CN00465	A	20070427	IN 2002-CN465	20020402
AU 2004203903	A1	20040909	AU 2004-203903	20040817
AU 2004203903	B2	20060907		
US 20070093558	A1	20070426	US 2006-638281	20061213
PRIORITY APPLN. INFO.:			GB 1999-21037	A 19990907
			AU 2000-70229	A3 20000905
			WO 2000-GB3426	W 20000905
			US 2002-91284	A3 20020305

AB An elec. neutral compn. in the form of a water-in-oil or an oil-in-water emulsion, in which droplets of the emulsion on discharge from an aerosol spray device are imparted with a unipolar electrostatic charge,

comprises (a) ≥ 1 propellant 2-80% weight/weight; (b) ≥ 1 nonionic surfactant 0.01-10% weight/weight; (c) optionally one or more oils or solvents, preferably aliphatic, linearly conjugated or aromatic, within the oil phase $\leq 40\%$ weight/weight; (d) ≥ 1 polar or ionic or aromatic or linearly conjugated compound 0.01-80% weight/weight based on the nonionic surfactant; and water. The theor. conductivity of the emulsion is less than the bulk conductivity of the emulsion. Thus a compn. comprising ethoxylated (7EO) alc. (C12-15) 0.24 weight/volume, sodium lauryl sulfate 3% weight/weight of the nonionic surfactant, deionized water 47 volume/volume, and decane 53 volume/volume was prepared, showing measured conductivity of the bulk emulsion 22.3 S cm⁻¹, measured conductivity of the separated external phase 39.4 S cm⁻¹, measured conductivity of the separated internal phase 4.0 S cm⁻¹, and theor. conductivity of the emulsion 14.1 S cm⁻¹.
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 64 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2000:600787 CAPLUS
 DOCUMENT NUMBER: 133:168358
 TITLE: Film type pharmaceutical preparation
 INVENTOR(S): Choe, Soo-bo; Yun, Tae-kyu; Choe, Jae-young; Ahn, Joo-hoon; Choe, Bong-soo
 PATENT ASSIGNEE(S): S. Korea
 SOURCE: Repub. Korea, No pp. given
 CODEN: KRXXFC
 DOCUMENT TYPE: Patent
 LANGUAGE: Korean
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 9608225	B1	19960620	KR 1993-5836	19930407 <--
PRIORITY APPLN. INFO.:			KR 1993-5836	19930407

AB The film-type transdermal pharmaceutical is composed of pharmaceuticals such as steroid-based antiphlogistics, antibiotics, vitamins, nicotine, antihistamines, oxybenzone, hydrous benzoyl peroxide, aloe vera gel or placental exts., one or more agents selected from polyvinyl alc., PVP, sodium CM-cellulose, gelatin, sodium alginate or pectin, one or more agents selected from glycerin, propylene glycol or ethylene glycol, moisture evaporation promoter like ethanol or methanol, water and surfactant.

L16 ANSWER 65 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1998:776644 CAPLUS
 DOCUMENT NUMBER: 130:29075
 TITLE: Skin care compositions comprising vitamin B3 and a skin conditioning component
 INVENTOR(S): Boyd, Roberta Atwood; Deckner, George Endel; Sanogueira, James Pedrosa, Jr.; Zukowski, Joseph Michael
 PATENT ASSIGNEE(S): The Procter & Gamble Co., USA
 SOURCE: PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9852529	A1	19981126	WO 1998-IB782	19980520 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KR, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 2013	H1	20020205	US 1997-863089	19970523 <--
AU 9870747	A	19981211	AU 1998-70747	19980520 <--
JP 2001525849	T	20011211	JP 1998-550176	19980520 <--
PRIORITY APPLN. INFO.:			US 1997-863089	A 19970523
			WO 1998-IB782	W 19980520

AB Disclosed are topical comps. providing a high level of hydration and which comprise a vitamin B3 compound and a conditioning component for regulating the condition of skin. A compn. was prepared containing cetyl alc. 0.72, stearyl alc. 0.48, stearic acid 0.1, PEG-100 stearate 0.1, Araltone 2121 1, iso-Pr isostearate 2, Silicone Q21403 2, SEFA crotonate 0.67, glycerin 7, Carbopol 954 0.5, Carbopol 1382 0.1, TiO2 0.75, niacinamide 2, Glydant Plus 0.1, and EDTA 0.1.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 66 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:836400 CAPLUS
 DOCUMENT NUMBER: 139:318718
 TITLE: Fiber-supported pesticidal compositions
 INVENTOR(S): Hoffmann, Michael P.; Gardner, Jeffrey; Curtis, Paul D.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 41 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030198659	A1	20031023	US 2002-281088	20021025 <--
PRIORITY APPLN. INFO.:			US 2001-345349P	P 20011025

AB The invention provides fibrous pest deterrents that combine the useful properties of a phys. barrier in the form of a nonwoven fibrous matrix with a chemical deterrent such as a pesticide, behavior-modifying compound or a pest repellent. The use of such fibrous pest deterrents protects plants, animals and structures in both agricultural and nonagricultural settings from damage inflicted by pests. Unlike traditional pesticides, the behavior-modifying compound, pesticide or chemical deterrent of the invention is adsorbed or attached to a fibrous matrix, and so it is not so readily dispersed into the environment. Hence, use of the fibrous pest deterrents can reduce the levels of pesticides that inadvertently contaminate nontarget areas and pollute water supplies.

L16 ANSWER 67 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1998:239790 CAPLUS
 DOCUMENT NUMBER: 128:301298

ORIGINAL REFERENCE NO.: 128:59581a,59584a
 TITLE: Pyrophosphate baths for decorative electroplating layers of Cu-Sn alloys with good gloss
 INVENTOR(S): Kaneko, Mitsuru
 PATENT ASSIGNEE(S): Nippon New Chrome Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10102278	A	19980421	JP 1996-258426	19960930 <--
JP 3674887	B2	20050727		
PRIORITY APPLN. INFO.:			JP 1996-258426	19960930

AB Title baths contain 1:1 reaction products of amine derivs. and epihalohydrin and aldehyde derivs. The baths may contain tension-controlling additives and/or N-benzylpyridinium derivs. The epihalohydrin may be epichlorohydrin, and the amines may be ≥ 1 of ammonia, ethylenediamine, diethylenetriamine, piperazine, n-propylamine, 1,2-propanediamine, 1,3-propanediamine, 1-(2-aminoethyl)piperazine, 3-diethylaminopropylamine, dimethylamine, hexamethylenetetramine, tetraethylenepentamine, triethanolamine, hexamethylenediamine, and/or isopropanolamine. The baths provide beautiful alloy films with good gloss.

L16 ANSWER 68 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:420916 CAPLUS
 DOCUMENT NUMBER: 133:48888
 TITLE: Improved release of medicament active agents from a chewing gum coating
 INVENTOR(S): Johnson, Sonya S.; Record, David W.; Greenberg, Michael J.; Reed, Michael A.; Gudas, Victor V.; Schnell, Philip G.; Seielstad, Donald A.; Typrin, Henry T.; Russell, Michael P.; Witkewitz, David L.; Song, Joo H.; Townsend, Donald J.; Yotka, Robert J.; Ream, Ronald L.; Corriveau, Christine L.; Wokas, William J.
 PATENT ASSIGNEE(S): Wm. Wrigley Jr. Co., USA; et al.
 SOURCE: PCT Int. Appl., 84 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 22
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035296	A1	20000622	WO 1999-US29742	19991214 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2271889	A1	19980604	CA 1996-2271889	19961127 <--
CA 2271889	C	20040127		

CA 2431848	A1	19980604	CA 1996-2431848	19961127 <--
CA 2431848	C	20070717		
CA 2431856	A1	19980604	CA 1996-2431856	19961127 <--
WO 9823165	A1	19980604	WO 1996-US18977	19961127 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG				
AU 9712745	A	19980622	AU 1997-12745	19961127 <--
EP 969733	A1	20000112	EP 1996-943523	19961127 <--
EP 969733	B1	20060621		
R: DE, FR, GB				
CA 2272703	A1	19980604	CA 1996-2272703	19961223 <--
CA 2272703	C	20020924		
AU 9717432	A	19980622	AU 1997-17432	19961223 <--
AU 719781	B2	20000518		
EP 967883	A1	20000105	EP 1996-945948	19961223 <--
EP 967883	B1	20030924		
R: DE, DK, FR, GB				
US 6165516	A	20001226	US 1999-308972	19990527 <--
CA 2355779	A1	20000622	CA 1999-2355779	19991214 <--
CA 2355779	C	20060207		
AU 2000021843	A	20000703	AU 2000-21843	19991214 <--
AU 765999	B2	20031009		
BR 9916303	A	20011002	BR 1999-16303	19991214 <--
EP 1139774	A1	20011010	EP 1999-966257	19991214 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6355265	B1	20020312	US 2000-510878	20000223 <--
US 6322806	B1	20011127	US 2000-618808	20000718 <--
US 6627234	B1	20030930	US 2000-621643	20000721 <--
US 6444241	B1	20020903	US 2000-651514	20000830 <--
US 20010024642	A1	20010927	US 2001-759561	20010111 <--
US 6558692	B2	20030506		
EP 1347746	A1	20031001	EP 2001-953503	20010717 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20020012633	A1	20020131	US 2001-956445	20010919 <--
US 6592850	B2	20030715		
US 6426090	B1	20020730	US 2001-955870	20010919 <--
US 20020159956	A1	20021031	US 2001-990628	20011113 <--
US 20030049208	A1	20030313	US 2001-992122	20011113 <--
US 6773716	B2	20040810		
US 20020164398	A1	20021107	US 2001-24631	20011217 <--
US 7163705	B2	20070116		
AU 773949	B2	20040610	AU 2002-23197	20020308
US 20040180007	A1	20040916	US 2003-743609	20031222
US 7078052	B2	20060718		
AU 2004200574	A1	20040311	AU 2004-200574	20040213
AU 2004200574	B2	20060202		
AU 2004233478	A1	20041223	AU 2004-233478	20041125
AU 2004233478	B2	20070628		
CA 2629954	A1	20070524	CA 2005-2629954	20051115
EP 1948141	A1	20080730	EP 2005-851615	20051115
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
W: 1996-US18977 US 1998-112389P US 1999-286818				
A2 19961127 P 19981215 A 19990406				

PRIORITY APPLN. INFO.:

US 1999-308972	A2 19990527
US 1999-389211	A2 19990902
CA 1996-2271889	A3 19961127
AU 1997-13382	A3 19961223
WO 1996-US20329	W 19961223
AU 2000-19377	A3 19991210
WO 1999-US29742	W 19991214
WO 1999-US29792	A1 19991214
US 2000-510878	A2 20000223
US 2000-618808	A2 20000718
US 2000-621643	A2 20000721
US 2000-621780	A2 20000721
US 2000-631326	A3 20000803
US 2000-671552	B1 20000927
US 2000-714571	A3 20001116
US 2001-888057	A2 20010622
WO 2001-US22360	W 20010717
AU 2002-21302	A3 20020306
WO 2005-US41189	W 20051115

AB A method for producing a chewing gum with an improved release of active agent, as well as the chewing gum so produced, is obtained by adding an active agent to a chewing gum coating. The active agent is added to the coating in a coating soln. or premixed with a flavor or solvent. The coating soln. may contain sweetener or other transdermal enhancing agents to obtain increased transmucosal absorption. An active agent may also be used in the gum core. Formulations, e.g., sugar 48.7, gum base 30.0, corn syrup 19.0, glycerin 1.0, peppermint flavor 1.0 and dyclonin-HCl 0.3 weight % were given.

L16 ANSWER 69 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1992:433676 CAPLUS
 DOCUMENT NUMBER: 117:33676
 ORIGINAL REFERENCE NO.: 117:5899a,5902a
 TITLE: Nicotine-containing patches for applying
 oral mucous membrane
 INVENTOR(S): Yamada, Akiya; Wato, Takahiko; Konishi, Tatsuya;
 Mizobuchi, Tadafumi
 PATENT ASSIGNEE(S): Teikoku Seiyaku Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
JP 03209327	A	19910912	JP 1990-4038	19900111 <--
PRIORITY APPLN. INFO.:			JP 1990-4038	19900111
AB Patches for applying oral mucous membrane are composed of (i) adhesive film containing nicotine or its salts and (ii) supported film on the adhesive film. Jurmyer EN-05 (water-insol. polymer) 5.0, poly(vinyl alc.) 10.0, nicotine 2.7, 1,3-butanediol 4.0, H2O 40.0, and EtOH 38.0 g were mixed and spread on a removal paper to give an adhesive film. Et cellulose 15.0, castor oil 7.0, TiO2 1.0, and EtOH 97.0 g were mixed and spread on a release paper to give an supported film. The adhesive film and the supported film were laminated and cut to give oval-shaped patches (size ≈1.9 cm2), which showed nicotine elution rate of 87.3, 94.3, and 95.8% after 30, 60, and 120 min, resp., in vitro, 31.8 and 45.0% after 60, 120 min, resp., in volunteers, and good storage stability.				

L16 ANSWER 70 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1993:109713 CAPLUS
 DOCUMENT NUMBER: 118:109713
 ORIGINAL REFERENCE NO.: 118:19021a,19024a
 TITLE: A controlled-release delivery system for smoking cessation containing lobeline
 INVENTOR(S): Kitchell, Judith A.; Muni, Indu A.; Boyer, Yvonne N.
 PATENT ASSIGNEE(S): Dynagen, Inc., USA
 SOURCE: PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9219241	A1	19921112	WO 1992-US3860	19920507 <--
W: AU, CA, FI, HU, JP, KR, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
CA 2102507	A1	19921108	CA 1992-2102507	19920507 <--
AU 9220160	A	19921221	AU 1992-20160	19920507 <--
AU 657973	B2	19950330		
JP 06507416	T	19940825	JP 1992-512030	19920507 <--
HU 69390	A2	19950928	HU 1993-3146	19920507 <--
EP 720478	A1	19960710	EP 1992-923346	19920507 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
US 5486362	A	19960123	US 1993-140280	19931021 <--
PRIORITY APPLN. INFO.:				
			US 1991-696637	A 19910507
			US 1992-880959	B1 19920507
			WO 1992-US3860	A 19920507

AB A drug delivery system useful in aiding individuals in the cessation of smoking or chewing nicotine-containing products comprises a phys. constraint modulation system (PCMS) containing lobeline (I). The system is capable of delivering I to an individual in a controlled-release manner. The PCMS may be a biodegradable polymer containing I capable of s.c. or i.v. injection or implantation into the individual or may be part of a transdermal patch. Thus, poly(lactide-glycolide) and I were dissolved in CH₂Cl₂ and the soln. was cast onto a plated glass, the solvent evaporated, and the film was peeled, extruded to rods and ground into small particles containing 30% I. A homogeneous suspension containing above microparticles was s.c. injected to volunteers who smoked on average .apprx.20 cigarettes/day. The number of cigarettes smoked in the period following the injection of the suspension decreased substantially.

L16 ANSWER 71 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1994:541677 CAPLUS
 DOCUMENT NUMBER: 121:141677
 ORIGINAL REFERENCE NO.: 121:25487a,25490a
 TITLE: Drug delivery systems, characterized by a photolabile linkage
 INVENTOR(S): Guillet, James E.; Bakhtiyari, Hamid
 PATENT ASSIGNEE(S): Medipro Sciences Ltd., Can.
 SOURCE: PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9409826	A2	19940511	WO 1993-CA466	19931101 <--
WO 9409826	A3	19940929		
W:	AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, VN			
RW:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5482719	A	19960109	US 1992-971996	19921030 <--
CA 2175479	A1	19940511	CA 1993-2175479	19931101 <--
AU 9454141	A	19940524	AU 1994-54141	19931101 <--
PRIORITY APPLN. INFO.:			US 1992-971996	A 19921030
			WO 1993-CA466	W 19931101

OTHER SOURCE(S): MARPAT 121:141677

AB A photoactivatable drug delivery system is provided, in which a drug is combined with a photosensitive macromol. by covalent bonding, incorporation in a matrix, or encapsulation. The macromol. is large enough to prevent migration of the combination within the body, so that the combination can be implanted at a location of maximum effectiveness. The drug is released from the combination, in therapeutically active form, upon appropriate irradiation. Thus, 3-nitro-4-bromomethylbenzoic acid was treated with thionyl chloride and PEG to give a conjugate, which was reacted with indomethacin Cs salt to form a drug-photolabile group-polymer compound

L16 ANSWER 72 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:991318 CAPLUS

DOCUMENT NUMBER: 140:31507

TITLE: Nanoparticulate sterol formulations and sterol combinations

INVENTOR(S): Cooper, Eugene R.; Kline, Laura J.; Liversidge, Gary G.; Ryde, Niels P.

PATENT ASSIGNEE(S): Elian Pharma International, Ltd., Ire.

SOURCE: PCI Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003103633	A1	20031218	WO 2003-US15410	20030610 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TG, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2488617	A1	20031218	CA 2003-2488617	20030610 <--
AU 2003241478	A1	20031222	AU 2003-241478	20030610 <--
US 20040033202	A1	20040219	US 2003-457787	20030610
EP 1511468	A1	20050309	EP 2003-731214	20030610
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			

JP 2005531606 T 20051020 JP 2004-510753 20030610
 PRIORITY APPLN. INFO.: US 2002-387324P P 20020610
 WO 2003-US15410 W 20030610

AB The present invention is directed to nanoparticulate compns. comprising one or more sterols or stanols, such as sitosterol or phytosterol. The sterol particles of the compn. have an effective average particle size of less than about 2000 nm. The compns. comprise particles of at least one sterol and at least one surface stabilizer. In another aspect of this invention, novel combinations of sterols and other cholesterol lowering agents are described and methods of using same are taught.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 73 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:991317 CAPLUS
 DOCUMENT NUMBER: 140:31506
 TITLE: Nanoparticulate polyicosanol formulations and novel polyicosanol combinations
 INVENTOR(S): Cooper, Eugene R.; Kline, Laura J.; Liversidge, Gary G.; Ryde, Niels P.
 PATENT ASSIGNEE(S): Elian Pharma International, Ltd., Ire.
 SOURCE: PCT Int. Appl., 75 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003103632	A1	20031218	WO 2003-US15409	20030610 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2488498	A1	20031218	CA 2003-2488498	20030610 <--
AU 2003241477	A1	20031222	AU 2003-241477	20030610 <--
EP 1511467	A1	20050309	EP 2003-731213	20030610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005531605	T	20051020	JP 2004-510752	20030610
PRIORITY APPLN. INFO.:			US 2002-387463P P 20020610	
			WO 2003-US15409 W 20030610	

AB The present invention is directed to nanoparticulate compns. comprising one or more polyicosanols. The polyicosanol particles of the compn. have an effective average particle size of <2000 nm. The compns. comprise at least one surface stabilizers. In another aspect of this invention, novel combinations of polyicosanols and other cholesterol lowering agents are described and methods of using same are taught.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 74 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:45784 CAPLUS
 DOCUMENT NUMBER: 118:45784
 ORIGINAL REFERENCE NO.: 118:8127a,8130a
 TITLE: A controlled, sustained-release delivery system for treating drug dependency
 INVENTOR(S): Kitchell, Judith P.; Muni, Indu A.; Boyer, Yvonne N.
 PATENT ASSIGNEE(S): Dynagen, Inc., USA
 SOURCE: PCT Int. Appl., 67 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9219226	A1	19921112	WO 1992-US3859	19920507 <--
W: AU, CA, FI, HU, JP, KR, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
CA 2102507	A1	19921108	CA 1992-2102507	19920507 <--
AU 9221548	A	19921221	AU 1992-21548	19920507 <--
HU 69390	A2	19950928	HU 1993-3146	19920507 <--
US 5486362	A	19960123	US 1993-140280	19931021 <--
PRIORITY APPLN. INFO.:				
			US 1991-696637	A 19910507
			US 1992-880959	B1 19920507
			WO 1992-US3859	A 19920507

AB A drug delivery system useful in treating an individual for drug dependence is described. One embodiment of the system is useful for aiding individuals in the cessation of smoking or chewing nicotine -containing products. The delivery system includes a phys. constraint modulation system (PCMS) containing lobeline (I). The drug delivery system is capable of delivering I to an individual in a controlled, sustained-release manner and providing long-term therapeutic levels of I to the individual. The delivery of I in such a manner reduces or eliminates the individual's smoking or chewing habit. The PCMS may be a biodegradable polymer containing the I capable of s.c. or i.m. injection or implantation into the individual or may be a part of a transdermal patch containing I. Also described are methods of using the drug delivery systems in treating other drug dependencies and kits containing the drug delivery systems. A suspension formulation for s.c. administration was prepared which included lactic acid-glycolic acid copolymer microparticles containing 35 weight% I. In tests with volunteers, the formulation substantially decreased the number of cigarettes smoked.

L16 ANSWER 75 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2002:675886 CAPLUS
 DOCUMENT NUMBER: 137:221810
 TITLE: Composition for aroma delivery with improved stability and reduced foaming
 INVENTOR(S): Li, Yujun
 PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
 SOURCE: PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002068005	A1	20020906	WO 2001-US6092	20010226 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TT, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2439118	A1	20020906	CA 2001-2439118	20010226 <--
AU 2001241766	A1	20020912	AU 2001-241766	20010226 <--
EP 1363678	A1	20031126	EP 2001-913053	20010226 <--
EP 1363678	B1	20050518		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004533493	T	20041104	JP 2002-567368	20010226
AT 295743	T	20050615	AT 2001-913053	20010226
ES 2242734	T3	20051116	ES 2001-913053	20010226
US 20040000660	A1	20040101	US 2003-644287	20030820

PRIORITY APPLN. INFO.: WO 2001-US6092 W 20010226

AB A reaction mixture that is especially suited to generate heat in a controllable manner. The reaction mixture includes exothermic heat-generating particles having a water soluble coating made from polyethylene glycol with a mol. weight between 2000 and 6000; a volatile component, a buffer, an anti-foaming agent, and optionally including an aqueous soln. and a thickening agent. The reaction components are mixed together and the mixture increases in temperature to a set temperature within a predetd. time, and the mixture remains at

the set temperature for a longer period of time. In this manner, volatile components can be controllably released to the surrounding environment. The visual enhancement agents are selected from the group consisting of a dye, a chemiluminescence agent, a fluorescence agent, a pearlescence agent, and mixts. thereof. More preferably, the visual enhancement agent is selected from the group consisting of fire-fly luciferase, ATP, ethylene glycol distearate and mixts. thereof.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 76 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1991:69087 CAPLUS
DOCUMENT NUMBER: 114:69087
ORIGINAL REFERENCE NO.: 114:11689a,11692a
TITLE: Solubility modulated drug delivery system
INVENTOR(S): McClelland, Gregory A.; Zentner, Gaylen M.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 12 pp. Cont.-in-part of U.S. Ser. No. 100,664, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4946686	A	19900807	US 1989-348099	19890501 <--
ZA 8807009	A	19890830	ZA 1988-7009	19880920 <--

PRIORITY APPLN. INFO.: US 1987-100664 B2 19870924

AB A controlled-release drug delivery device comprises (1) a core compn. containing a controlled-release solubility modulating units

surrounded by a water-insol. coat containing ≥ 1 pore-forming additive dispersed throughout the coat or dispersed in an individual matrix substrate and an active ingredient and (2) a water-insol. microporous wall surrounding the core compn. and prepared from a water-permeable polymer impermeable to solute and ≥ 1 water-leachable pore forming additive dispersed throughout the wall. The solubility modulating agent can be an acid, a base, a complexing agent, or a surfactant. Lactose and Na dodecyl sulfate (SDS) were granulated and coated with cellulose acetate butyrate soln. to obtain controlled-release SDS followed by sorbitol soln. coating. Simvastatin, mannitol, SDS, and controlled-release SDS were granulated and formed into core tablets and coated with cellulose acetate butyrate soln followed by sorbitol soln. coating.

L16 ANSWER 77 OF 136 CAPLUS COPYRIGHT 2009 ACS on SIN

ACCESSION NUMBER: 2000:420917 CAPLUS

DOCUMENT NUMBER: 133:48889

TITLE: Chewing gum containing medicament active agents

INVENTOR(S): McGrew, Gordon N.; Barkalow, David G.; Johnson, Sonya S.; Record, David W.; Patel, Mansukh M.; Nimz, Jack D.; Zibell, Steven E.; Yotka, Robert J.; Greenberg, Michael J.; Aumann, Rebecca A.; Zyck, Daniel J.; Sitler, Daniel J.; Hook, Jeffrey S.; Maxwell, James R.; Reed, Michael A.; Gudas, Victor V.; Schnell, Philip G.; Tyrpin, Henry T.; Russell, Michael P.; Witkewitz, David L.; Song, Joo H.; Townsend, Donald J.; Seielstad, Donald A.

PATENT ASSIGNEE(S): Wm. Wrigley Jr. Company, USA; et al.

SOURCE: PCT Int. Appl., 127 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035298	A1	20000622	WO 1999-US29792	19991214 <--
W: US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2271889	A1	19980604	CA 1996-2271889	19961127 <--
CA 2271889	C	20040127		
CA 2431848	A1	19980604	CA 1996-2431848	19961127 <--
CA 2431848	C	20070717		
CA 2431856	A1	19980604	CA 1996-2431856	19961127 <--
WO 9823165	A1	19980604	WO 1996-US18977	19961127 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG				
AU 9712745	A	19980622	AU 1997-12745	19961127 <--
EP 969733	A1	20000112	EP 1996-943523	19961127 <--
EP 969733	B1	20060621		
R: DE, FR, GB				
CA 2272703	A1	19980604	CA 1996-2272703	19961223 <--
CA 2272703	C	20020924		
AU 9717432	A	19980622	AU 1997-17432	19961223 <--

AU 719781	B2	20000518		
EP 967883	A1	20000105	EP 1996-945948	19961223 <--
EP 967883	B1	20030924		
R: DE, DK, FR, GB				
US 6165516	A	20001226	US 1999-308972	19990527 <--
BR 9916304	A	20011113	BR 1999-16304	19991214 <--
EP 1221863	A1	20020717	EP 1999-966283	19991214 <--
R: DE, DK, FR, GB, IT, NL				
US 6949264	B1	20050927	US 2000-621780	20000721
US 6444241	B1	20020903	US 2000-651514	20000830 <--
US 6531114	B1	20030311	US 2000-714571	20001116 <--
EP 1347746	A1	20031001	EP 2001-953503	20010717 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20020164398	A1	20021107	US 2001-24631	20011217 <--
US 7163705	B2	20070116		
AU 773949	B2	20040610	AU 2002-23197	20020308
US 20030180414	A1	20030925	US 2002-280688	20021025 <--
AU 2004200574	A1	20040311	AU 2004-200574	20040213
AU 2004200574	B2	20060202		
AU 2004233478	A1	20041223	AU 2004-233478	20041125
AU 2004233478	B2	20070628		
CA 2629954	A1	20070524	CA 2005-2629954	20051115
EP 1948141	A1	20080730	EP 2005-851615	20051115

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.:

WO 1996-US18977	A2	19961127
US 1998-112389P	P	19981215
US 1999-308972	A2	19990527
US 1999-389211	A2	19990902
CA 1996-2271889	A3	19961127
AU 1997-13382	A3	19961223
WO 1996-US20252	W	19961223
WO 1996-US20329	W	19961223
US 1999-286618	A2	19990406
US 1999-286818	A	19990406
US 1999-319054	A2	19990526
AU 2000-19377	A3	19991210
WO 1999-US29742	A1	19991214
WO 1999-US29792	W	19991214
US 2000-621643	A2	20000721
US 2000-621780	A2	20000721
US 2001-888057	A2	20010622
WO 2001-US22360	W	20010717
AU 2002-21302	A3	20020306
WO 2005-US41189	W	20051115

AB A method for producing a chewing gum with a controlled release active agent, as well as the chewing gum so produced, is obtained by phys. modifying the release properties of the active agent by coating and drying. The active agent is coated by encapsulation, partially coated by agglomeration, entrapped by absorption, or treated by multiple steps of encapsulation, agglomeration, and absorption. The coated active agent is preferably then co-dried and particle sized to produce a release-modified active agent for use in chewing gum. The active agent may also be used in a coating on a chewing gum product, as part of a rolling compound applied to the chewing gum product, or as a part of the liquid in a liquid-center chewing gum product. A compn. contained sugar 62.5, base 19.2, corn syrup 15.9, peppermint flavor 0.9, glycerin 1.4, and liquid/drug (e.g., dyclonine-HCl) blend 0.1 weight%.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 78 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1993:678769 CAPLUS
 DOCUMENT NUMBER: 119:278769
 ORIGINAL REFERENCE NO.: 119:49719a,49722a
 TITLE: Manufacture of multilayered controlled-release
 transdermal patches
 INVENTOR(S): Wick, John; Weimann, Ludwig J.; Pollock, Wayne C.
 PATENT ASSIGNEE(S): Mli Acquisition Corp. II, USA
 SOURCE: Eur. Pat. Appl., 35 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 563507	A1	19931006	EP 1992-850190	19920813 <--
EP 563507	B1	19980527		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2075517	A1	19931002	CA 1992-2075517	19920807 <--
CA 2075517	C	19970311		
AT 166574	T	19980615	AT 1992-850190	19920813 <--
ES 2118124	T3	19980916	ES 1992-850190	19920813 <--
BR 9203172	A	19931019	BR 1992-3172	19920814 <--
JP 3354185	B2	20021209	JP 1992-300666	19921014 <--
PRIORITY APPLN. INFO.:			US 1992-861534	A 19920401

AB Controlled-release transdermal prepn.s. comprise an active ingredient carrier layer, a backing layer, and an adhesive layer. The carrier layer contains the active ingredient melt-blended with a thermoplastic matrix capable of controlling the drug release and the adhesive layer is also capable of controlling the rate at which the drug is released from carrier layer to the skin or mucosa. For example, Pebax 4033 resin was melt-blended with nicotine and extruded into pellets, which were made into a film. Disks from a film were affixed to Saran/Hytrel occlusive film disks with a Gelva 737 acrylic pressure-sensitive adhesive. The opposite side of the disk was coated with a Gelva 737 and covered with a release liner. Release of the nicotine from the patch was in vitro tested and compared with that of com. available Nicotinell-TTS 20.

L16 ANSWER 79 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1992:201112 CAPLUS
 DOCUMENT NUMBER: 116:201112
 ORIGINAL REFERENCE NO.: 116:33941a,33944a
 TITLE: Polyalkylene oxide-amino acid copolymers as drug carriers and charged copolymers based thereon
 INVENTOR(S): Zalipsky, Samuel; Bolikal, Durgadas; Nathan, Aruna; Kohn, Joachim Benjamin
 PATENT ASSIGNEE(S): Enzon, Inc., USA
 SOURCE: PCT Int. Appl., 97 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9200748	A1	19920123	WO 1991-US4797	19910708 <--
W: AU, CA, HU, JP, SU				

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE
 JP 05508879 T 19931209 JP 1991-512668 19910708 <--
 PRIORITY APPLN. INFO.: US 1990-549494 A 19900706
 US 1991-726301 A 19910705
 WO 1991-US4797 W 19910708

AB Copolymers of polyalkylene oxides and amino acids or peptide sequences are disclosed, which amino acids or peptide sequences have pendant functional groups that are capable of being conjugated with pharmaceutically active compds. for drug delivery systems and crosslinked to form polymer matrixes as hydrogel membranes. The copolymers can also be formed into conductive materials by combination with electrolyte salts. Thus, polyethylene glycol-lysine copolymer was treated with N-hydroxysuccinimide and dicyclohexyl carbodiimide. Cephradine dissolved in a water-dioxane mixture was reacted with the derivatized polyethylene glycol-lysine copolymer to prepare a conjugate.

L16 ANSWER 80 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:991166 CAPLUS
 DOCUMENT NUMBER: 140:47511
 TITLE: Nanoparticulate polycosanols formulations
 INVENTOR(S): Cooper, Eugene R.; Kline, Laura; Liversidge, Gary G.; Ryde, Niels P.
 PATENT ASSIGNEE(S): Elan Pharma International, Ltd., USA
 SOURCE: U.S. Pat. Appl. Publ., 22 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030232796	A1	20031218	US 2003-457811	20030610 <--
PRIORITY APPLN. INFO.:			US 2002-387463P	P 20020610

AB The present invention is directed to nanoparticulate compns. comprising one or more polycosanols. The polycosanol particles of the compn. have an effective average particle size of <2000 nm. In another aspect of this invention, novel combinations of polycosanols and other cholesterol lowering agents are described. Two grades of polycosanol were evaluated, labeled OCTA-60 (Formulation A) and OCTA-95 (Formulation B). The 1-octacosanol content is 60% in Formulation A and 95% in Formulation B. Both contain a total of 97-98% long chain aliphatic alcs., such as 1-octacosanol, 1-triacontanol, 1-dotriacontanol, 1-hexacosanol, and 1-heptacosanol. The polycosanol particle sizes for Formulations A and B were measured. The product of higher purity, OCTA-95, produces a more stable dispersion as indicated by the size before and after sonication. While the OCTA-60 formulation initially seems prone to aggregation, it relaxes into a more stable dispersion upon aging. Thus, both types of polycosanol are suitable for the nanoparticulate polycosanol compns.

L16 ANSWER 81 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:590606 CAPLUS
 DOCUMENT NUMBER: 139:111626
 TITLE: Method for treatment of sepsis with high doses of riboflavin or derivatives
 INVENTOR(S): Araki, Seiichi; Kato, Akira; Onai, Katsumi
 PATENT ASSIGNEE(S): Japan
 SOURCE: U.S. Pat. Appl. Publ., 7 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030143265	A1	20030731	US 2001-25032	20011219 <--
PRIORITY APPLN. INFO.:			US 2001-25032	20011219

AB It has unexpectedly been found that the administration of high doses of riboflavin or derivs. thereof (including, but not limited to salts and prodrugs), results in an effective treatment for sepsis. Thus, the present invention provides methods for treating sepsis by administering to a subject in need thereof a high dose of a compn . comprising riboflavin or derivs. thereof.

L16 ANSWER 82 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:396646 CAPLUS
DOCUMENT NUMBER: 138:382266
TITLE: Method and composition for mentholation of charcoal filtered cigarettes
INVENTOR(S): Shi, Xuling
PATENT ASSIGNEE(S): Vector Tobacco Inc., USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003041521	A2	20030522	WO 2002-US35741	20021107 <--
WO 2003041521	A3	20030828		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002340407	A1	20030526	AU 2002-340407	20021107 <--
EP 1441603	A2	20040804	EP 2002-778767	20021107
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
JP 2005508648	T	20050407	JP 2003-543419	20021107
PRIORITY APPLN. INFO.:			US 2001-338168P	P 20011109
			WO 2002-US35741	W 20021107

AB The present invention relates to smoking articles such as cigarettes, and in particular to a method and compn. for mentholation of smoking articles, including microencapsulation of menthol or other flavorants in a material melting below the pyrolysis zone of the smoking article.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 83 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:637534 CAPLUS
DOCUMENT NUMBER: 137:190733
TITLE: Hydrogen peroxide-containing compositions

INVENTOR(S): for removal of acrochordon
 MILLER, Mickey; Ancira, Margaret
 PATENT ASSIGNEE(S): Physician's Choice of Arizona, Inc., USA
 SOURCE: PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064151	A1	20020822	WO 2002-US3530	20020208 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2437823	A1	20020822	CA 2002-2437823	20020208 <--
AU 2002251894	A1	20020828	AU 2002-251894	20020208 <--
EP 1365781	A1	20031203	EP 2002-720927	20020208 <--
EP 1365781	B1	20080604		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
CN 1501804	A	20040602	CN 2002-807988	20020208
JP 2004518715	T	20040624	JP 2002-563944	20020208
BR 2002007163	A	20040629	BR 2002-7163	20020208
NZ 527673	A	20050324	NZ 2002-527673	20020208
AT 397452	T	20080615	AT 2002-720927	20020208
MX 2003PA07151	A	20041015	MX 2003-PA7151	20030808
IN 2003DN01310	A	20050527	IN 2003-DN1310	20030818
AU 2007203283	A1	20070802	AU 2007-203283	20070716
PRIORITY APPLN. INFO.:			US 2001-267978P	P 20010209
			AU 2002-251894	A3 20020208
			WO 2002-US3530	W 20020208

AB The subject of the present invention is acrochordon removal and prevention utilizing safe dependable effective biocompatible treatments with no scarring, bleeding, twisting, yanking, choking, burning, freezing, shocking, screaming and hypo pigmentation or hyper pigmentation. Methods for acrochordon removal comprise application of high concns. of hydrogen peroxide (at least 23%). The compn. further comprises a vitamin, an amino acid, a melanin inhibitor, an organic acid, a hormone, a sulfoxide, an alc., a fatty acid, a polyol, an amide, a surfactant, a terpene, etc. For example, the compn. comprises 35% hydrogen peroxide, 0.5% L-ascorbic acid, 0.5% niacin, 0.5% glycine, 0.5% hydroquinone, 0.5% superoxide dismutase, 5% galacturonic acid, and 14% ethanol.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 84 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2001:208119 CAPLUS
 DOCUMENT NUMBER: 134:236643
 TITLE: Stable carotene-xanthophyll beadlet compositions and methods of use
 INVENTOR(S): Lang, John C.
 PATENT ASSIGNEE(S): Alcon Universal Ltd., Switz.

SOURCE: PCT Int. Appl., 39 pp.
 DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019383	A1	20010322	WO 2000-US24439	20000906 <--
W: AU, BR, CA, JP, MX, TR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6582721	B1	20030624	US 1999-397472	19990917 <--
TW 232103	B	20050511	TW 2000-89115937	20000808
CA 2382008	A1	20010322	CA 2000-2382008	20000906 <--
EP 1212071	A1	20020612	EP 2000-959942	20000906 <--
EP 1212071	B1	20070103		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2003516720	T	20030520	JP 2001-523015	20000906 <--
BR 2000014087	A	20030729	BR 2000-14087	20000906 <--
AU 780168	B2	20050303	AU 2000-71172	20000906
AT 350062	T	20070115	AT 2000-959942	20000906
MX 2002PA01837	A	20020812	MX 2002-PA1837	20020221 <--
US 6716447	B1	20040406	US 2002-88188	20020314
HK 1048247	A1	20070629	HK 2002-107712	20021024
PRIORITY APPLN. INFO.:			US 1999-397472 A	19990917
			WO 2000-US24439 W	20000906

AB Beadlets comprising xanthophylls and carotenes and/or retinoids, dietary supplements comprising these beadlets and methods of use are disclosed.
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 85 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2000:240727 CAPLUS
 DOCUMENT NUMBER: 132:250401
 TITLE: Process for the preparation of a flowable, particulate methionine product
 INVENTOR(S): Korfer, Martin; Hornung, Gundolf; Huthmacher, Klaus; Hasselbach, Hans Joachim; Bonig, Klaus
 PATENT ASSIGNEE(S): Degussa-Huls Aktiengesellschaft, Germany
 SOURCE: Eur. Pat. Appl., 8 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 992490	A1	20000412	EP 1999-119279	19990928 <--
EP 992490	B1	20030528		
EP 992490	B2	20070829		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
DE 19846825	A1	20000413	DE 1998-19846825	19981010 <--
AT 241598	T	20030615	AT 1999-119279	19990928 <--
ES 2200450	T3	20040301	ES 1999-119279	19990928
CN 1250608	A	20000419	CN 1999-120844	19990930 <--
CN 1184897	C	20050119		

AU 9953481 A 20000413 AU 1999-53481 19991006 <--
 JP 2000116336 A 20000425 JP 1999-286836 19991007 <--
 KR 2000028898 A 20000525 KR 1999-43226 19991007 <--
 BR 9904455 A 20000829 BR 1999-4455 19991007 <--
 MX 9909235 A 20041028 MX 1999-9235 19991008
 PRIORITY APPLN. INFO.: DE 1998-19846825 A 19981010
 AB A flowable particulate (especially extruded) methionine product, which
 has use as a feed (no data), etc. (no data), is prepared which has a bulk
 weight of 300-850 kg/m³, a particle size range of 63-5000 µm, and a
 methionine content of 60-98%.
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 86 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1996:701655 CAPLUS
 DOCUMENT NUMBER: 125:339128
 ORIGINAL REFERENCE NO.: 125:63199a,63202a
 TITLE: Method of making a pressure sensitive skin adhesive
 sheet material containing a liquid
 INVENTOR(S): Garbe, James E.; Northey, Paul J.; Peterson, Timothy
 A.
 PATENT ASSIGNEE(S): Minnesota Mining and Manufacturing Co., USA
 SOURCE: PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9630001	A1	19961003	WO 1996-US2785	19960226 <--
W: AU, CA, JP, NZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2215258	A1	19961003	CA 1996-2215258	19960226 <--
CA 2215258	C	20070515		
AU 9649979	A	19961016	AU 1996-49979	19960226 <--
AU 706825	B2	19990624		
EP 818994	A1	19980121	EP 1996-906654	19960226 <--
EP 818994	B1	20011024		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE				
JP 11502840	T	19990309	JP 1996-529397	19960226 <--
NZ 303614	A	20000128	NZ 1996-303614	19960226 <--
AT 207347	T	20011115	AT 1996-906654	19960226 <--
ES 2162034	T3	20011216	ES 1996-906654	19960226 <--
PT 818994	T	20020429	PT 1996-906654	19960226 <--
IL 117332	A	20000716	IL 1996-117332	19960301 <--
PRIORITY APPLN. INFO.:			US 1995-414721 A 19950331	
			WO 1996-US2785 W 19960226	

AB A method of making a pressure sensitive skin adhesive sheet material is
 disclosed, whereby a coating medium involving a liquid and a polymer
 is applied to a base layer of a polymer, and the liquid is allowed
 to diffuse into the base layer. An adhesive soln. comprising
 22% isooctylacrylate-acrylamide-vinyl acetate copolymer in 91:9 Et
 acetate:methanol was extrusion die coated onto the non-release side of a
 silicone coated polyethylene terephthalate release liner. The coated
 release liner was oven dried at 65° for 1 min, then at 135°
 for 1 min. A coating medium was prepared by dissolving 20% of 94:6 isooctyl
 acrylate-acrylic acid adhesive copolymer in iso-Pr myristate, then it was
 applied to the base layer using direct gravure coating to obtain a
 pressure sensitive adhesive.

L16 ANSWER 87 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1992:546726 CAPLUS
 DOCUMENT NUMBER: 117:146726
 ORIGINAL REFERENCE NO.: 117:25345a,25348a
 TITLE: Controlled method of reducing electrophoretic mobility
 of macromolecules, particles, or cells
 INVENTOR(S): Van Alstine, James M.
 PATENT ASSIGNEE(S): United States National Aeronautics and Space
 Administration, USA
 SOURCE: U.S., 11 pp. Cont.-in-part of U.S. Ser. No. 3/6,487.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5108568	A	19920428	US 1990-599601	19901018 <--
US 376487	A0	19900201	US 1989-376487	19890707 <--
PRIORITY APPLN. INFO.:			US 1989-376487	A2 19890707

AB A method of reducing electrophoretic mobility of macromols., particles, cells and other substances is provided which comprises interacting (in a conventional electrophoretic separating procedure) the substances with a polymer-linked affinity compound comprised of a hydrophilic neutral polymer such as polyethylene glycol bound to a second component such as a hydrophobic compound, an immunocompd. such as an antibody or antibody active fragment, or a ligand such as a hormone, drug, antigen, or a hapten. The reduction of electrophoretic mobility achieved is directly proportional to the concentration of the polymer-linked affinity compound employed, and such reduction can comprise up to 100% for particular particles and cells. Electrophoretic separation can be achieved for substances whose native surface charge structure had prevented them from being separated by normal electrophoretic means.

L16 ANSWER 88 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:1215 CAPLUS
 DOCUMENT NUMBER: 138:61315
 TITLE: Controlled and sustained release dosage forms
 containing hydrophilic carriers and diffusion
 enhancers
 INVENTOR(S): Chhabra, Harinderpal; Sarkar, Shyamal K.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S., 23 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6500459	B1	20021231	US 1999-358732	19990721 <--
CA 2314298	A1	20010121	CA 2000-2314298	20000721 <--
PRIORITY APPLN. INFO.:			US 1999-358732	A 19990721

AB A pharmaceutical compn. for controlled onset and sustained release of an active ingredient, comprises: (i) a core comprising: (a) an active ingredient; (b) a hydrophilic carrier; (c) a hydrodynamic diffusion enhancer; and optionally (d) conventional excipients selected from the group consisting of binders, fillers and

lubricants and combinations thereof; and (ii) a functional coating membrane surrounding the core. Thus, 240 g verapamil-HCl was sieved through a mesh sieve and blended with 150 g E50 premium HPMC. To this blend was added 270.0 g croscarmellose sodium and mixed for 15 min. This blend was granulated with PVP K-29/32 soln. in iso-PrOH (30% weight/weight). The wet mass obtained in the above step was dried at 60° for 3 h. After drying, the granules were passed a mesh sieve. The granules were then mixed with 2.5 g of Magnesium Stearate and 15 g of Stearic acid in a V blender. This granule blend was compressed in a tablet press by using appropriate size tooling. The granules were then mixed with 2.5 g of Mg stearate and 15 g of stearic acid in a V blender. This granule blend was compressed in a tablet press by using appropriate size tooling. These tablets were then coated by using a perforated coating pan. A seal coating membrane was applied on the surface of tablets to achieve a weight gain of 1.66% of the weight of the core. The seal coating dispersion of Opadry Clear in water at 10% was sprayed on to the surface of the tablets by using a perforated coating pan.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 89 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:168118 CAPLUS

DOCUMENT NUMBER: 134:204751

TITLE: Metal binding compounds and their use in cell culture medium compositions

INVENTOR(S): Epstein, David A.; Battista, Paul; Gruber, Dale; Judd, David

PATENT ASSIGNEE(S): Life Technologies, Inc., USA

SOURCE: PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016294	A2	20010308	WO 2000-US23580	20000828 <--
WO 2001016294	A3	20010907		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2383460	A1	20010308	CA 2000-2383460	20000828 <--
AU 2000070815	A	20010326	AU 2000-70815	20000828 <--
EP 1210410	A2	20020605	EP 2000-959504	20000828 <--
EP 1210410	B1	20080116		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2003508046	T	20030304	JP 2001-520842	20000828 <--
US 6767741	B1	20040727	US 2000-650339	20000828
AT 384120	T	20080215	AT 2000-959504	20000828
US 20040214327	A1	20041028	US 2004-853697	20040526
US 20080286868	A1	20081120	US 2008-135926	20080609
PRIORITY APPLN. INFO.:			US 1999-151055P	P 19990827

US 2000-650339 A1 20000828
 WO 2000-US23580 W 20000828
 US 2004-853697 B1 20040526

AB The present invention is directed generally to metal binding compds. which may be added to cell culture media to replace factors required for cultivation of the cells (e.g. transferrin) which are of animal or human origin. More specifically, the invention is directed to metal binding compds. or complexes thereof comprising one or more transition element cations (such as ferrous or ferric ions), which are added to cell and tissue culture medium compns. The metal binding compds. may be added to the media alone or may be first complexed with a transition metal ion. The invention is also directed to methods of use of such compns., including, for example, methods for the cultivation of eukaryotic cells, particularly animal cells, in vitro. The invention also relates to compns. comprising such culture media and one or more cells, and to kits comprising one or more of the above-described compns. The compns. of the present invention obviate the need for naturally derived metal-binding proteins, such as transferrin and ceruloplasmin, which may contain blood-borne pathogens.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 90 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:509085 CAPLUS

DOCUMENT NUMBER: 129:127192

ORIGINAL REFERENCE NO.: 129:25947a,25950a

TITLE: Preparation of particles for inhalation

INVENTOR(S): Edwards, David A.; Hanes, Justin; Evora, Carmen; Langer, Robert S.; Vanbever, Rita; Mintzes, Jeffrey; Wang, Jue; Chen, Donghao

PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA; The Penn State Research Foundation

SOURCE: PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 10

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9831346	A1	19980723	WO 1997-US20930	19971117 <--
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5855913	A	19990105	US 1997-784421	19970116 <--
CA 2277801	A1	19980723	CA 1997-2277801	19971117 <--
CA 2277801	C	20021015		
EP 954282	A1	19991110	EP 1997-947545	19971117 <--
EP 954282	B1	20050119		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001526634	T	20011218	JP 1998-534332	19971117 <--
JP 3884484	B2	20070221		
EP 1498115	A1	20050119	EP 2004-19571	19971117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 287257	T	20050215	AT 1997-947545	19971117
PT 954282	T	20050630	PT 1997-947545	19971117
ES 2236832	T3	20050716	ES 1997-947545	19971117
PRIORITY APPLN. INFO.:			US 1997-784421	A 19970116
			US 1997-59004P	P 19970915

EP 1997-947545 A3 19971117
WO 1997-US20930 W 19971117

AB Particles incorporating a surfactant and/or a hydrophilic or hydrophobic complex of a pos. or neg. charged therapeutic agent and a charged mol. of opposite charge for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the particles are made of a biodegradable material and have a tap d. less than 0.4 g/cm³ and a mass mean diameter 5-30 µm, which together yield an aerodynamic diameter of the particles of 1-3 µm. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of poly(lactic acid) or poly(glycolic acid) or copolymers thereof. Alternatively, the particles may be formed solely of a therapeutic or diagnostic agent and a surfactant. Surfactants can be incorporated on the particle surface for example by coating the particle after particle formation, or by incorporating the surfactant in the material forming the particle prior to formation of the particle. Exemplary surfactants include phosphoglycerides such as dipalmitoyl phosphatidylcholine (DPPC). The particles can be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of wide a variety of therapeutic agents. Formation of complexes of pos. or neg. charged therapeutic agents with mols. of opposite charge can allow control of the release rate of the agents into the blood stream following administration. Porous particles were prepared by spray drying a soln. containing insulin 2, albumins 19, lactose 19, and dipalmitoylphosphatidylcholine 60 %.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 91 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:991324 CAPLUS

DOCUMENT NUMBER: 140:47516

TITLE: Nanoparticulate formulations comprising HMG CoA reductase inhibitors (statins)

INVENTOR(S): Cooper, Eugene R.; Hovey, Douglas; Carey, Greta; Lindner, Marie; Liversidge, Elaine; Liversidge, Gary G.; Ryde, Tuula

PATENT ASSIGNEE(S): Elan Pharma International, Ltd, Ire.

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 23

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003103640	A1	20031218	WO 2003-US16206	20030610 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TG, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2488499	A1	20031218	CA 2003-2488499	20030610 <--
AU 2003245313	A1	20031222	AU 2003-245313	20030610 <--
EP 1531799	A1	20050525	EP 2003-738952	20030610

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2005532352 T 20051027 JP 2004-510760 20030610
 US 20080213378 A1 20080904 US 2007-980586 20071031
 PRIORITY APPLN. INFO.: US 2002-387404P P 20020610
 US 1998-164351 B2 19981001
 US 1999-337675 A1 19990622
 US 2003-457810 B1 20030610
 WO 2003-US16206 W 20030610
 US 2006-367716 A1 20060306

AB The present invention is directed to nanoparticulate compns.
 comprising statin such as lovastatin or simvastatin including a surface
 stabilizer. The statin particles of the compn. have an
 effective average particle size of <2000 nm. In another aspect of this
 invention, novel combinations of statins and other cholesterol
 lowering agents are described. Thus, a formulation comprised lovastatin
 5, HPC 1.25, and sodium diocylsulfosuccinate 0.05%.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 92 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:338762 CAPLUS

DOCUMENT NUMBER: 134:362292

TITLE: Methods of determining individual hypersensitivity to
 a pharmaceutical agent from gene expression
 profile

INVENTOR(S): Farr, Spencer

PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA

SOURCE: PCT Int. Appl., 222 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103 <--
WO 2001032928	A3	20020725		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 1999-165398P P 19991105
 US 2000-196571P P 20000411

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to determine the hypersensitivity of individuals to a given agent, such as drug or other chemical, in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes associated with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes associated with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile

of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes associated with hypersensitivity. The expression of the genes predetd. to be associated with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and apparatus useful for identifying hypersensitivity in a subject are also disclosed.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 93 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2001:279398 CAPLUS
 DOCUMENT NUMBER: 134:285474
 TITLE: A washing composition for keratinous materials based on a surfactant, a polyorganosiloxane and an acrylic terpolymer
 INVENTOR(S): Maurin, Veronique; Beauquey, Bernard
 PATENT ASSIGNEE(S): L'oreal, Fr.
 SOURCE: Eur. Pat. Appl., 15 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1092419	A1	20010418	EP 2000-402656	20000926 <--
EP 1092419	B1	20040225		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2798845	A1	20010330	FR 1999-12163	19990929 <--
FR 2798845	B1	20011123		
AT 260084	T	20040315	AT 2000-402656	20000926
CN 1292256	A	20010425	CN 2000-124960	20000927 <--
BR 2000004511	A	20010410	BR 2000-4511	20000928 <--
JP 2001131035	A	20010515	JP 2000-295351	20000928 <--
US 6432894	B1	20020813	US 2000-671195	20000928 <--
CA 2321287	A1	20010329	CA 2000-2321287	20000929 <--
PRIORITY APPLN. INFO.:			FR 1999-12163	A 19990929
AB A hair wash comprising a surfactant, a polyorganosiloxane, and an acrylic terpolymer is disclosed (Markush structures given). A shampoo contained propylene glycol 0.1, 30% cocoyl betaine 8, Jaguar C13S 0.05, polydimethylsiloxane 2.7, a mixture of 1-(hexadecyloxy)-2-octadecanol cetyl alc. 2.5, perfume 0.5, copra acid monoisopropanolamide 0.5, sodium lauryl ether sulfate 22, Structure Plus (an acrylic terpolymer) 1, citric acid 0.05, preservatives q.s. and water q.s. 100 g.				
REFERENCE COUNT:	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L16 ANSWER 94 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1993:456181 CAPLUS
 DOCUMENT NUMBER: 119:56181
 ORIGINAL REFERENCE NO.: 119:10001a,10004a
 TITLE: Adhesive hydrogels having extended use lives, process for the preparation of same, and use in preparation of patches
 INVENTOR(S): Fox, Adrien S.; Czapa, Christine A.; Wiser, Robin R.
 PATENT ASSIGNEE(S): Nepera, Inc., USA
 SOURCE: PCT Int. Appl., 61 pp.

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9310163	A2	19930527	WO 1992-US9651	19921112 <--
WO 9310163	A3	19930624		
W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, UA				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU 9230708	A	19930615	AU 1992-30708	19921112 <--
EP 612253	A1	19940831	EP 1992-924378	19921112 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
PRIORITY APPLN. INFO.: US 1991-790968 A 19911112				
WO 1992-US9651 A 19921112				

AB A nonstring adhesive hydrophilic gel is disclosed which comprises an aqueous mixture of a radiation-crosslinkable water-soluble polymer, e.g. poly(ethylene oxide), ≥ 1 humectant, e.g. glycerol, effective to extend the moisture-retaining characteristics of the gels and which inhibits the ability of radiant energy to crosslink the water-soluble polymer, a pharmacol. active agent, and a crosslinking promoter, e.g. N,N'-methylene-bis-acrylamide, effective to counteract the crosslinking inhibitory effect of the humectant. The aqueous mixture is exposed to radiant energy effective to provide a nonstringy adhesive cohesive homogeneous hydrophilic gel that has an extended in-use lifetime. The gels can be formed into patches for long-term application of the pharmacol. active agent to a patient. Preparation and characterization of the gels is described.

L16 ANSWER 95 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2002:71778 CAPLUS
 DOCUMENT NUMBER: 136:123748
 TITLE: Methods and apparatus for delivering a volatile component via a controlled exothermic reaction
 INVENTOR(S): Li, Yu-jun; Mao, Mark Hsiang-kuen; Tamura, Haruo
 PATENT ASSIGNEE(S): Procter and Gamble Company, USA
 SOURCE: PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005620	A2	20020124	WO 2000-US19080	20000713 <--
WO 2002005620	A3	20021010		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GW, ML, MR, NE, SN, TD, TG				

CA 2414161	A1	20020124	CA 2000-2414161	20000713 <--
AU 2001013246	A	20020130	AU 2001-13246	20000713 <--
EP 1299500	A2	20030409	EP 2000-975155	20000713 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2004503668	T	20040205	JP 2002-511571	20000713
MX 2003PA00355	A	20030602	MX 2003-PA355	20030113 <--
US 20030111637	A1	20030619	US 2003-341196	20030113 <--
US '235187	B2	20070626		

PRIORITY APPLN. INFO.: WO 2000-US19080 W 20000713

AB Reaction mixts. that include exothermic generating particles having a water soluble coating encasing a portion of the particles, a volatile component and, optionally an aqueous soln., and a buffer are disclosed. The reaction mixts. are especially suited to generate heat in a controlled manner. In one such controlled reaction, the reaction components are mixed together and the mixture increases in temperature to a set temperature within a predetd. time, and the mixture remains at the set temperature for a longer period of time. In this manner, volatile components can be controllably released to the surrounding environment. The volatile components can be, e.g., a perfume, a fragrance, an insect repellent, a fumigant, a disinfectant, a bactericide, an insecticide, a pesticide, a germicide, an acaricide, a sterilizer, a deodorant, a fogging agent and mixture of these. Apparatuses and methods that use these reaction mixts. are also disclosed. Exothermic generating particles are coated with PEG as follows. A premix is made by combining magnesium powder and anhydrous citric acid (1:6.5), and then a fragrant oil is added to this premix. The premix is then added into melted PEG. The melted PEG is a mixture of 3 different mol. wts., PEG 600, PEG 1000, and PEG 2000. The melted PEG mixture is around 50°. The mixture is then cooled to for 10 min to approx. 20-25°. The product comprises PEG of 3 different mol. wts., a fragrant oil, magnesium powder and anhydrous citric acid powder, and is a gel with suspended particles.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 96 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2002:89795 CAPLUS
 DOCUMENT NUMBER: 136:139843
 TITLE: Method of regulating hair growth using metal complexes of oxidized carbohydrates
 INVENTOR(S): Gardlik, John Michael; Severynse-Stevens, Diana; Comstock, Bryan Gabriel
 PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
 SOURCE: PCI Int. Appl., 46 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002007685	A2	20020131	WO 2001-US23424	20010725 <--
WO 2002007685	A3	20020829		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG

US 20020035070 A1 20020321 US 2001-909441 20010719 <--
 AU 2001080779 A 20020205 AU 2001-80779 20010725 <--
 PRIORITY APPLN. INFO.: US 2000-220755P P 20000726
 WO 2001-US23424 W 20010725

AB A method for regulating the growth of hair comprising administering to a mammal, an effective amount of a compn. comprising: (a) about 0.001-99.9%, by weight, of at least one metal complex of an oxidized carbohydrate, wherein the metal complex of an oxidized carbohydrate is neither zinc gluconate nor manganese gluconate; and (b) about 0.1-99.999%, by weight, of a vehicle. The compn. is administered orally, parenterally, or topically. For example, a topical compn. contained zinc lactobionate 5.0%, zinc gluconate 1.0%, zinc pyrithione 1.0%, Tween 20 1.0%, propylene glycol 10.0%, dimethylisoboride 18.0%, EtOH 30.0%, and water and minors up to 100%. Also, tablets were prepared containing zinc lactobionate 100 mg, Crospovidone 15 mg, lactose 200 mg, microcryst. cellulose 80 mg, and magnesium stearate 5 mg.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 97 OF 136 CAPLUS COPYRIGHT 2009 ACS on SIN

ACCESSION NUMBER: 1997:558025 CAPLUS
 DOCUMENT NUMBER: 127:252997
 ORIGINAL REFERENCE NO.: 127:49339a,49342a
 TITLE: Skin preparations containing polyrotaxane
 INVENTOR(S): Takei, Masumi
 PATENT ASSIGNEE(S): NOEVIR Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09216815	A	19970819	JP 1996-48250	19960208 <--
JP 3565975	B2	20040915		

PRIORITY APPLN. INFO.: JP 1996-48250 19960208

AB Skin prepn. contain polyrotaxanes, which are safe and biocompatible. The polyrotaxanes may be formed from cyclodextrins and water-soluble or hydrophobic polymers or chain substances. An antiinflammatory skin powder containing polyrotaxane (from bufexamac polyethylene glycol ester and α -cyclodextrin) 40.0, talc 53.0, ZnO 3.0, and Mg stearate 4.0 weight% was stable at 25° for 3 mo.

L16 ANSWER 98 OF 136 CAPLUS COPYRIGHT 2009 ACS on SIN

ACCESSION NUMBER: 2002:72227 CAPLUS
 DOCUMENT NUMBER: 136:137011
 TITLE: Methods and reaction mixtures for controlling exothermic reactions
 INVENTOR(S): Li, Yu-Jun; Mao, Mark Hsiang-Kuen
 PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
 SOURCE: PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006421	A1	20020124	WO 2000-US19079	20000713 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2414191	A1	20020124	CA 2000-2414191	20000713 <--
EP 1299499	A1	20030409	EP 2000-952148	20000713 <--
EP 1299499	B1	20060906		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2004504580	T	20040212	JP 2002-512316	20000713
AT 338800	T	20060915	AT 2000-952148	20000713
ES 2272307	T3	20070501	ES 2000-952148	20000713
US 20030101984	A1	20030605	US 2003-341048	20030113 <--
MX 2003PA00357	A	20040913	MX 2003-PA357	20030113
PRIORITY APPLN. INFO.:			EP 2000-952148	A 20000713
			WO 2000-US19079	W 20000713

AB Reaction mixts. include exothermic generating particles having a water soluble coating encasing a portion of the particles and, optionally an aqueous soln., and a buffer. The reaction mixts. are especially suited to generate heat in a controllable manner. In one such controlled reaction, the reaction components are mixed together and the mixture increases in temperature to a set temperature within a predetd. time, and the mixture remains at the set temperature for a longer period of time. Apparatus and methods that use these reaction mixts. are also disclosed.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 99 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1959:85967 CAPLUS

DOCUMENT NUMBER: 53:85967

ORIGINAL REFERENCE NO.: 53:15486a-c

TITLE: The effect of selected additives on the stability of glucose solutions

AUTHOR(S): Parke, Russell F.; Sperandio, Glen J.

CORPORATE SOURCE: Butler Univ., Indianapolis, IN

SOURCE: Bull. Parenteral Drug Assoc. (1959), 13, 17-24

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB The color in aged glucose solns. was determined spectrophotometrically with and without various stabilizers. An inhibition index was derived by dividing the area beneath the glucose curve by the area beneath the glucose-additive curve. Results showed that initial pH, pH change, and final pH bore no relation to the extent of decomposition as shown by color formation. The chemical type of additive was

of primary importance in the inhibition of color formation. Compds. of the alc. type were the best with 1,6-hexanediol giving the greatest degree of stabilization of all compds. studied.

L16 ANSWER 100 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2000:573623 CAPLUS
 DOCUMENT NUMBER: 133:183062
 TITLE: Gels formed by the interaction of poly(aldehyde) with various substances
 INVENTOR(S): Eknoian, Michael
 PATENT ASSIGNEE(S): Hydromer, Inc., USA
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047149	A1	20000817	WO 2000-US763	20000112 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6121375	A	20000919	US 1999-248591	19990211 <--
CA 2359872	A1	20000817	CA 2000-2359872	20000112 <--
CA 2359872	C	20081007		
EP 1164991	A1	20020102	EP 2000-904312	20000112 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000008129	A	20020205	BR 2000-8129	20000112 <--
HU 2001005366	A2	20020429	HU 2001-5366	20000112 <--
TR 200102333	T2	20020521	TR 2001-2333	20000112 <--
JP 2002536118	T	20021029	JP 2000-598103	20000112 <--
NZ 513492	A	20021126	NZ 2000-513492	20000112 <--
AU 761930	B2	20030612	AU 2000-26091	20000112 <--
RU 2225185	C2	20040310	RU 2001-124859	20000112
NO 2001003913	A	20011010	NO 2001-3913	20010810 <--
NO 322419	B1	20061002		
MX 2001PA08099	A	20020424	MX 2001-PA8099	20010810 <--
PRIORITY APPLN. INFO.:			US 1999-248591	A 19990211
			WO 2000-US763	W 20000112

AB The present invention, which addresses the needs of the prior art, provides irreversible, hydrophilic gels which can be incorporated into dressing compns., dermatol. compatible compns., wound packings, wound dressings, burn dressings, drug delivery dressings, dry films, cosmetic masks and cosmetic wrap dressings. The gels of the invention include a blend of a hydrophilic poly(aldehyde) and a polymer selected from the group consisting of a poly(amide), a poly(amide) and a poly(alc.). A hydrogel was prepared from PVP soln., PEG, acrolein, and poly(ethylenediamine).

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 101 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1996:388306 CAPLUS
 DOCUMENT NUMBER: 125:41791
 ORIGINAL REFERENCE NO.: 125:7937a,7940a
 TITLE: Polyacrylate matrix for transdermal drug delivery

INVENTOR(S): Garbe, James E.; Duan, Daniel C.; Moore, Cheryl L.;
 Keister, Jamieson C.
 PATENT ASSIGNEE(S): Minnesota Mining and Manufacturing Co., USA
 SOURCE: PCT Int. Appl., 84 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9608229	A2	19960321	WO 1995-US12163	19950912 <--
WO 9608229	A3	19960725		
W: AU, CA, JP, KR, NZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9536397	A	19960329	AU 1995-36397	19950912 <--
AU 702593	B2	19990225		
EP 781122	A2	19970702	EP 1995-933919	19950912 <--
EP 781122	B1	20000705		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
JP 10508296	T	19980818	JP 1996-510432	19950912 <--
JP 4102901	B2	20080618		
AT 194281	T	20000715	AT 1995-933919	19950912 <--
ES 2147858	T3	20001001	ES 1995-933919	19950912 <--
PT 781122	T	20001130	PT 1995-933919	19950912 <--
US 7097853	B1	20060829	US 1997-968519	19971112
GR 3033859	T3	20001031	GR 2000-401412	20000706 <--
AU 776102	B2	20040826	AU 2002-18039	20020222
US 20060099242	A1	20060511	US 2005-318312	20051223
PRIORITY APPLN. INFO.:				
			US 1994-305833	A 19940914
			US 1995-523762	B1 19950905
			AU 1995-36397	A3 19950912
			WO 1995-US12163	W 19950912
			US 1997-968519	A1 19971112

AB A transdermal drug delivery device comprises a backing layer and an adherent macromonomer-containing acrylate or methacrylate copolymer matrix which contains a dissolved softener and a drug. The matrix containing the softener may also be used as a pressure-sensitive skin adhesive. The structure and amount of comonomers in the polymer, the inherent viscosity of the copolymer, and the amount and structure of the drug and softener are such as to provide the matrix with a compliance value of $2 + 10^{-6} - 4 + 10^{-3}$ cm²/dyne. This matrix compn. allows dissoln. of the drug and relatively heavy loading with oily excipients and can be removed cleanly from the skin. Thus, 50 g isooctyl acrylate/2-hydroxyethyl acrylate/polystyrene macromonomer (54:36:10) copolymer [41% soln. in EtOAc/iso-PrOH (95:5)] was combined with 1.08 g iso-Pr myristate (softener) and spread 305 μ m thick onto a silicone release liner which was dried and laminated onto polyethylene film. The compliance of this matrix, measured in a shear-creep rheometer, was $0.42 + 10^{-5}$ cm²/dyne.

L16 ANSWER 102 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1980:188275 CAPLUS
 DOCUMENT NUMBER: 92:188275
 ORIGINAL REFERENCE NO.: 92:30396h,30397a
 TITLE: Bath for bright zinc plating
 INVENTOR(S): Popescu, Francine
 PATENT ASSIGNEE(S): Fr.
 SOURCE: Ger. Offen., 26 pp.

DOCUMENT TYPE: CODEN: GWXXBX
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 1 German
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2931809	A1	19800221	DE 1979-2931809	19790806 <--
FR 2433061	A1	19800307	FR 1978-23312	19780808 <--
FR 2433061	B1	19810109		
GB 2030177	A	19800402	GB 1979-27478	19790807 <--
GB 2030177	B	19820915		
US 4222829	A	19800916	US 1979-64504	19790807 <--
PRIORITY APPLN. INFO.:			FR 1978-23312	A 19780808

AB The title brighteners are alkyleneamine polymers which contain an acyl group of the formula, RCO, where R is an alkyl, alkenyl, Ph, alkylphenyl, naphthyl, pyridyl, furyl, or thienyl group either not substituted or substituted with 1 or more of OH-, alkyl, COOH-, or SO3-, or halide. Thus, 100 g of a 50% aqueous soln. of a polyethyleneamine (mol. weight 700) and 12.8 g of a 50% NaOH soln. were reacted. To this was added 15 g propionyl chloride dropwise with stirring and cooling so that the temperature remained <30°. The mixture was refluxed for 1 h and the resulting soln. containing approx. 50% acylated polyethylenimine was used as a brightener in an alkaline Zn bath.

L16 ANSWER 103 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:203381 CAPLUS

DOCUMENT NUMBER: 138:223306

TITLE: Alkyl polyglycoside surfactant systems for agriculturally active compounds

INVENTOR(S): Hopkinson, Michael J.; Moore, Carolyn E.; Fowler, Jeffrey D.

PATENT ASSIGNEE(S): Syngenta Crop Protection, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 11 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030050194	A1	20030313	US 2002-235276	20020905 <--
US 6746988	B2	20040608		
CA 2459698	A1	20030320	CA 2002-2459698	20020905 <--
WO 2003022049	A1	20030320	WO 2002-US28207	20020905 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002323597	A1	20030324	AU 2002-323597	20020905 <--
EP 1423001	A1	20040602	EP 2002-757590	20020905
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

BR 2002012549 A 20041013 BR 2002-12549 20020905
 HU 2004001655 A2 20041228 HU 2004-1655 20020905
 MX 2004PA02176 A 20040629 MX 2004-PA2176 20040305
 PRIORITY APPLN. INFO.: US 2001-317474P P 20010907
 WO 2002-US28207 W 20020905

AB An agricultural compn. comprises at least one agriculturally active compound; at least one alkyl polyglycoside; at least one anionic surfactant selected from a polyaryphenol polyalkoxyether sulfate and a polyaryphenol polyalkoxyether phosphate; and at least one basic compound; wherein the at least one anionic surfactant is neutralized to the inflection point in the titration curve with the at least one basic compound
 REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 104 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1999:763819 CAPLUS
 DOCUMENT NUMBER: 132:1812
 TITLE: Cryopreservation of human red blood cells
 INVENTOR(S): Livesey, Stephen Anthony; Burnett, Michael Brian; Connor, Jerome; Wagner, Christopher Todd
 PATENT ASSIGNEE(S): Lifecell Corporation, USA
 SOURCE: PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9960849	A1	19991202	WO 1999-US11674	19990526 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2332986	A1	19991202	CA 1999-2332986	19990526 <--
AU 9942097	A	19991213	AU 1999-42097	19990526 <--
AU 758703	B2	20030327		
EP 1082006	A1	20010314	EP 1999-925899	19990526 <--
EP 1082006	B1	20060201		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2002516254	T	20020604	JP 2000-550327	19990526 <--
AT 316757	T	20060215	AT 1999-925899	19990526
ES 2257050	T3	20060716	ES 1999-925899	19990526
US 20060127375	A1	20060615	US 2006-334950	20060118
PRIORITY APPLN. INFO.:			US 1998-86836P	P 19980526
			WO 1999-US11674	W 19990526
			US 2000-623846	B1 20000907

AB A red blood cell storage compn. includes a compn. of red blood cells and biochem. altering reagents, the biochem. altering reagents being present at a concentration so as to reduce the percent hemolysis of the red blood cells during the freeze-thaw cycle below that of the percent hemolysis of the red blood cells in the absence of the biochem. altering reagents. The red blood cell storage compn. preferably includes reagents selected from: modifiers of glycolytic/metabolic components, modifiers of antioxidant potential, effectors of intracellular

ionic distribution, modifiers of membrane fluidity, modifiers of cytoskeletal structure, effectors of the cyclooxygenase second messenger pathway, effectors of the lipoxigenase second messenger pathway, effectors of the hexose monophosphate second messenger pathway, effectors of the phosphorylation second messenger pathway, modifiers of specific messenger mols., and combinations thereof.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 105 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1999:70413 CAPLUS
 DOCUMENT NUMBER: 130:115052
 TITLE: Method and device for producing a multilayer, physiologically tolerated dosage form
 INVENTOR(S): Greither, Peter; Engel, Dieter Wolfgang; Brocker, Erich; Tomka, Ivan; Menard, Rico
 PATENT ASSIGNEE(S): Switz.
 SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9902136	A1	19990121	WO 1998-CH294	19980706 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9879045	A	19990208	AU 1998-79045	19980706 <--
EP 998270	A1	20000510	EP 1998-929190	19980706 <--
EP 998270	B1	20050112		
R:	CH, DE, ES, FR, GB, IT, LI			
ES 2235337	T3	20050701	ES 1998-929190	19980706
PRIORITY APPLN. INFO.:			EP 1997-111668	A 19970709
			WO 1998-CH294	W 19980706

AB A multilayer, physiol. tolerated dosage form for medicines, etc., is produced by injecting a core component and a coating component into a shared tool cavity in such a way that the core component is fully coated by the coating component. At least the coating component is made of a polymeric, preferably biopolymeric, material processed thermoplastically. This method allows for the simultaneous production and filling of a dosage form with simple means and using a broad range of materials. Even coatings made of hard material can be produced and filled seamlessly. Thus, capsules were produced by injection molding, in which a coating component (native potato starch (water content 6%) 6.5 and glycerol 3.5 kg/h) and a core component (PEG-6000 20 and hydrocortisone acetate 0.2 kg/h) were introduced into the mold cavities from sep. extruders at 150° and 65°, resp., and a pressure of 50 bar.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 106 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:1311702 CAPLUS

DOCUMENT NUMBER: 144:57525
 TITLE: Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
 INVENTOR(S): Wilson, Michelle; Desai, Kishorkumar J.; Pauletti, Giovanni M.; Antoon, Mitchell K.; Clendening, Chris E. USA
 PATENT ASSIGNEE(S):
 SOURCE: U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 126,863
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 12
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050276836	A1	20051215	US 2005-180076	20050712
US 6197327	B1	20010306	US 1998-79897	19980515 <--
US 6086909	A	20000711	US 1999-249963	19990212 <--
US 6572874	B1	20030603	US 2000-626025	20000727 <--
NZ 508130	A	20020301	NZ 2000-508130	20001113 <--
AU 765269	B2	20030911	AU 2001-54192	20010703 <--
US 20030049302	A1	20030313	US 2002-226667	20020821 <--
US 6982091	B2	20060103		
US 20040005345	A1	20040108	US 2003-349029	20030122
US 6905701	B2	20050614		
US 20040043071	A1	20040304	US 2003-600849	20030620
US 20050249774	A1	20051110	US 2005-126863	20050510

PRIORITY APPLN. INFO.:

US 1997-49325P	P	19970611
US 1998-79897	A2	19980515
US 1999-249963	A2	19990212
US 2000-626025	A2	20000727
US 2002-226667	A2	20020821
US 2003-349029	A2	20030122
US 2003-600849	A2	20030620
US 2004-587454P	P	20040712
US 2005-126863	A2	20050510
AU 1998-76976	A3	19980610
NZ 1998-502120	A1	19980610
US 1999-146218P	P	19990728
US 2001-315877P	P	20010829
US 2002-390748P	P	20020621

AB Disclosed is a vaginal device for delivering therapeutical and/or health-promoting agents. The vaginal device partly or completely coated by, covered by or combined with a coating or covering comprising a film, foam, strip, cap, cup or particles. The coating of the device comprises a mucoadhesive compn. comprising a therapeutical and/or health-promoting agent. For example, sumatriptan vaginal suppository were prepared from Suppocire AS2X, hydroxypropyl Me cellulose as a mucoadhesive agent, and Transcutol as a permeation enhancer.

L16 ANSWER 107 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2002:392219 CAPLUS
 DOCUMENT NUMBER: 136:406945
 TITLE: Methods for in vivo drug delivery based on monitoring blood flow parameters
 INVENTOR(S): Kensey, Kenneth R.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 727,950.

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

CODEN: USXXCO

Patent

English

8

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020061835	A1	20020523	US 2001-828761	20010409 <--
US 6019735	A	20000201	US 1997-919906	19970828 <--
CA 2301161	A1	19990304	CA 1998-2301161	19980826 <--
WO 9910724	A2	19990304	WO 1998-US17657	19980826 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
HU 2001000201	A2	20010528	HU 2001-201	19980826 <--
HU 2001000201	A3	20040329		
NZ 502905	A	20010831	NZ 1998-502905	19980826 <--
JP 2001514384	T	20010911	JP 2000-507994	19980826 <--
US 6322524	B1	20011127	US 1999-439795	19991112 <--
US 6322525	B1	20011127	US 2000-501856	20000210 <--
NO 2000000944	A	20000225	NO 2000-944	20000225 <--
MX 200002073	A	20010821	MX 2000-2073	20000228 <--
US 6428488	B1	20020806	US 2000-615340	20000712 <--
WO 2002009583	A2	20020207	WO 2001-US23696	20010730 <--
WO 2002009583	A3	20020425		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002043806	A2	20020606	WO 2001-US44352	20011127 <--
WO 2002043806	A3	20030327		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002026986	A	20020611	AU 2002-26986	20011127 <--
US 20020088953	A1	20020711	US 2001-33841	20011227 <--
US 6624435	B2	20030923		
WO 2002079778	A2	20021010	WO 2002-US3984	20020207 <--
WO 2002079778	A3	20030710		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			

UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GO, GW, ML, MR, NE, SN, TD, TG

US 20020184941 A1 20021212 US 2002-156165 20020528 <--
 US 6571608 B2 20030603

PRIORITY APPLN. INFO.:

US 1997-919906 A2 19970828
 US 1999-439795 A2 19991112
 US 2000-501856 A2 20000210
 US 2000-628401 A2 20000801
 US 2000-727950 A2 20001201
 US 1997-966076 A 19971107
 WO 1998-US17657 W 19980826
 US 2000-615340 A3 20000712
 US 2000-228612P P 20000828
 US 2001-789350 B2 20010221
 US 2001-819924 A 20010328
 US 2001-828761 A 20010409
 US 2001-839785 A 20010420
 US 2001-841389 A 20010424
 US 2001-897164 A3 20010702
 WO 2001-US44352 W 20011127

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

L16 ANSWER 108 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2002:39555 CAPLUS
 DOCUMENT NUMBER: 136:107223
 TITLE: Cleansing articles for skin and/or hair
 INVENTOR(S): Albacarys, Lourdes Dessus; Mcatee, David Michael;
 Deckner, George Endel
 PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
 SOURCE: U.S., 32 pp., Cont.-in-part of U.S. Ser. No. 65,991,
 abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 8
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6338855	B1	20020115	US 1999-296334	19990422 <--
PRIORITY APPLN. INFO.:			US 1996-738145	B2 19961025
			US 1996-738668	B1 19961025
			US 1997-974033	B2 19971119
			US 1998-65991	B2 19980424
			US 1998-83015P	P 19980424

AB The present invention relates to a substantially dry, disposable, personal

cleansing article useful for both cleansing the skin or hair and delivering skin care actives onto the skin or hair. These articles are used by the consumer by wetting the dry article with water and generating lather by subjecting the wetted article to mech. forces, e.g., rubbing. The article comprises a water insol. substrate, a lathering surfactant, and a skin care active component. Preferably, the articles of the present invention further comprise a deposition aid and/or a conditioning component. The following ingredients containing PEG 0.5 and water qs to 100%. To the above mixture was added disodium EDTA 0.10, sodium lauroyl sarcosinate 3.33, cocamidopropyl betaine 3.33, decyl polyglucoside 3.33, methylparaben 0.25, phenoxyethanol 0.3, and benzyl alc. 0.3%. The following components water 2.0, butylene glycol 2.0, and propylparaben 0.15% were added to the above surfactant mixture. A skin-care active compn. containing sucrose esters with cotton fatty acids 48.00, sucrose ester with behenic acid 12.00, petrolatum 10.00, tribehenin 5.00, and C10-30 cholesterol/lanosterol esters 18.00% and was added to the surfactant mixture

REFERENCE COUNT: 95 THERE ARE 95 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 109 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1999:811045 CAPLUS
 DOCUMENT NUMBER: 132:40559
 TITLE: Cosmetic or dermopharmaceutical beads comprising a hydrophobic wax, an oil, and talcum
 INVENTOR(S): Ioulalen, Karim; Raynal, Rosanne
 PATENT ASSIGNEE(S): Fr.
 SOURCE: PCT Int. Appl., 15 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9965448	A2	19991223	WO 1999-FR1445	19990616 <--
WO 9965448	A3	20000217		
W: AU, CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2779962	A1	19991224	FR 1998-7612	19980617 <--
FR 2779962	B1	20021206		
CA 2341580	A1	19991223	CA 1999-2341580	19990616 <--
EP 1030687	A2	20000830	EP 1999-925113	19990616 <--
EP 1030687	B1	20050824		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 302614	T	20050915	AT 1999-925113	19990616
ES 2247804	T3	20060301	ES 1999-925113	19990616
US 6572892	B1	20030603	US 2001-719852	20010319 <--
PRIORITY APPLN. INFO.: FR 1998-7612 A 19980617				
WO 1999-FR1445 W 19990616				

AB The invention concerns an anhydrous solid compn. comprising at least a hydrophobic wax, an oil and talcum, having preferably the form of beads with size ranging from 1 to 10000 μ . The beads can contain a cosmetic or pharmaceutical active principle, pigments or an agri-food constituent. The invention also concerns the method for preparing said beads. Vitamin beads were prepared from paraffin oil 55, paraffin 16, silicone oil 6, PEG 6, talc 6, vitamin E 0.5, provitamin A 0.3, silica 4, titanium dioxide 3, sunscreens 3, and preservatives 0.2 g.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 110 OF 136 CAPLUS COPYRIGHT 2009 ACS ON STN
ACCESSION NUMBER: 2003:33867 CAPLUS
DOCUMENT NUMBER: 138:108386
TITLE: Reactive dye-based aqueous jet ink compositions with good storage stability and light, water, and clogging resistance
INVENTOR(S): Onishi, Yasuharu; Endo, Hiroyuki; Ueki, Hiroyuki
PATENT ASSIGNEE(S): Fuji Xerox Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 24 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003012976	A	20030115	JP 2001-199323	20010629 <--
PRIORITY APPLN. INFO.:			JP 2001-199323	20010629

AB The ink comps. comprise C.I. Reactive Dyes, organic solvents, surfactants, and 0.1-5.0% comps. (catalysts for dyeing cellulose fibers), 1 g of which increase pH of 100 g pure water. The inks may further contain polyethylene glycol (I). Color and optical d. of printed images of the inks are also specified. Thus, an aqueous ink containing Reactive Yellow 97, I, and Na2CO3 showed no fogging of printed images.

L16 ANSWER 111 OF 136 CAPLUS COPYRIGHT 2009 ACS ON STN
ACCESSION NUMBER: 1996:392780 CAPLUS
DOCUMENT NUMBER: 125:67555
ORIGINAL REFERENCE NO.: 125:12755a
TITLE: Simplex lattice design for the optimization of the microencapsulation of water soluble drug using poly(lactic acid) and poly(lactide co-glycolide) copolymer
AUTHOR(S): Elkhesheh, S.
CORPORATE SOURCE: Dep. Pharmaceutics, Faculty Pharmacy, Cairo Univ., Cairo, 11562, Egypt
SOURCE: Journal of Microencapsulation (1996), 13(4), 447-462
CODEN: JOMIEF; ISSN: 0265-2048
PUBLISHER: Taylor & Francis
DOCUMENT TYPE: Journal
LANGUAGE: English
AB An emulsion solvent evaporation technique was applied to prepare microspheres of nicotinic acid as a water-soluble vitamin. Poly(lactic acid) of 2 mol. wts., 2000 and 100,000 and poly(lactide-co-glycolide) (50:50) of mol. weight 18 000 were used. A Simplex lattice design with the aid of a computer program was applied to study the effect of the previously mentioned polymers on different characteristics of the prepared microcapsules. The studied characteristics included the yield, the percentage drug loading and the particle size of microcapsules. Microcapsules were examined by light microscope for particle size determination and by electron scanning microscope for surface morphol. characterization. The release pattern of the drug from the microcapsules was evaluated on the basis of the burst effect, the rate of release and the extent of

release after 24 h. A model equation was developed to be the best representation of the relationship between the above polymers and the measured characteristics. The goodness of fit of the developed equations was checked, both statistically and exptl. The release of the drug from microcapsules mainly followed the Higuchi diffusion model. Poly(lactic acid) of a mol. weight 100 000 had the most pronounced delaying effect on the release rate of the drug. However, poly(lactic acid) of a mol. weight 2000 showed the highest improvement effect on the yield and the drug loading characteristics of the microcapsules. Poly(lactide-co-glycolide) exhibited the lowest burst effect and the most steady drug release pattern.

L16 ANSWER 112 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:569681 CAPLUS
 DOCUMENT NUMBER: 141:117191
 TITLE: Seborrhic keratosis treatment using hydrogen peroxide
 INVENTOR(S): Ancira, Margaret; Miller, Mickey
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 72,829.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040137077	A1	20040715	US 2003-684136	20031009
US 7381427	B2	20080603		
US 20030008018	A1	20030109	US 2002-72829	20020208 <--
US 7138146	B2	20061121		
AU 2007203283	A1	20070802	AU 2007-203283	20070716
PRIORITY APPLN. INFO.:			US 2001-267978P	P 20010209
			US 2002-72829	A2 20020208
			AU 2002-251894	A3 20020208

AB The subject of the present invention is seborrhic keratosis removal and prevention utilizing safe dependable effective biocompatible treatments with no scarring, bleeding, burning, freezing, shocking, and hypopigmentation or hyperpigmentation. Seborrhic keratoses are removed by: (a) obtaining a compn. comprising hydrogen peroxide in a concentration of at least about 23 %; and (b) applying the compn. to a seborrhic keratosis on a seborrhic keratoses afflicted person or domesticated animal. Patients were treated with applications of 35 % hydrogen peroxide. Comps. are presented.

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 113 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1996:231195 CAPLUS
 DOCUMENT NUMBER: 124:311577
 ORIGINAL REFERENCE NO.: 124:57623a,57626a
 TITLE: Solving bioanalytical problems by the method of matrix-assisted laser desorption/ionization mass spectrometry [MALDI-MS]
 AUTHOR(S): Zhao, Shankai; Zhong, Feng; Zhu, Zhihua
 CORPORATE SOURCE: Instrumentation Analysis & Research Center, Zhongshan Univ., Canton, Peop. Rep. China
 SOURCE: Analytical Sciences (1996), 12(2), 363-6
 CODEN: ANSCEN; ISSN: 0910-6340
 PUBLISHER: Japan Society for Analytical Chemistry

DOCUMENT TYPE: Journal
LANGUAGE: English

AB MALDI-MS was used to solve some bioanal. problems that are difficult to analyze by general methods. For the selection of a proper laser wavelength and matrixes, 7 matrixes were used with laser wavelengths of 266 and 355 nm. The results show that with a wavelength of 355 nm better results could be obtained with most of the matrixes. The mol. weight of cytochrome c, which was separated by gel electrophoresis and electroblotted onto nitrocellulose membrane, was determined by MALDI-MS. The accuracy was better than 0.1%, which is much higher than that of SDS-PAGE. The 3 components of a protein mixture extracted from crude peanut oil were directly determined by MALDI-MS. The result also demonstrated that these proteins are in a free state. Since these proteins are in a 2S bond, with the traditional method, SDS-PAGE, it is not possible to decide whether the proteins exist in a combined mode or in a free state. Water-soluble polymers stained with dyes are used in the technique of 2-phase aqueous solns., which is used for separating biomaterials. By using MALDI, the number of the dye mols. that react with the polymer mols. can be determined, which is difficult to determine by other methods.

L16 ANSWER 114 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:796416 CAPLUS

DOCUMENT NUMBER: 139:307686

TITLE: Preparation of 2,3-diphenylpyridines as cannabinoid-1

receptor antagonists and inverse agonists

INVENTOR(S): Finke, Paul E.; Meurer, Laura C.; Debenham, John S.;

Toupence, Richard B.; Walsh, Thomas F.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 211 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082191	A2	20031009	WO 2003-US9005	20030324 <--
WO 2003082191	A3	20040115		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
CA 2479744	A1	20031009	CA 2003-2479744	20030324 <--
AU 2003225964	A1	20031013	AU 2003-225964	20030324 <--
AU 2003225964	B2	20081120		
EP 1492784	A2	20050105	EP 2003-745578	20030324
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005531520	T	20051020	JP 2003-579734	20030324
US 20050182103	A1	20050818	US 2004-508043	20040917
US 7271266	B2	20070918		


PRIORITY APPLN. INFO.:

US 2002-368334P P 20020328
WO 2003-US9005 W 20030324

OTHER SOURCE(S): MARPAT 139:307686



I



II

AB Title compds. I [wherein R1 = H, halo, CN, or (un)substituted alkyl, heterocycloalkyl(alkyl), heteroaryl, (hetero)arylalkyl, acyl, carboxy, (thio)ether, amino, carbamoyl, acylamino, carboxyamino, or ureido; R2 = H, CN, carboxy, halo, NO₂, CF₃, or (un)substituted carbamoyl; provided that R1 and R2 are not both H; R3 = H, CF₃, or (un)substituted (cyclo)alkyl; R4-R7 = independently H, halo, amino, carboxy, alkyl, alkoxy, aryl(alkyl), OH, CF₃, alkanoyloxy, or carbamoyloxy; provided that R6 and R7 are not both H; and pharmaceutically acceptable salts thereof] were prepared as cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists (no data). For example, benzyl 4-chlorophenyl ketone was condensed with DMF dimethylacetal in DMF to give 3-(dimethylamino)-1-(4-chlorophenyl)-2-phenylprop-2-en-1-one. Cyclocondensation of the vinyl ketone with cyanoacetamide using NaH in DMF and MeOH provided the 3-cyano-2-pyridone. Conversion of the nitrile to the carboxylic acid with 50% H₂SO₄, followed by esterification using HCl in MeOH gave Me 6-(4-chlorophenyl)-5-phenyl-2-oxo-1,2-dihydropyridine-3-carboxylate. O-alkylation of the pyridone with benzyl bromide in the presence of Cs₂CO₃ in DMF afforded the title 2,3-diphenylpyridine II. Compds. of the invention and their pharmaceutical compns. serve as centrally acting drugs for the treatment, prevention, and suppression of diseases mediated by the CB1 receptor, such as psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome, the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia (no data). I are also useful for the treatment of substance abuse disorders, obesity or eating disorders, asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver (no data).

REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 115 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1996:717987 CAPLUS
 DOCUMENT NUMBER: 126:152215
 ORIGINAL REFERENCE NO.: 126:29277a
 TITLE: End-functionalized polyethylene oxide coated silica particles for packed capillary column supercritical fluid chromatography
 AUTHOR(S): Shen, Y.; Lee, M. L.
 CORPORATE SOURCE: Department Chemistry, Brigham Young University, Provo, UT, 84602, USA
 SOURCE: Chromatographia (1996), 43(7/8), 373-379
 CODEN: CHRGB7; ISSN: 0009-5893
 PUBLISHER: Vieweg
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Polyethylene oxide (PEO)-based polymers with HO, MeO, and MeHC(NH2)H2C terminal groups were coated on diol functionalized and hexamethyldisilazane end-capped silica particles. Proton-donor and proton-acceptor test solutes, including carboxylic acids, hydroxy-containing compds., arylamines, and alkylamines were used to evaluate the chromatog. performances of these polymer coated particles under SFC conditions with neat CO2 as mobile phase. It was found that the particles coated with hydroxy-terminated PEO were suitable for the separation of proton-donor compds. such as hydroxy-containing compds. and carboxylic acids, and the particles coated with amino-propoxy-terminated PEO could be used for the separation of amines. The proton-accepting stationary phase is suitable for the separation of proton accepting solutes, including strong basic alkylamines (pKb .apprx.4), using neat CO2 as mobile phase, while the proton-donating stationary phase is suitable for the separation of proton-donating compds. such as carboxylic acids (pKa .apprx.4). Hydrogen bond basicity was found to be a critical factor for the chromatog. of basic amines. Low volatility acidic and basic drugs were chromatographed using the new stationary phases. The stability of the PEO coated particles was determined by measuring the loss of organic carbon under SFC conditions.
 Approx.
 18% of the coating (Mn .apprx.15,000) was washed out of the particles by supercrit. CO2 after 7 h at 350 atm and 50°.

L16 ANSWER 116 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1990:538500 CAPLUS
 DOCUMENT NUMBER: 113:138500
 ORIGINAL REFERENCE NO.: 113:23421a,23424a
 TITLE: Matrix for transdermal drug release comprising a copolymer of organosiloxane and polyurethane
 INVENTOR(S): Sweet, Randall Paul; Lee, Chi Long; Gornowicz, Gerald Alphonse
 PATENT ASSIGNEE(S): Dow Corning Corp., USA
 SOURCE: Eur. Pat. Appl., 9 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 338819	A2	19891025	EP 1989-303914	19890420 <--
EP 338819	A3	19900221		
EP 338819	B1	19931124		

R: CH, DE, FR, GB, IT, LI
 CA 1323473 C 19931026 CA 1989-593743 19890315 <--
 JP 01311016 A 19891215 JP 1989-100386 19890421 <--
 JP 07025668 B 19950322

PRIORITY APPLN. INFO.: US 1988-184748 A 19880422

AB A transdermal drug delivery system is provided which includes an impermeable backing member, a matrix containing a medicinally active ingredient, and a pressure sensitive adhesive for affixing the system to the skin of a patient. The matrix is drug permeable (including to hydrophilic drugs) and is formed of a copolymer which can be softened sufficiently at 45-160° to incorporate the drugs without damage by heat or chemical reactions. The matrix is formed of a linear block copolymer which is a reaction product of a polydiorganosiloxane which forms soft segments in the reaction product and a diisocyanate which forms hard segments. The copolymer has a glass transition temperature of 45-160°. The soft segments comprise 80-99% based on the weight of the copolymer. The average mol. weight of the copolymer is 15,000-500,000. 4,4'-Dicyclohexylmethyl diisocyanate (53 g) was refluxed with 1397.2 g N-methylaminoisobutyl-end blocked polydimethylsiloxane, to give a urea copolymer. When loaded with 1% progesterone, the copolymer showed a release rate of 171 µg/cm²/h.

L16 ANSWER 117 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1967:51710 CAPLUS
 DOCUMENT NUMBER: 66:51710
 ORIGINAL REFERENCE NO.: 66:9743a,9746a
 TITLE: Zinc cyanide electroplating bath and process
 INVENTOR(S): Rushmere, John D.
 PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co.
 SOURCE: U.S., 6 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3296105		19670103	US 1964-357291	19640403 <--
AB Compds. which contain an .tp1bond. N-O group and which are soluble in a Zn(CN) ₂ plating bath are proposed as brighteners for Zn electrodeposits. When used in combination with a soluble organic polymer, a synergistic brightening effect is obtained. Suitable brighteners include Me3N N-oxide, nicotinic acid N-oxide, m.(dimethylamino)phenol N-oxide, pyridine N-oxide, isoquinoline-5-sulfonic acid N-oxide, and nicotine-1'-N-oxide. Soluble polymers include poly(vinyl alc.), poly(ethyleneimine), gelatin, and peptone. The concentration of N-oxide used is 0.1-10.0 g./l., that of the polymer 0.05-5 g./l., and the N-oxide to polymer ratio 3-9:1. The brighteners can be used in either barrel or still plating, show a wide, bright c.d. range in Hull cell tests, and are stable over a 9-day storage period.				

L16 ANSWER 118 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1995:606795 CAPLUS
 DOCUMENT NUMBER: 122:322513
 ORIGINAL REFERENCE NO.: 122:58487a,58490a
 TITLE: Manufacture of adhesive hydrogels for long-term use
 INVENTOR(S): Fox, Adrian S.; Czap, Christine A.; Wiser, Robin R.
 PATENT ASSIGNEE(S): Nepera, Inc., USA
 SOURCE: U.S., 17 pp. Cont.-in-part of U.S. Ser. No. 790,968,

abandoned.
 CODEN: USXXAM
 Patent
 English
 DOCUMENT TYPE:
 LANGUAGE:
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5405366	A	19950411	US 1992-974449	19921112 <--
PRIORITY APPLN. INFO.:			US 1991-790968	B2 19911112

AB This invention relates to a non-stringy adhesive hydrophilic gel comprising an aqueous mixture of a radiation crosslinkable water-soluble polymer, at least one humectant effective to extend the moisture retaining characteristics of the gel and which inhibits the ability of radiant energy to crosslink the water-soluble polymer, a pharmacol. active agent, and a crosslinking promoter effective to counteract the crosslinking inhibitory effect of humectant. The aqueous mixture is exposed to radiant energy effective to provide a non-stringy adhesive cohesive homogeneous hydrophilic gel that has an extended in-use lifetime. The gels can be formed into patches for long term application of the pharmacol. active agent to a patient. A feedmix containing glycerol, polyethylene oxide, and water was mixed with N,N'-methylene-bis-acrylamide. A LDPE sheet was coated with the above mixture and irradiated to have a crosslinked hydrogel, which remained soft to the touch.

L16 ANSWER 119 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1988:82110 CAPLUS
 DOCUMENT NUMBER: 108:82110
 ORIGINAL REFERENCE NO.: 108:13461a,13464a
 TITLE: Sheet-type buccal adhesive tapes for sustained drug delivery in oral cavity
 INVENTOR(S): Mizobuchi, Tadafumi; Oji, Yoshikimi; Sako, Seiichi; Rokusha, Kaneyoshi
 PATENT ASSIGNEE(S): Teikoku Seiyaku Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62178513	A	19870805	JP 1986-20468	19860201 <--
JP 07029915	B	19950405		
US 4876092	A	19891024	US 1987-8771	19870130 <--
PRIORITY APPLN. INFO.:			JP 1986-20468	A 19860201

AB Sheet-type adhesive tapes for oral cavity consist of an adhesive layer containing carboxyvinyl polymers, water-insol. methacrylate copolymers, polyhydric alcs., and active ingredients and a water-nonpermeable and -insol. support layer containing pharmacol. acceptable, water-insol., film-forming polymers and plasticizers. An adhesive tape consisted of an adhesive layer containing Hiviswako 12, Eudragit RS 0.12, polyethylene glycol 400 2, TiO2 0.6, triamcinolone acetonide 0.06 g and Ethocel 140 mL and a support layer made from a mixture containing Ethocel 15, castor oil 4 g, red color number 10 mg and EtOH 140 mL.

L16 ANSWER 120 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:71788 CAPLUS
 DOCUMENT NUMBER: 136:139647
 TITLE: Multi-layer reaction mixtures and apparatuses for delivering a volatile component via a controlled exothermic reaction
 INVENTOR(S): Li, Yu-Jun; Mao, Mark Hsiang-Kuen; Tamura, Haruo; Hu, Hsin-Yuan
 PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
 SOURCE: PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005640	A1	20020124	WO 2000-US19081	20000713 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2414166	A1	20020124	CA 2000-2414166	20000713 <--
AU 2000063445	A	20020130	AU 2000-63445	20000713 <--
EP 1298993	A1	20030409	EP 2000-950328	20000713 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2004503669	T	20040205	JP 2002-511590	20000713
US 20030105192	A1	20030605	US 2003-340993	20030113 <--
US 7081211	B2	20060725		
MX 2003PA00354	A	20040913	MX 2003-PA354	20030113
PRIORITY APPLN. INFO.: WO 2000-US19081			W 20000713	
AB Multilayer reaction mixts. that include exothermic generating particles having a water soluble coating encasing a portion of the particles, a volatile component and, optionally, a buffer, an aqueous soln. or both are disclosed. At least two layers of the reaction mixture contain exothermic generating particles and at least one layer of the reaction mixture contains a portion of the exothermic generating particles suspended in a gel that includes the water soluble coating. These multilayer reaction mixts. are especially suited to generate heat in a controllable manner, so that volatile components can be controllably released to the surrounding environment. Apparatus and methods using these multilayer reaction mixts. are also disclosed.				
REFERENCE COUNT:	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L16 ANSWER 121 OF 136 CAPLUS COPYRIGHT 2009 ACS ON STN
 ACCESSION NUMBER: 1999:133630 CAPLUS
 DOCUMENT NUMBER: 130:187230
 TITLE: Sterile bioerodible implant device containing a retinoid with improved biocompatibility
 INVENTOR(S): Olejnik, Orest; Hughes, Patrick M.; Kent, John S.
 PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9907418	A2	19990218	WO 1998-US16589	19980810 <--
WO 9907418	A3	19990603		
W: AU, CA, JP RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2300154	A1	19990218	CA 1998-2300154	19980810 <--
CA 2300154	C	20080708		
AU 9887777	A	19990301	AU 1998-87777	19980810 <--
AU 738338	B2	20010913		
EP 1003569	A2	20000531	EP 1998-939319	19980810 <--
EP 1003569	B1	20041020		
R: DE, ES, FR, GB, IT				
JP 2001513369	T	20010904	JP 2000-507004	19980810 <--
ES 2232005	T3	20050516	ES 1998-939319	19980810
HK 1026377	A1	20050506	HK 2000-105715	20000911
JP 2008272512	A	20081113	JP 2008-187428	20080718

PRIORITY APPLN. INFO.:

US 1997-908094 A 19970811
 JP 2000-507004 A3 19980810
 WO 1998-US16589 W 19980810

AB A plantable device is provided which incorporates a retinoid for improving the biocompatibility of the device in tissue. The device may be bioerodible for the purpose of systemically or locally releasing a therapeutic agent in tissue or it may be a permanent implant which includes a surface treated with a retinoid for increasing the biocompatibility thereof. Poly(D,L-lactic acid) was mixed with retinoid 6-[(4,4-di-Me thiochroman-6-y)ethynyl] nicotinic acid and the mixture was extruded at 85° into a homogeneous rod. The retinoid was incorporated into the polymeric plug at a concentration of 10%. The extruded plug was then cut to a length of 3.0 mm and had a diameter of 1.5 mm. A 0.5 mm hole was drilled into the distal end of the plug to allow for suture fixation to the sclera and sterilized by γ -irradiation. The plugs were inserted through a sclerotomy 3 mm posterior to the corneoscleral limbus in rabbit eyes and were then fixated with suture uses to close the sclerotomy. The plug disappeared in the processing of the eye and the capsule surrounding the retinoid had very little fibrous inflammation.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 122 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1955:25131 CAPLUS

DOCUMENT NUMBER: 49:25131

ORIGINAL REFERENCE NO.: 49:4884c-d

TITLE: Short-term cultures for drug assays

AUTHOR(S): Pomerat, Charles M.; Leake, Chauncey D.

CORPORATE SOURCE: Univ. of Texas Med. Branch, Galveston

SOURCE: Annals of the New York Academy of Sciences (1954), 58, 1110-28

CODEN: ANYAA9; ISSN: 0077-8923

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB A table is given surveying the toxicity of 112 compds., as evidenced by tissue cultures. The tissues used were chick spinal cord, heart, and spleen and human skin explants.

L16 ANSWER 123 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2002:964913 CAPLUS
 DOCUMENT NUMBER: 138:12163
 TITLE: Water-miscible insecticide containing a synergistic cocktail of alkaloids
 INVENTOR(S): Wu, Chang-An; Wu, Hong; Lei, Lin
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S. 6,372,239.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020192256	A1	20021219	US 2001-26361	20011221 <--
US 6372239	B1	20020416	US 2000-655613	20000906 <--
PRIORITY APPLN. INFO.:			US 2000-655613	A2 20000906
			CN 2000-100591	A 20000128

AB Comps. and methods are provided for controlling pests by using cocktails of plant alkaloids. The compn. is formulated with a water-miscible solvent and comprises two or more alkaloids selected from toosendanin, azadirachtin, tomatine, stemonine, nicotine, anabasine, matrine, oxymatrine, sophocarpine, N-oxyphocarpine, cytosine, and aloperine. The water-miscible insecticide can be used to protect crops, wood structures and animals from damages by harmful pests, overcome resistance of pests to current com. pesticides, and reduce contamination to the environment.

L16 ANSWER 124 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:950045 CAPLUS
 DOCUMENT NUMBER: 140:770
 TITLE: Administration of acetylcholinesterase inhibitors via intranasal delivery to the cerebral spinal fluid for treatment of cognitive disorders
 INVENTOR(S): Quay, Steven C.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 23 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030225031	A1	20031204	US 2003-439108	20030515 <--
CA 2482161	A1	20040108	CA 2003-2482161	20030519
WO 2004002402	A2	20040108	WO 2003-US15653	20030519
WO 2004002402	A3	20041007		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003269874	A1	20040119	AU 2003-269874	20030519
EP 1505971	A2	20050216	EP 2003-751761	20030519

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005532372	T	20051027	JP 2004-517563	20030519
NZ 535192	A	20060526	NZ 2003-535192	20030519
US 20040254146	A1	20041216	US 2004-831031	20040423
ZA 2004007420	A	20060628	ZA 2004-7420	20040915
IN 2004KN01664	A	20071012	IN 2004-KN1664	20041108
US 20060003989	A1	20060105	US 2005-112950	20050422

PRIORITY APPLN. INFO.:
 US 2002-382122P P 20020521
 US 2003-439108 A2 20030515
 WO 2003-US15653 W 20030519
 US 2004-831031 A2 20040423

AB Methods and compns. are disclosed that provide acetylcholinesterase inhibitors for the prevention and treatment of diseases and disorders of the central nervous system, including dementia such as Alzheimer's disease, to the central nervous system via intranasal delivery. The methods and compns. of the present invention provide therapeutic concns. of the acetylcholinesterase inhibitor in the cerebrospinal fluid of a mammal without the attendant disadvantages, risks and side effects of oral or injection delivery.

L16 ANSWER 125 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:678288 CAPLUS
 DOCUMENT NUMBER: 139:202459
 TITLE: Solubilized riboflavin
 INVENTOR(S): Hird, Geoffrey; Lambert, Bill
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 11 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 20030161871	A1	20030828	US 2001-24876	20011219 <--
PRIORITY APPLN. INFO.:			US 2001-24876	20011219

AB To facilitate the use of riboflavin as a pharmaceutical and addnl. to increase the efficacy of water soluble forms of riboflavin (that may contain precipitated riboflavin), the present invention provides solubilized riboflavin, methods for solubilizing riboflavin and kits comprising solubilized riboflavin. A vial contained riboflavin 5'-phosphate sodium 419.2, sucrose 800.0, sodium hydroxide 23.64, hydrochloric acid, and water 7229 mg which was then lyophilized.

L16 ANSWER 126 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1977:436100 CAPLUS
 DOCUMENT NUMBER: 87:36100
 ORIGINAL REFERENCE NO.: 87:5697a,5700a
 TITLE: Water and glycol bonding dispersions for synthetic fibers
 INVENTOR(S): Morie, Gerald P.; Sloan, Cephas H.
 PATENT ASSIGNEE(S): Eastman Kodak Co., USA
 SOURCE: U.S., 6 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4022740	A	19770510	US 1975-573228	19750430 <--
CA 1038984	A1	19780919	CA 1975-231193	19750710 <--
BE 835736	A4	19760519	BE 1975-162011	19751119 <--
DK 7600633	A	19760217	DK 1976-633	19760217 <--
PRIORITY APPLN. INFO.:			US 1973-411117	A2 19731030
			US 1974-498349	A2 19740819
			DK 1974-5634	A 19741029
			US 1975-573228	A 19750430

AB Thermoplastic polymer compns. dispersed in glycols containing 0.1-20% water were prepared for bonding man-made fibers together for use as tobacco filter rods. Thus a mixture consisting of 70% propylene glycol, 5% water, and 25% of a copolyester composed of 90 mol % isophthalic acid, 10% sodiosulfisophthalic acid, and 100 mol % diethylene glycol was sprayed on a tow consisting of cellulose acetate fibers crimped to 12 crimps/in. Filters were prepared from the tow after drying, and incorporated into cigarettes which were machine smoked. The filters had a resistance to draw of 2.6 in. of water, and removed 36% total particulate matter (TPM) and nicotine, comparing favorably (37 and 35%, resp.) to control filters containing glycerol triacetate. Filters were prepared using several other diols and fibers. Filters prepared in this way when placed in water and agitated for several min were not recognizable as filters.

L16 ANSWER 127 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:242218 CAPLUS
 DOCUMENT NUMBER: 138:260398
 TITLE: Method for removing noxious substances from blood or fermentation broth using functionalized hollow fiber adsorbers
 INVENTOR(S): Hoffmann, Michael; Horres, Roland; Hoffmann, Erika; Kuesters, Sabine; Erdtmann, Martin
 PATENT ASSIGNEE(S): Hemoteg G.m.b.H., Germany
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024587	A2	20030327	WO 2002-DE3527	20020920 <--
WO 2003024587	A3	20030710		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10147463	A1	20030417	DE 2001-10147463	20010920 <--

AU 2002339305 A1 20030401 AU 2002-339305 20020920 <--
 PRIORITY APPLN. INFO.: DE 2001-10147463 A 20010920
 WO 2002-DE3527 W 20020920

AB The invention relates to a method for producing an adsorber for removing
 noxious substances from full blood and/or plasma and cell culture media.
 The invention further relates to an adsorber in the form of hollow fibers
 or non-aggregated particles and to the use of said adsorber, and to a
 method for removing noxious substances from full blood and/or plasma using
 a device that comprises the adsorber according to the invention.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 128 OF 136 CAPLUS COPYRIGHT 2009 ACS ON STN
 ACCESSION NUMBER: 2001:165718 CAPLUS
 DOCUMENT NUMBER: 134:212054
 TITLE: Method and apparatus for removal of pollutants from
 gases, for example tobacco smoke from air
 INVENTOR(S): Bayer, Michael
 PATENT ASSIGNEE(S): Clariant G.m.b.H., Germany
 SOURCE: Ger. Offen., 4 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10055515	A1	20010308	DE 2000-10055515	20001109 <--
WO 2001066228	A1	20010913	WO 2001-EP1897	20010220 <--
W: CN, JP, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1272258	A1	20030108	EP 2001-919317	20010220 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2003525734	T	20030902	JP 2001-564873	20010220 <--
US 20030075076	A1	20030424	US 2002-220774	20020905 <--
US 7056481	B2	20060606		

PRIORITY APPLN. INFO.: DE 2000-10011031 A 20000307
 DE 2000-10046015 A 20000918
 DE 2000-10055515 A 20001109
 WO 2001-EP1897 W 20010220

AB A solid pellet containing a wax, having a m.p. of 40-150°, a fusion
 viscosity 2-20000 mPas, a needle penetration number of 1-50, and containing
 ≥1 alkoxylated compound, is used to filter nicotine, ozone,
 formaldehyde, and products of tobacco combustion from air.

L16 ANSWER 129 OF 136 CAPLUS COPYRIGHT 2009 ACS ON STN
 ACCESSION NUMBER: 2003:261864 CAPLUS
 DOCUMENT NUMBER: 138:282444
 TITLE: Cloning, purification and characterization of
 polypeptides from pathogenic bacteria involved in
 membrane biosynthesis, and drug screening and drug
 design applications
 INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Alam,
 Muhammad Zahoor; Awrey, Donald; Beattie, Bryan;
 Canadien, Veronica; Domagala, Megan; Houston, Simon;
 Kanagarajah, Dhushy; Li, Qin; Mansoury, Kamran;
 McDonald, Merry-Lynn; Necakov, Sasha; Ng, Ivy; Pinder,
 Benjamin; Sheldrick, Bay; Vallee, Francois; Viola,

PATENT ASSIGNEE(S): Cristina; Wrezel, Olga
 Affinium Pharmaceuticals, Inc., Can.
 SOURCE: PCT Int. Appl., 312 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003027139	A2	20030403	WO 2002-CA1443	20020924 <--
WO 2003027139	A3	20040219		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002328231	A1	20030407	AU 2002-328231	20020924 <--
PRIORITY APPLN. INFO.:			US 2001-324449P	P 20010924
			US 2001-324504P	P 20010924
			US 2001-326269P	P 20011001
			US 2001-326887P	P 20011003
			US 2001-339560P	P 20011024
			US 2001-337471P	P 20011025
			US 2001-340000P	P 20011026
			US 2001-340002P	P 20011026
			US 2001-340027P	P 20011026
			US 2001-341767P	P 20011218
			US 2001-344307P	P 20011221
			US 2001-343946P	P 20011227
			WO 2002-CA1443	W 20020924

AB The present invention relates to polypeptide targets for pathogenic bacteria. A number of antimicrobial target enzymes and proteins have been identified, expressed, and purified from *Staphylococcus aureus*, *Helicobacter pylori*, *Streptococcus pneumoniae*, and *Pseudomonas aeruginosa*. Cloning, the nucleotide sequences and the encoded amino acid sequences of genes *ftsZ*, *fabZ*, *acpS*, *murD*, *murC*, *fabH*, *tagD*, *obg*, and *fabG* from *S. aureus*, *H. pylori*, *S. pneumoniae*, and *P. aeruginosa* are disclosed. The invention also provides biochem. and biophys. characteristics of those polypeptides. The polypeptides are characterized by using mass spectrometry, NMR, x-ray crystallog., and bioinformatics anal. The polypeptides of the invention can be used for drug screening, drug design, in diagnostic assays and in pharmacol. applications.

L16 ANSWER 130 OF 136 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2003:242368 CAPLUS

DOCUMENT NUMBER: 138:282426

TITLE: Cloning, purification and characterization of polypeptides from pathogenic bacteria involved in nucleic acid processing and drug screening and drug design applications

INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Alam, Muhammad Zahoor; Arrowsmith, Cheryl; Awrey, Donald; Beattie, Bryan; Canadien, Veronica; Cox, Brian; Domagala, Megan; Houston, Simon; Li, Qin; Nethery,

Kathleen; Ng, Ivy; Ouyang, Hui; Pinder, Benjamin;
 Sheldrick, Bay; Viola, Cristina; Wrezel, Olga
 Affinium Pharmaceuticals, Inc., Can.
 PATENT ASSIGNEE(S):
 SOURCE: PCT Int. Appl., 298 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 16
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003025004	A2	20030327	WO 2002-CA1411	20020918 <--
WO 2003025004	A3	20040304		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002328215	A1	20030401	AU 2002-328215	20020918 <--
PRIORITY APPLN. INFO.:			US 2001-323040P	P 20010918
			US 2001-325307P	P 20010927
			US 2001-325421P	P 20010927
			US 2001-325891P	P 20010928
			US 2001-326337P	P 20011001
			US 2001-326774P	P 20011003
			US 2001-327193P	P 20011004
			US 2001-340922P	P 20011030
			US 2001-338709P	P 20011105
			US 2001-333269P	P 20011106
			US 2001-341679P	P 20011218
			WO 2002-CA1411	W 20020918

AB The present invention relates to polypeptide targets for pathogenic bacteria. A number of antimicrobial target enzymes and proteins have been identified, expressed, and purified from *Staphylococcus aureus*, *Helicobacter pylori*, *Streptococcus pneumoniae*, and *Pseudomonas aeruginosa*. Cloning, the nucleotide sequences and the encoded amino acid sequences of genes *nrdE*, *pyrH*, *pnpA*, *ung*, *rho*, *pnp*, *pyrE*, *lig*, *dnaN*, *nrdF*, and *nrdE* from *S. aureus*, *H. pylori*, *S. pneumoniae*, and *P. aeruginosa* are disclosed. The invention also provides biochem. and biophys. characteristics of those polypeptides. The polypeptides are characterized by using mass spectrometry, NMR, x-ray crystallog., and bioinformatics anal. The polypeptides of the invention can be used for drug screening, drug design, in diagnostic assays and in pharmacol. applications.

L16 ANSWER 131 OF 136 CAPLUS COPYRIGHT 2009 ACS ON STN
 ACCESSION NUMBER: 2003:472697 CAPLUS
 DOCUMENT NUMBER: 139:49457
 TITLE: Optically transparent substrate for a MALDI measuring system and the use thereof
 INVENTOR(S): Kresbach, Gerhard M.; Oroszlan, Peter; Schaer, Martin
 PATENT ASSIGNEE(S): Zeptosens Ag, Switz.
 SOURCE: PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003050517	A1	20030619	WO 2002-EP13312	20021126 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002357547	A1	20030623	AU 2002-357547	20021126 <--
EP 1454127	A1	20040908	EP 2002-804574	20021126
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
PRIORITY APPLN. INFO.:			CH 2001-2296	A 20011213
			WO 2002-EP13312	W 20021126

OTHER SOURCE(S): MARPAT 139:49457

AB Transparent substrates for MALDI mass spectrometer systems are described which sequentially facilitate ≥ 1 optical and ≥ 1 mass-spectrometric measurements. Corresponding coupled optical and mass-spectrometric detection methods and their use, especially in the anal. of biochem. systems, are also described.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 132 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:585185 CAPLUS
DOCUMENT NUMBER: 139:106516
TITLE: Gels containing hardly water-soluble medications
INVENTOR(S): Kashiwai, Toshiyuki; Doi, Ikuko; Sugiyama, Takashi; Koike, Yasushi; Sato, Masahiro
PATENT ASSIGNEE(S): Lion Corp., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003212760	A	20030730	JP 2002-8750	20020117 <--
PRIORITY APPLN. INFO.:			JP 2002-8750	20020117
AB	This invention relates to topical gels and sheets containing hardly water-soluble medications with improved percutaneous absorption and adhesion to the skin. The gel comps. comprise difficultly water-soluble drugs 0.01-30, hydroxypropyl cellulose 2-20, polyhydric alcs. which do not dissolve or swell hydroxypropyl cellulose 3-40, and polyhydric alcs. which dissolve or swell hydroxypropyl cellulose 40-92, and distilled water 3-30 %. For example, a topical gel contained ellagic acid 1, hydroxypropyl cellulose 2, glycerin 3, PEG-300 43, isoprene glycol 10, dipropylene glycol 10, maleic anhydride-alkyl vinyl ether copolymer 1, and distilled water 30 %.			

L16 ANSWER 133 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1960:28004 CAPLUS

DOCUMENT NUMBER: 54:28004

ORIGINAL REFERENCE NO.: 54:5409e-i,5410a

TITLE: Effect of some surface-active substances on the

corrosion of electrolytic zinc

Bundzhe, V. G.; Kir'yakov, G. Z.

SOURCE: Izvestiya Akademii Nauk Kazakhskoi SSR, Seriya

Khimicheskaya (1959) 18-25

CODEN: IKAKAK; ISSN: 0002-3205

DOCUMENT TYPE: Journal

LANGUAGE: Russian

AB The effect of surface-active substances of different classes of organic compds. (mainly quaternary NH_4 salts and H_2O -soluble dyes) on the corrosion of Zn, in acid ZnSO_4 solns., both in absence of metal impurities and in presence of metals more electropos. than Zn is studied. In the presence of metal impurities the selective effect of the additives is observed. In the presence of Sb and Co, some additives act as corrosion inhibitors, but with Cu and in absence of metal impurities as promoters. There is a marked effect of inorg. anions, that are part of the surface-active additives, in determining the promoting action on corrosion. Based on the effect of surfactants on the corrosion rate of Zn in the presence of metal impurities, the surfactants can be classified in 4 groups: (1) surfactants acting as corrosion inhibitors in the presence or absence of impurities include diethylaminopropylene stearamide, the quaternary salt of a polyglycol ether of 2-dimethylaminomethylphenol, aminomethylated Stearox-6, aminomethylated Stearox T-2, uranin, gelatin; (2) surfactants acting as promoters of corrosion in the presence or absence of metal impurities include methyl violet, chrysoidine, neutral red, amidol, hydroquinone, resorcinol, pyrogallol; (3) surfactants that within limits of concns. taken can be considered practically inactive include N-methyl-N-ethylmorpholine iodide, tetraethylammonium nicotinate, propyldiethyl(hydroxyethyl)ammonium nicotinate, tartrazine, Congo red, erythrosin; and (4) surfactants of mixed activity acting as inhibitors of corrosion in presence of Sb and Co, and as promoters of Zn corrosion in presence of Cu and without metal impurities include stearylaminomethylpyridinium chloride, auramine, malachite green, eosin N, rhodamine S, Acridine Yellow, and tryptaflavine. The majority of the latter group influences cation-active substances; usual deposition results from the anode region, but the possibility is not excluded of adsorption on the cathode portion. Since the process of corrosion results from the presence of O, it may be assumed that organic cations contribute increased protection by formation of a film on the Cu. It follows that formation of an O film on Cu is very difficult, thus for Cu, O acts chiefly as promoter of corrosion. Tests with Cl^- impurity in the electrolyte in the presence of surfactants gave indefinite results, making it difficult to estimate the effect of halide anions. The effect of gelatin on the corrosion of Zn in the presence of Cu is noteworthy; at first it retards corrosion, but afterwards starts to increase corrosion; apparently the resulting reduction of gelatin results in the formation of substances which reduce the overvoltage of H.

L16 ANSWER 134 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1965:405884 CAPLUS

DOCUMENT NUMBER: 63:5884

ORIGINAL REFERENCE NO.: 63:1085h,1086a

TITLE: Effects of drugs and reagents on the deformability of dense red cell packs

Jacobs, H. R.

CORPORATE SOURCE: Northwestern Univ., Evanston, IL

SOURCE: Biorheology (1965), 2(4), 183-8

CODEN: BRHLAU; ISSN: 0006-355X

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB Three classes of compds. were established. They were (1) those increasing the deformability of the cell pack, comprising the salicylates, the anticoagulants, the synthetic estrogens, Ultratan, Butazolidine, a few alcs. and several phenols, notably the cresols; (2) those decreasing deformability, the phenothiazines, the antihistaminics, phemerol, brilliant green, bromelin, and some phenols, notably thymol and o-phenylphenol; (3) those without effect.

L16 ANSWER 135 OF 136 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:824459 CAPLUS

DOCUMENT NUMBER: 143:189122

TITLE: Cloning and physical characterization of microbial polypeptides and their use as antimicrobial targets

INVENTOR(S): Edwards, Aled

PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.

SOURCE: U.S. Pat. Appl. Publ., 637 pp., Cont.-in-part of Appl. No. PCT/CA03/00483.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 16

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050181464	A1	20050818	US 2004-953901	20040929
WO 2003084987	A2	20031016	WO 2003-CA465	20030404 <--
WO 2003084987	A3	20050428		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003087146	A2	20031023	WO 2003-CA482	20030408 <--
WO 2003087146	A3	20040318		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003087145	A2	20031023	WO 2003-CA483	20030408 <--
WO 2003087145	A3	20040617		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2002-385611P	P	20020604
US 2002-385747P	P	20020604
US 2002-385962P	P	20020605
US 2002-386022P	P	20020605
US 2002-386024P	P	20020605
US 2002-386087P	P	20020605
US 2002-386141P	P	20020605
US 2002-386350P	P	20020605
US 2002-386586P	P	20020605
US 2002-386368P	P	20020606
US 2002-386369P	P	20020606
US 2002-386436P	P	20020606
US 2002-386441P	P	20020606
US 2002-386528P	P	20020606
US 2002-386573P	P	20020606
US 2002-386834P	P	20020606
US 2002-399839P	P	20020731
US 2002-399861P	P	20020731
US 2002-399969P	P	20020731
US 2002-399970P	P	20020731
US 2002-399983P	P	20020731
US 2002-399984P	P	20020731
US 2002-399985P	P	20020731
US 2002-400154P	P	20020801
US 2002-400230P	P	20020801
US 2002-400268P	P	20020801
US 2002-400363P	P	20020801
US 2002-400365P	P	20020801
US 2002-400374P	P	20020801
US 2002-400380P	P	20020801
US 2002-400433P	P	20020801
US 2002-400434P	P	20020801
US 2002-400436P	P	20020801
US 2002-400442P	P	20020801
US 2002-400463P	P	20020801
WO 2003-CA465	A2	20030404
WO 2003-CA482	A2	20030408
WO 2003-CA483	A2	20030408
US 2002-369819P	P	20020404
US 2002-369826P	P	20020404
US 2002-369831P	P	20020404
US 2002-370060P	P	20020404
US 2002-370681P	P	20020408
US 2002-370806P	P	20020408
US 2002-370852P	P	20020408
US 2002-370868P	P	20020408
US 2002-370959P	P	20020409
US 2002-370978P	P	20020409
US 2002-371008P	P	20020409
US 2002-371009P	P	20020409
US 2002-371014P	P	20020409
US 2002-371025P	P	20020409
US 2002-371064P	P	20020409
US 2002-371065P	P	20020409
US 2002-371094P	P	20020409
US 2002-371114P	P	20020409
US 2002-371180P	P	20020409

AB The present invention relates to polypeptide targets for pathogenic bacteria. Reliable, high throughput methods are developed to identify, express, and purify a number of antimicrobial targets from *Staphylococcus aureus*, *Escherichia coli*, *Streptococcus pneumoniae*, *Enterococcus faecalis*, *Hemophilus influenzae*, and *Pseudomonas aeruginosa*. The nucleic acid and amino acid sequences are provided for a number of microbial genes and their encoded protein products. The invention also provides bioinformatic, biochem. and biophys. characteristics of those polypeptides, in particular characterization by mass spectrometry, NMR spectrometry, and x-ray crystallog.

L16 ANSWER 136 OF 136 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2004:101291 CAPLUS

DOCUMENT NUMBER: 140:177313

TITLE: Cloning and physical characterization of deoxyuridine 5'-triphosphatase from pathogenic bacteria and their use as antimicrobial targets

INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Domagala, Megan; Mansoury, Kamran; Kimber, Matthew; Houston, Simon; Awrey, Donald; Beattie, Bryan

PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.

SOURCE: PCT Int. Appl., 220 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 16

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004011638	A2	20040205	WO 2003-CA1129	20030731
WO 2004011638	A3	20040701		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SJ, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003087354	A2	20031023	WO 2003-CA485	20030408 <---
WO 2003087354	A3	20040304		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003250684	A1	20040216	AU 2003-250684	20030731
PRIORITY APPLN. INFO.:			US 2002-399971P	P 20020731
			WO 2003-CA485	A 20030408
			US 2002-371067P	P 20020409
			US 2002-386548P	P 20020605
			US 2002-386826P	P 20020606

US 2002-386869P	P	20020606
US 2002-424380P	P	20021106
US 2002-425086P	P	20021108
US 2002-436243P	P	20021224
US 2002-436288P	P	20021224
US 2002-436566P	P	20021226
US 2002-436567P	P	20021226
US 2002-436708P	P	20021227
US 2002-436947P	P	20021230
US 2002-436971P	P	20021230
US 2002-437038P	P	20021230
US 2002-437141P	P	20021230
US 2002-437620P	P	20021231
US 2002-437638P	P	20021231
WO 2003-CA1129	W	20030731

AB The present invention relates to novel drug targets for pathogenic bacteria. Reliable, high throughput methods are developed to identify, express, and purify deoxyuridine 5'-triphosphatase from *Enterococcus faecalis* and *Streptococcus pneumoniae*. The nucleic acid and encoded amino acid sequences for the deoxyuridine 5'-triphosphatase from *E. faecalis* and *S. pneumoniae* are provided. The invention also provides bioinformatic, biochem. and biophys. characteristics of the polypeptides of the invention, in particular characterization by mass spectrometry, NMR spectrometry, and x-ray crystallog. Crystal structure of deoxyuridine 5'-triphosphatase from *S. pneumoniae* is provided.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT